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Abstract 
 
Thesis title: Evaluation of a botulinum neurotoxin chimera containing two SNAP-25 cleaving 
proteases for anti-nociceptive activity in rodent neuropathic and inflammatory pain models 
Author: John Nealon 
 
Botulinum neurotoxin A (BoNT/A), a 150 kDa di-chain protein produced by Clostridium botulinum, 
is used to treat chronic pain. It inhibits neuronal exocytosis by cleaving synaptosomal-associated 
protein 25 (SNAP-25) with its light chain protease (LC/A). The LC of serotype BoNT/E (LC/E) cleaves 
17 more residues from SNAP-25 than LC/A; in vitro results have shown that unlike LC/A, the more 
extensive cleavage of SNAP-25 by LC/E prevents capsaicin-induced release of the pain mediating 
neuropeptide calcitonin gene-related peptide (CGRP). By attaching LC/E to BoNT/A, the short half-
life of LC/E is extended to match BoNT/A, resulting in a chimera with potentially greater anti-
nociceptive capabilities than BoNT/A. In the rat spared nerve injury (SNI) model of neuropathic pain, 
injections of LC/E-BoNT/A showed greater alleviation of mechanical pain than BoNT/A or LC/E-
BoTIM/A, a BoNT/A and LC/E chimera with an inactive LC/A. Unfortunately, intra-articular knee 
injections of LC/E-BoNT/A or BoNT/A induced confounding muscle paralysis, even at doses 
tolerated for intra-plantar injections; therefore, it was not feasible to inject enough neurotoxin to 
relieve symptoms of an inflammatory knee pain model. Injections of LC/E-BoNT/A prior to induction 
of nocifensive behaviours in the capsaicin or formalin models, resulted in more striking anti-
nociceptive effects than BoNT/A pre-injections. LC/E-BoNT/A reduced formalin-induced phase I 
flinching behaviour and was comparable to sub-cutaneous buprenorphine treatment in relieving 
capsaicin-induced lifting/licking behaviours and heat hypersensitivity. However, these observations 
were inconsistent between batches of BoNTs produced; results from an in vitro substrate cleavage 
assay and in vivo dose escalation studies indicated activity loss of LC/E-BoNT/A over long-term 
storage, explaining some of the inconsistencies in anti-nociceptive effects. A fresh batch of LC/E-
BoNT/A demonstrated anti-nociceptive effects in the capsaicin and SNI model, but further 
symptoms of systemic toxicity than the previous batch.
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Chapter 1 - Introduction  
Nociception and pain 
  
Pain is a complex and subjective experience which can evoke unpleasant physical and emotional 
responses, and thus serves a protective role against injury. This is highlighted by its definition 
according to the International Association for the Study of Pain (IASP) as “an unpleasant sensory 
and emotional experience associated with actual or potential tissue damage or described in terms 
of such damage”. These potentially/actually damaging tissue events are termed “noxious stimuli” 
and nociception is the “neural coding of noxious stimuli” (Loeser et al., 2011). The repercussions 
from a lack of pain sensation are best exemplified by the sufferers of congenital insensitivity to pain, 
a disease in which patients retain normal sensory responses (e.g. light touch perception and 
detection of differences in temperature) but feel no pain in response to noxious stimuli, and thus 
sustain unknown injuries. Complications of this condition include self-mutilation from the ages 0-4 
from biting of the tongue and mouth, frequent bruises and cuts, and histories of unreported 
fractures (Drenth and Waxman, 2007). While pain normally serves a self-protective role and is 
necessary for one’s well-being, it can become maladaptive and persist beyond recovery from the 
initial injury, despite the lack of a noxious stimulus. Chronic pain, generally defined as pain lasting 
or recurring for more than 3-6 months, is a worldwide problem that affects an estimated 20% of 
the general population (Merskey et al., 1994, Goldberg and McGee, 2011). Chronic pain is often 
associated with pathologies such as chronic inflammation (e.g. rheumatoid arthritis) but can also 
be neuropathic (e.g. diabetic neuropathy), or idiopathic in nature (e.g. chronic primary pain) 
(Treede et al., 2015). Symptoms of these conditions include spontaneously occurring pain and 
hypersensitisation to stimuli (Cervero and Laird, 1996), including hyperalgesia (heightened pain 
from a noxious stimuli) or allodynia (pain from a previously innocuous stimuli) (Loeser et al., 2011). 
Some chronic pain symptoms correlate directly with disease progression e.g. rheumatoid arthritis 
(Jansen et al., 2001), yet other chronic pain diseases show abnormal changes in the mechanisms of 
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physiological pain detection that persist past wound healing e.g. phantom limb pain (Vaso et al., 
2014, Flor et al., 2006). 
Physiological pain process 
 
The process of physiological pain detection can be broadly summarised in the following stages: 
transduction of the noxious stimulus, transmission, modulation, projection and perception (Fig. 1.1 
A). Noxious stimuli (mechanical, temperature or chemical) activate transducers such as transient 
receptor potential vanilloid 1 (TRPV1 – responds to temperatures of 43 °C) or transient receptor 
potential ankyrin 1, (TRPA1 – responds to mustard oil binding) on the terminals of high threshold 
sensory neurons termed nociceptors, found in the peripheral nervous system (PNS). Once 
activated, these receptors transduce the stimuli into action potentials which are transmitted by 
unmyelinated C- and/or thinly myelinated Aδ nociceptors to the cell body in the dorsal root 
ganglion (DRG), then continuing on the nociceptor’s central axon to the dorsal horn of the spinal 
cord (Muir and Woolf, 2001). Heavily myelinated, low-threshold Aβ fibres were originally believed 
to transmit only non-noxious signals, but research has found a population of Aβ fibres which 
transmit nocifensive signals (Djouhri and Lawson, 2004). The generation and propagation of these 
action potentials relies heavily on voltage gated sodium channels (Nav), which are highly expressed 
on nociceptors (Toledo-Aral et al., 1997, Djouhri et al., 2003). The C-fibres terminate in lamina I and 
II of the dorsal horn while the Aδ nociceptors terminate at lamina I and V, and Aβ fibres terminate 
in lamina III and IV (Fig. 1.1 B). Here, the central terminals of the nociceptors release glutamate, 
activating α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR) causing 
excitatory postsynaptic currents in the second order dorsal horn neurons which are modulated by 
interneurons and descending innervation as depicted in Fig. 1.1 C (Basbaum et al., 2009, Todd, 
2010). Projection neurons carry these signals to the brain stem, then thalamus via ascending 
pathways such as the spinothalamic and spinoreticulothalamic tracts. It is believed that the 
thalamus is responsible for processing poorly localised pain. Nocifensive action potentials are 
propagated towards the cortical structures such as the somatosensory cortex and adjacent cortical 
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areas, for processing of the original location and intensity of the incoming pain signal (Basbaum et 
al., 2009, Muir and Woolf, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1 Anatomical outline of physiological pain and spinal modulation of nociception (A) Noxious 
stimuli are transduced into action potentials by nociceptors and transmitted along axons, to the DRG and 
then dorsal horn for modulation. The modified signal is projected to the brain where it is perceived as 
pain (Muir and Woolf, 2001). (B) Thinly myelinated nociceptors called A fibres terminate in lamina I and 
V of the dorsal horn. Unmyelinated C-fibres terminate in lamina I-II, both A and C fibres respond to 
noxious stimuli and are nociceptors. Heavily myelinated non-nocifensive or nocifensive Aβ fibres pain 
terminate in lamina III-IV  (Woolf and Mannion, 1999). (C) Incoming action potentials induce 
depolarisation of the presynaptic terminal and exocytosis of pain-inducing neurotransmitters such as 
glutamate or sensitising neuropeptides such as substance P. Release of endogenous opioids, monoamines 
(e.g. serotonin) or inhibitory neurotransmitters (e.g. glycine) from descending innervation and inhibitory 
interneurons can modulate the release of excitatory neurotransmitters in the dorsal horn, by binding to 
their respective receptors on the primary afferent, or second-order neurons which transport the 
nociceptive signal to the brain. (A) taken from (Muir and Woolf, 2001), (B) taken from (RnCeus.com), (C) 
adapted from (RnCeus.com). 
C 
A B 
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Acute pain and the transition to chronic pain 
 
Acute pain is typically defined as pain that is present for less than 3 months, with subacute pain 
being a subset of this that persists for more than 6 weeks but less than 3 months (King, 2013). These 
pain states differ from chronic pain in that they are expected to recover with the associated injury 
(Richardson and Vasko, 2002), while chronic pain is recognised as “pain that persists past normal 
healing time” (Treede et al., 2015). Interestingly, overlapping mechanisms (discussed below) have 
been identified in acute and chronic pain, exemplified by the fact that high levels of unmanageable 
acute and subacute pain after traumatic injuries or surgical procedures are risk factors for the 
development of chronic pain (Lavand'homme, 2011, Pozek et al., 2016). That said, the mechanisms 
behind the transition from acute to chronic pain, and how chronic pain is maintained in the absence 
of injury are not fully understood.  
Peripheral sensitisation 
 
Following tissue injury, nociceptors innervating the wound become more responsive and 
demonstrate reduced thresholds to stimuli, via a process called peripheral sensitisation (Loeser et 
al., 2011).  As a result, the affected area becomes hypersensitive to both noxious and innocuous 
stimuli prompting guarded behaviour from the victim, thus allowing the wound to heal without 
further aggravation (Costigan et al., 2009). The release of pro-inflammatory and pro-algesic 
mediators (discussed in more detail below) by non-neuronal and damaged cells at the injury site 
(known as the “inflammatory soup”), drives peripheral sensitisation through excitation of 
nociceptors to cause spontaneous pain and/or by sensitising the neurons to noxious stimuli, via 
receptor augmentation or upregulation (Kidd and Urban, 2001).  
Tissue injury results in the release of adenosine tri-phosphate (ATP), protons and glutamate from 
damaged cells into the extracellular space (Amaya et al., 2013), while kininogen present in the 
plasma is enzymatically activated to produce bradykinin (Tiffany and Burch, 1989). Mast cells 
located near primary afferent nociceptors degranulate and release histamine, serotonin (5-HT), 
5 
 
nerve growth factor (NGF) and pro-inflammatory cytokines, including tumour necrosis factor 
(TNFα), interleukin 6 (IL-6), and IL-1β (Raoof et al., 2018, Chatterjea and Martinov, 2015). Some of 
these molecules such as bradykinin bind to their receptor to depolarise the nociceptor and initiate 
a noxious action potential (Liu et al., 2010); other inflammatory soup components sensitise the 
nociceptor to stimuli. For example, injections of 5-HT induce profound hyperalgesia to heat.  This is 
mediated by 5-HT binding to 5-HT2A, a G-protein coupled receptor found on TRPV1 expressing 
nociceptors, which activates the second messenger phospholipase C (PLC) and phosphokinase C 
(PKC) pathways causing phosphorylation, and thus augmentation of the TRPV1 receptor, mediating 
heat hyperalgesia (Loyd et al., 2011, Tokunaga et al., 1998, Sugiuar et al., 2004, Raymond et al., 
2001). Many of these above-mentioned mediators can elicit both excitatory currents in the 
nociceptor via ionotropic receptors and initiate mechanisms of sensitisation via binding to 
metabotropic receptors. For a list of the different components of the inflammatory soup that target 
nociceptors and their mechanisms of action, please refer to Table 1.1 and Fig. 1.2. 
A number of these molecules such as bradykinin and 5-HT further drive the inflammatory process. 
Bradykinin acts as a potent vasodilator and increases blood vessel permeability, thus promoting 
monocyte and neutrophil infiltration (Milner and Dohert, 2015). 5-HT can attract neutrophils to the 
injury via platelet aggregation (Duerschmied et al., 2013), while platelets also release 5-HT and 
histamine into the inflammatory soup (Li et al., 2007, Mannaioni et al., 1993, Cerrito et al., 1993). 
Monocytes and neutrophils are also attracted to the injury by the release of chemokines and 
complement components at the initial injury (Velnar et al., 2009). Recruited monocytes are 
converted to inflammatory macrophages, which release pro-inflammatory cytokines (TNFα, IL-1β, 
etc.) into the inflammatory soup, maintaining hypersensitisation (Table 1.1) (Lavin and Merad, 
2013, Zhang and An, 2007).  
IL-1β and bradykinin can induce synthesis of prostaglandins in several cell types (neurons, 
neutrophils and macrophages) (Pinho-Ribeiro et al., 2017, Supowit et al., 2011). Prostaglandins are 
derivatives of arachidonic acid and are synthesised by cyclooxygenase 1 and 2 (COX-1 and COX-2), 
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COX-2 is not expressed in peripheral tissues until upregulated by inflammatory cytokines such as 
IL-1β and TNFα (Bakhle and Botting, 1996, Lee et al., 2009, Ke et al., 2007). Prostaglandin E2 and I1 
(PGE2 and PGI2) are the most studied prostaglandins in peripheral sensitisation (Milner and Dohert, 
2015). PGE2 binding to EP1 or EP4 receptors can induce nociceptor hypersensitivity by modifying 
TRPV1, as summarised in Table 1.1. 
Nearly all the pain/inflammatory mediators described thus far, can induce the release of 
neuropeptides calcitonin gene-related peptide (CGRP) or Substance P (SP), or augment the release 
of said peptides from nociceptors (Table 1.1, Fig. 1.2). CGRP and SP are pro-inflammatory 
neuropeptides, with peripheral release of CGRP causing vasodilation (Brain et al., 1985), and SP 
inducing plasma extravasation (Lembeck and Holzer, 1979), driving the inflammatory process at the 
injury. SP can also bind to mast cells, inducing release of histamine (Johnson and Erdos, 1973) and 
increased TNFα expression (Ansel et al., 1993). This release of inflammatory mediators from 
neurons is called “neurogenic inflammation”.  
It is clear that the mechanisms of peripheral sensitisation can become a self-fulfilling cycle, if not 
managed through normal wound healing mechanisms or pharmacological interventions. Release of 
inflammatory mediators such as bradykinin at the initial insult drive inflammatory cell infiltration 
and hypersensitisation, while nociceptors release neuropeptides such as SP in response, promoting 
immune cell infiltration and upregulation of pro-inflammatory cytokines such as TNF in mast cells. 
Sustained activation of nociceptors along with augmentation and upregulation of ligand-gated and 
voltage-gated channels, result in increased firing of action potentials by nociceptors and their 
heightened sensitivity to stimuli (Pinho-Ribeiro et al., 2017). This increase of nocifensive signalling 
leads to the process of central sensitisation discussed below. 
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Fig. 1.2 Components of the inflammatory soup, source of their release and neuronal targets 
Pro-inflammatory and pro-algesic mediators activate and sensitise the nociceptor via voltage or 
ligand gated channel augmentation or upregulation, driving inflammation-induced pain. 
Activation of the nociceptor by the above mediators induces the release of neuropeptides CGRP 
and SP, which activate local inflammatory cells and recruit immune cell infiltration. Adapted 
from (Pinho-Ribeiro et al., 2017). H1/2 – Histamine receptors 1 & 2, TrkA - Tropomyosin 
receptor kinase A, TNFR1 – TNF receptor 1, IL-1R – IL-1β receptor, gp130 – glycoprotein 130, 
NMDAR - N-methyl-D-aspartate receptor, P2X/Y – ATP receptors, ASIC – acid-sensing ion 
channel, B1/2 – Bradykinin receptors 1 and 2. 
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MOLECULE RECEPTOR DEPOLARISE/ELICIT 
CURRENTS 
TOWARDS DRG 
SENSITISE NOCICEPTOR 
(HYPERALGESIA, ALLODYNIA) 
INDUCE OR 
AUGMENT 
RELEASE OF CGRP 
OR SP 
REFERENCES 
Bradykinin B1 & B2 Yes Activation of B2 receptors 
sensitises TRPV1 receptors 
heat and chemical stimuli via 
PKC and PLC pathways.  
Direct release of 
neuropeptides and 
augments evoked 
release of 
neuropeptides 
(Wang et al., 2006, 
Rohacs et al., 2008, 
Richardson and 
Vasko, 2002) 
Serotonin 5-HT3 & 
 5-HT2A 
Unclear Induces heat hyperalgesia, 
most likely through 
phosphorylation of TRPV1 via 
PLC/PKC pathways post 5-
HT2A activation. 
Unclear (Milner and Dohert, 
2015, Loyd et al., 
2013, Richardson 
and Vasko, 2002) 
ATP P2X and P2Y Yes Induces heat hyperalgesia, 
most likely through 
phosphorylation of TRPV1 via 
PLC/PKC pathways post P2Y 
activation. 
Augments evoked 
release of 
neuropeptides 
(Milner and Dohert, 
2015, Tominaga et 
al., 2001, 
Richardson and 
Vasko, 2002) 
Glutamate AMPAR, 
NMDAR, 
Kainate 
receptor 
Yes Intra-plantar injections of 
glutamate induce symptoms 
of sensitisation, but 
mechanisms are unclear. 
Increased expression of 
glutamate receptors in 
inflamed rat hind-paws have 
been detected. 
Unclear (Amaya et al., 2013, 
Gold and Gebhart, 
2010, Richardson 
and Vasko, 2002, 
Carlton and 
Coggeshall, 1999) 
Protons ASICs and 
TRPV1 
Yes Exposure to acidic 
environment allows for 
proton-induced TRPV1 
activation at temperatures 
below 43 °C 
Direct release of 
neuropeptides 
(Tominaga et al., 
1998, Richardson 
and Vasko, 2002) 
Histamine H1 & H2 Yes Upregulates NaV 1.8 
expression post H2 activation. 
No (Pinho-Ribeiro et 
al., 2017, Gábor 
Jancsó, 2009) 
TNFα TNFR1 & 
TNFR2 
No TNFR1 activation modulates 
TTX-R via p38 MAPK. TRPV1 is 
upregulated and modulated in 
a p38/MAP kinase and PKC 
dependent fashion. 
Augments evoked 
release of 
neuropeptides 
(Pinho-Ribeiro et 
al., 2017, Jin and 
Gereau, 2006, 
Constantin et al., 
2008, Richardson 
and Vasko, 2002) 
IL-1β IL1R No Sensitise TTX-R in a p38 MAPK 
dependent fashion 
Augments evoked 
release of 
neuropeptides 
(Pinho-Ribeiro et 
al., 2017, Binshtok 
et al., 2008, 
Richardson and 
Vasko, 2002) 
 
IL-6 gp130 No Activation of gp130 induces 
JAK/STAT dependent 
upregulation of TRPV1 and 
TRPA1 
Augments evoked 
release of 
neuropeptides 
(Pinho-Ribeiro et 
al., 2017, Fang et 
al., 2015, Malsch et 
al., 2014, 
Richardson and 
Vasko, 2002) 
NGF TrkA No TrkA activation causes p38 
MAPK dependent 
upregulation of TRPV1 
TrkA activates PI3K/Src kinase 
signalling, leading to 
phosphorylation and rapid 
membrane insertion of TRPV1  
Augments evoked 
release of 
neuropeptides 
(Amaya et al., 2013, 
Ji et al., 2002, Zhang 
et al., 2005, 
Richardson and 
Vasko, 2002) 
 
PGE2 EP1,2 &4 No Sensitise TRPV1 and TTX-R via 
PKA and PKC pathway, post 
activation of EP1, 2 or EP4 
receptors. 
 
Augments evoked 
release of 
neuropeptides 
(Kawabata, 2011, 
Richardson and 
Vasko, 2002) 
Table 1.1 Summary of mediators of the inflammatory soup and their actions on nociceptors 
p38 MAPK - p38 mitogen-activated protein kinases, JAK – Janus kinases, STAT – signal transducer 
and activator of transcription proteins, PI3K – phosphoinositide 3-kinase, TTX-R - Tetrodotoxin 
resistant sodium channels (NaV 1.8 or 1.9 are most commonly affected in peripheral 
sensitisation). 
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Central sensitisation 
 
Central sensitisation is the process by which neurons of the CNS become hyper-excitable, resulting 
in amplified processing of nociceptive signals, or nociceptive processing of sub-threshold signals 
(e.g. those from low-threshold Aβ fibres) (Basbaum et al., 2009, Loeser et al., 2011). The 
mechanisms of this are numerous, complex and not fully understood, and so this review will focus 
on the activity-dependent mechanisms of central sensitisation restricted to the spinal cord. Central 
sensitisation is initiated by intense and repetitive noxious signals to the CNS, typically originating 
from the increased activity of peripherally sensitised nociceptors (Milner and Dohert, 2015). Once 
a noxious action potential reaches the central terminal of the nociceptor in the dorsal horn, release 
of glutamate, SP and CGRP is induced. Glutamate binding to AMPAR evokes a fast (milliseconds) 
excitatory postsynaptic potential (EPSP) while SP binding to neurokinin 1 receptors (NK1) induces 
slow (seconds) depolarising currents (Millan, 1999, Murase and Randic, 1984). CGRP is often co-
localised with SP (Schaible, 2007, Aline Boer et al., 2005, Ma et al., 2001, Ribeiro-da-Silva, 1995) 
and upon release binds to CGRP1 receptors; the release of CGRP seems to potentiate the action of 
SP (Oku et al., 1987) and inhibit its degradation (Le Greves et al., 1985). Greater release of SP and 
CGRP due to increased peripheral activity results in a cumulative depolarisation induced by 
temporal summation of NK1 and CGRP1 mediated slow synaptic potentials; this results in the 
phenomenon of action potential “wind-up” (Latremoliere and Woolf, 2009, Budai and Larson, 
1996). This is characterised by gradual increases in action-potential discharges per each successive 
stimuli (Mendell and Wall, 1965). Wind-up facilitates the activation of NMDAR in the dorsal horn, 
which under normal conditions is inactive due to a Mg2+ plug in the channel pore; the increased 
depolarisation of the membrane mediated by wind-up forces the Mg2+ from the NMDAR pore, 
allowing its activation by glutamate released from nociceptor pre-synaptic terminals (Mayer et al., 
1984, Thompson et al., 1990). This step is vital in initiating the process of central sensitisation 
(Woolf and Thompson, 1991).  
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The inward current of Ca2+ resulting from the opening of NMDARs increases the levels of 
intracellular Ca2+, activating Ca2+ dependent kinases, which phosphorylate NMDARs and AMPARs. 
Phosphorylation of these receptors not only alters their sensitivity but their trafficking to plasma-
membrane, increasing dorsal horn excitability to primary nocifensive input (Carvalho et al., 2000, 
Chen and Roche, 2007, Lau and Zukin, 2007, Latremoliere and Woolf, 2009). Activation of 
intracellular kinase pathways responsible for phosphorylation of glutamate receptors, such as the 
PKC pathway, is also mediated by postsynaptic CGRP1 activation (Sun et al., 2004) and tropomyosin 
receptor kinase B (TrkA) activation by brain derived neurotrophic factor (BDNF) release, which is 
increased by CGRP (Buldyrev et al., 2006). Inhibitory neurons at the spinal cord typically modulate 
nocifensive signals through the release of inhibitory neurotransmitters, gamma-Aminobutyric acid 
(GABA) and glycine. During central sensitisation, the activation of kinase pathways such as the PKC 
pathway prevents GABA and glycine mediated inhibition of nocifensive signals to spinothalamic 
tract (STT) neurons (Lin et al., 1996). This disinhibition results in increased excitation of dorsal horn 
neurons to non-nociceptive Aβ fibre input (Baba et al., 2003). Together these changes in dorsal horn 
excitability and inhibition result in ascending tracts propagating a greater degree of nocifensive 
signals from the hyper excitable dorsal horn neurons. These activity-dependent changes are 
induced rapidly (within seconds) and dissipate within minutes to hours of cessation of nociceptive 
input, depending on the length and intensity of the original stimulus (Latremoliere and Woolf, 
2009). If heightened nociceptive activity is maintained, however, further transcription dependent 
mechanisms of central sensitisation serve to maintain long-lasting pathological forms of central 
sensitisation. 
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Inflammatory pain 
 
Diseases of chronic inflammatory pain are strongly driven by peripheral sensitisation, with common 
treatment responses being based on the use of non-steroidal anti-inflammatory drugs (NSAID) 
which inhibit COX enzymes and the formation of prostaglandins (Kidd and Urban, 2001). Efforts to 
fully understand the peripheral disease mechanisms of arthritis have identified a strong neurogenic 
inflammatory component. The connective tissue and synovium of human joints are strongly 
innervated by peptidergic afferents expressing CGRP and SP, and autonomic fibres expressing 
vasodilatory neuropeptides such as vasoactive intestinal peptide (VIP) and neuropeptide Y (NPY) 
(Kidd et al., 1990, Milner and Dohert, 2015, Gronblad et al., 1988, Mapp et al., 1990). In conditions 
of chronic, unrelenting inflammation such as rheumatoid arthritis, peptidergic nociceptors and 
autonomic neurons receive constant noxious stimulation causing the release of these inflammatory 
neuropeptides, thus maintaining chronic swelling via neuronal stimulation. Levels of CGRP and SP 
are also raised in the joints of animal models of arthritis (Donaldson, 2009), and these symptoms 
can be reduced by intervention with CGRP receptor antagonists (Hirsch et al., 2013). The heat 
sensing receptor TRPV1 is shown to be highly up-regulated in rodent models of chronic 
inflammatory pain, both at the site of inflammation (hind-paw skin), the sciatic nerve and DRG (Ji 
et al., 2002). TRPV1 antagonists are effective at relieving symptoms in rodent models of arthritis 
but have been dismissed as potential therapies in humans due to  side-effects such as hyperthermia 
(Wong and Gavva, 2009). 
At the site of inflammation low-threshold, heavily-myelinated Aβ fibres are exposed to pro-
inflammatory mediators such as NGF, which results in a phenotypic switch in these neurons. NGF 
stimulates large DRG neurons to begin expressing SP and BDNF, so that innocuous stimulation of 
the peripheral Aβ fibres induces a release of SP and BDNF in the dorsal horn (Neumann et al., 1996).  
This phenotypic switch aids in triggering central sensitisation in inflammatory based pain. 
Peripheral inflammation also alters the function and cytokine expression profiles of spinal microglia 
(Raghavendra et al., 2004), specifically resulting in activation of p38 MAPK (Svensson et al., 2003) 
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and subsequent synthesis and release of IL-1β (Samad et al., 2001) and TNFα (Kawasaki et al., 2008). 
These induce activation of COX-2 in the dorsal horn neurons, driving production of PGE2. Binding 
of PGE2 to its EP2 receptor can potentiate AMPAR and NMDAR currents (Kohno et al., 2008), while 
binding to presynaptic EP4 receptors enhances neurotransmitter release from central terminals 
(Vasko et al., 1994). Many treatments of inflammatory pain seek to inhibit the driving mechanisms 
of peripheral sensitisation and inflammation (e.g. NSAID treatment) (Kidd and Urban, 2001), and as 
a result the activity dependent mechanisms of central sensitisation are ablated. This differs from 
the central changes that occur in other chronic pain states, such as in neuropathic pain described 
below. 
Neuropathic pain 
 
The various diseases associated with neuropathic pain show diverse pathological mechanisms, 
including peripheral (trauma) or central nerve injury (stroke), infection-induced neuropathy (post-
herpetic neuralgia) or chemically induced neuropathy (chemotherapy) (Campbell and Meyer, 
2006). This overview will focus on peripheral and central mechanisms of peripheral nerve injury 
derived neuropathic pain. Following peripheral nerve injury, the aforementioned mechanisms of 
peripheral sensitisation occur, including macrophage infiltration of the damaged nerve and 
increased expression of pro-inflammatory cytokines by these cells.  Peripheral sensitisation in 
neuropathic pain also shows unique features, with denervation of Schwann cells and the resulting 
inflammation being of particular importance. Following injury, Schwann cells can further recruit 
macrophages to the site by secretion of leukaemia inhibitory factor and monocyte chemoattractant 
protein-1 (Sugiura et al., 2000), and possibly signal nearby uninjured neurons, contributing to 
sensitisation of these adjacent afferents (Schafers et al., 2003, Campbell and Meyer, 2006). Another 
distinctive feature of neuropathic pain is the generation of ectopic activity by the injured nerve, 
nearby uninjured nerves and from the DRG (Amir et al., 2005, Wu et al., 2002). Ectopic action 
potentials (not derived from a stimulus) induce spontaneous pain (Bostock et al., 2005, Baron, 
2006) and are driven by NaV activity, as demonstrated by the ablation of peripheral nerve injury 
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pain by topical lidocaine application (a non-selective sodium channel blocker) (Meier et al., 2003). 
Interestingly, application of sub-anaesthetic doses of lidocaine (i.e. 20% of the normal spinal dose 
required for analgesia) into the DRG relieved spontaneous phantom limb pain (Vaso et al., 2014), 
indicating an important role for ectopic impulse generation from the DRG in maintaining 
neuropathic pain despite injury recovery.  
The generation of ectopic action potentials plays a vital role in driving the central sensitisation 
mechanisms of nerve injury pain. During neuropathic pain, Aβ neurons undergo a similar 
phenotypic switch as seen in inflammatory pain conditions, with large DRG neurons now expressing 
SP and BDNF. However, the number of different transcriptional changes that occur in the DRG are 
approximately 100-fold greater than those observed in inflammatory pain conditions (Latremoliere 
and Woolf, 2009). Central neuron death resulting from the peripheral injury causes structural 
changes in the dorsal horn in the form of sprouting of Aβ fibres from lamina III-IV into lamina I-II, 
where they may contact nociceptors and possibly alter activity (Woolf et al., 1992, Shortland et al., 
1997, Lekan et al., 1996). Neuronal death also seems to have a far greater effect in activating spinal 
glial cells than inflammatory pain conditions, with them releasing a number of cytokines, trophic 
factors and neurotransmitters to drive sensitisation of dorsal horn neurons (Romero-Sandoval et 
al., 2008, Watkins and Maier, 2002). These enhanced changes (compared to inflammatory pain) in 
the central processing of neuropathic pain may leave victims of nerve injury at particular risk of 
developing chronic pain after recovery, with chronic pain occurrence rates ranging from 5 – 60% 
depending on the severity of the injury (Costigan et al., 2009).  
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Treatment of chronic pain and societal impacts 
 
Treatment of chronic pain typically follows a ladder of drug escalation according to the World 
Health Organisation (WHO) cancer pain relief guidelines (WHO, 1996), with drugs being prescribed 
based on the patient’s symptoms (Schnitzer, 2006, Dworkin et al., 2007). The treatment of chronic 
pain is dominated by NSAIDs, weak and strong opioids, paracetamol and COX-2 inhibitors. Further 
drug options are available for chronic neuropathic pain (which tends to be less responsive to 
treatment) which include tricyclic antidepressants (TCAs), selective serotonin and norepinephrine 
reuptake inhibitors (SSNRIs), calcium channel α2-δ ligands and topical lidocaine (Dworkin et al., 
2007). Despite the wide range of analgesics available, a pan European study revealed that 27-61% 
of chronic pain sufferers were unsatisfied with the treatment of their pain and that 31% reported 
that their pain was so severe they could not tolerate it anymore (Breivik et al., 2006).  
Treatment discontinuation for chronic pain is high, reported at 26%, with 34% of these patients 
discontinuing their medication due to side effects, lack of efficacy or addiction risks (Breivik et al., 
2006).  As a result, treatments are tailored specifically based on each patient’s response to the 
different drugs available. Therefore, clinicians are walking a fine line of reducing side effects and 
drug dependency while maintaining adequate pain relief. Examples of the adverse effects causing 
patients to discontinue treatment include higher risks of cardiovascular death and events caused 
by NSAIDs and COX-2 inhibitors (Schnitzer, 2006) as well as nausea, sedation and respiratory 
depression induced by opioids (Eisenberg et al., 2005, Furlan et al., 2006, Dahan et al., 2010). Due 
to the severe and long-lasting nature of chronic pain, patients prescribed opioids can become 
dependent on these medications and at risk of developing an opiate addiction. This risk was 
exemplified in a study where 49% of patients who discontinued opioid use cited fear of addiction 
or dependence as a motive, and 18% admitted to quitting due to difficulty in controlling their opioid 
use. Patients who remain on opioid treatment risk drug dependence, insufficient analgesia due to 
tolerance and developing opioid-induced hyperalgesia (developing hypersensitivity to specific pain 
stimuli from prolonged opioid exposure) (Varrassi et al., 2010, Lee et al., 2011a). These issues not 
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only come at a high cost to patients’ well-being but also to the economy, with the cost of chronic 
non-cancer pain reaching €5.34 billion per year in Ireland (Raftery et al., 2012).  These issues clearly 
show an unmet need for long-lasting effective pain treatment with minimal side effects and no risk 
of addiction. 
SNARE-mediated exocytosis and its contributions to pain 
 
Pre-synaptic, vesicular release of neurotransmitters is a vital mechanism in the physiological pain 
process, and Soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) 
proteins are essential mediators of vesicle fusion. As shown in Fig. 1.3 A, these SNARE proteins form 
a complex which mediates the fusion of synaptic vesicles containing neurotransmitters, or large 
dense core vesicles (LDCVs) containing neuropeptides to the presynaptic membrane, thus resulting 
in exocytotic release of neurotransmitters and propagation of the pain signal. The SNARE complex 
is made up of the proteins syntaxin, vesicle-associated membrane protein (VAMP/synaptobrevin) 
and synaptosomal-associated protein Mr of 25 k (SNAP-25). Neuronal SNARE complexes are formed 
as these constituent parts assemble into a parallel four-α-helical bundle, with one α helix 
contributed by synaptobrevin, one by syntaxin 1 and two from SNAP-25 (Rizo, 2018, Gustavsson et 
al., 2012). As shown in Fig. 1.3 B, synaptobrevin is a vesicle bound protein while SNAP-25 and 
syntaxin are bound to the plasma membrane. This complex docks the vesicle to the plasma 
membrane; following an action potential the resultant influx of Ca2+ allows for binding of Ca2+ to 
vesicle bound synaptotagmin, triggering the fusion of the vesicle to the plasma membrane and 
exocytosis of its contents (Jahn and Fasshauer, 2012). 
Stimulated release of the CGRP from cultured rat trigeminal ganglia neurons (TGNs) was found to 
be Ca2+ dependent and inhibited by proteolysis of SNAP-25 and VAMP/1 (Meng et al., 2007, Meng 
et al., 2009); furthermore, the trafficking and docking of TRPV1 and TRPA1 were also dependent on 
these same SNAREs (Meng et al., 2016), with TRPV1 and CGRP likely trafficked via the same LDCVs 
(Devesa et al., 2014). Targeting any one of these mediators would be advantageous in the 
treatment of chronic pain. Inhibition of CGRP release from peripheral nociceptors could inhibit the 
16 
 
neurogenic driving component of the inflammatory soup, while preventing TRPV1/TRPA1 
membrane fusion would inhibit the peripheral upregulation of these receptors, and subsequent 
sensitisation of the nociceptor. This would reduce nocifensive signalling to the dorsal horn and 
inhibit induction of central sensitisation. The botulinum neurotoxins (BoNTs) are a group of 
neuroparalytic proteins that cleave specific SNARE proteins, thus inhibiting the formation of SNARE 
complexes (Pirazzini et al., 2017). By preventing SNARE complex formation in nociceptors these 
neurotoxins could inhibit multiple mechanisms of sensitisation such as CGRP release and TRP 
channel membrane fusion via inhibition of LDCV membrane fusion, along with preventing the 
membrane fusion of any other SNARE dependent pro-algesic or pro-inflammatory mediators. 
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Fig. 1.3 SNARE-mediated vesicle fusion and neurotransmitter release 
(A) Vesicles containing neurotransmitters fuse to the presynaptic 
membrane via SNARE complex assembly, resulting in vesicular release. 
(B) Vesicle bound synaptobrevin forms a parallel alpha helix with a 
single syntaxin chain and two SNAP-25 chains. Following binding of Ca2+ 
to synaptotagmin, vesicle fusion with the presynaptic plasma 
membrane is triggered. Panel A taken from (Biolegend.com).  Panel B 
taken from (Purves, 2004).  
A 
B 
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Botulinum neurotoxin structure and mechanism of action 
 
BoNTs were originally discovered as the highly potent inhibitors of neuroexocytosis that cause the 
disease botulism. These neurotoxins are produced by Clostridium botulinum and target the 
synapses of cholinergic neurons, inhibiting membrane fusion of vesicles containing acetylcholine, 
resulting in a blockade of cholinergic transmission, and the flaccid paralysis characteristic of 
botulism. Seven naturally occurring serotypes of the neurotoxin have been identified (A-G); with 
BoNT serotypes A, B, E and F causing botulism (CDC, 1998). As shown in Fig. 1.4 A, BoNTs are 
homologous di-chain proteins with a molecular mass of ~150 kDa. This di-chain consists of a 50 kDa 
light chain (LC) and 100 kDa heavy chain (HC) linked together by a di-sulphide bridge. The HC is 
made up of the 50 kDa N terminal translocation domain (HN) and 50 kDa C-terminal binding domain 
(HC). The HC contains two sub-domains, HCN and HCC, both of which are 25 kDa (Pirazzini et al., 2017). 
Intoxication of BoNT sensitive neurons is summarised in Fig. 1.4 B, and begins with binding of the 
HCC to a ganglioside coreceptor, followed by binding to the luminal domain of a synaptic vesicle 
protein (see Table 1.2 for BoNT specific surface protein acceptors) (Binz and Rummel, 2009). The 
exact function of HCN has not been fully elucidated but recent work indicates that the HCN is required 
for binding and internalisation of the neurotoxin (Wang et al., 2017b). After binding, the toxin is 
internalised into the cell by receptor mediated endocytosis (Pirazzini et al., 2016). Acidification of 
the vesicle leads to protonation of the BoNT resulting in a conformational change of the HN and LC 
allowing for interaction with the membrane lipids of the vesicle, opening a pore in the membrane 
and leading to translocation of the LC into the cytosol (Colasante et al., 2013). Reduction of the di-
sulphide bond between the LC and HN releases the LC into the cytosol to cleave a specific SNARE 
protein (Fischer and Montal, 2007) (see Table 1.2 for BoNT specific substrates).  
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Fig. 1.4 BoNT di-chain structure and process of neuron intoxication (A) BoNTs are 150 kDa di-chains with 
a catalytic, 50 kDa light chain tethered to a 100 kDa heavy chain via a di-sulphide bridge. The heavy chain 
consists of the 50 kDa binding domain and the 50 kDa translocation domain. Graphic taken from (Rossetto 
et al., 2014, McCleane, 2008). (B) Botulinum neurotoxins, via the heavy chain binding domain, bind to the 
luminal domain of their respective protein receptors, which are exposed during vesicular release. The 
toxin is then internalised into the cell where the translocation domain plays a role in forming a pore in 
the vesicle, allowing the light chain to be released into the cytosol and cleave its target SNAREs. Graphic 
taken from  (Saravanan et al., 2015) 
A 
B 
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SNARE cleavage results in either the inability to form SNARE complexes or the formation of 
functionally impaired, SDS-resistant SNARE complexes (caused by BoNT/A cleavage of SNAP-25) 
(Hayashi et al., 1994). Without fully functioning SNARE complexes vesicle fusion to the membrane 
is impaired, thus inhibiting exocytosis and causing neuroparalysis in the case of the neuromuscular 
junction (Humeau et al., 2000). These same paralytic properties resulted in patenting of clostridial 
produced BoNT/A multi-protein complex as a treatment of numerous disorders of muscle 
hyperexcitability. The BoNT/A protein complex BOTOX® is a 900 kDa complex consisting of the 150 
kDa neurotoxin and several non-toxic proteins that serve to stabilise its entry into the body via 
ingestion (Gu and Jin, 2013, Frevert, 2010). These non-toxic proteins are disassociated from the 
neurotoxin after it crosses the intestinal wall into the bloodstream (Eisele et al., 2011). BOTOX® first 
received FDA approval for the treatment of strabismus, blepharospasm and hemifacial spasm in 
1989, with numerous other clinical indications now approved (Chen, 2012). Studies have shown 
that BoNT/A purified neurotoxins demonstrate similar efficacy to BoNT/A multi-protein complexes 
in the treatment of cervical dystonia (Benecke et al., 2005) and are gradually receiving FDA approval 
similar to that of BoNT/A complexes (Pharmaceuticals, 2011). 
 
 
 
 
 
 
BONT SEROTYPE PROTEIN RECEPTOR CATALYTIC TARGET 
/A SV2 A-C, fibroblast growth factor receptor 3 SNAP-25 
/B Synaptotagmin I and II VAMP 1/2 
/C Unknown SNAP-25 & syntaxin 1 
/D SV2 A, B and C VAMP 1/2 
/E Glycosylated SV2 A and B SNAP-25 
/F SV2 A, B and C VAMP 1/2 
/G Synaptotagmin I and II VAMP 1/2 
Table 1.2 BoNT serotypes, protein receptors and catalytic targets in humans 
(Pirazzini et al., 2017) 
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Botulinum neurotoxins and the relief of chronic pain: 
 
During clinical trials for the use of BoNT/A complex (BOTOX®, Allergan Inc.) to treat hyper-functional 
facial lines, patients treated with BOTOX® reported a reduction in migraine symptoms (Binder et 
al., 2000). This was eventually confirmed in a double blind, vehicle controlled study which 
demonstrated multiple site injections of BOTOX® into the peri-cranial muscles reduced the number 
and severity of migraines for up to three months after injections (Silberstein et al., 2000). In 2010, 
BOTOX® received FDA approval for the treatment of chronic migraine and is an attractive treatment 
option due to its long lasting prophylactic effects (potentially > 6 months) (Dodick et al., 2005). The 
observation that chronic migraine patients show greater levels of pain relief with each BOTOX® 
treatment is another attractive benefit, particularly compared to drug tolerance that can develop 
from current treatments for chronic pain mentioned above (Aurora et al., 2014).  
BOTOX® has numerous off-label uses in different painful conditions, including (but not limited to) 
diabetic neuropathy, chronic musculoskeletal pain, temporomandibular joint disorder, post-
herpetic neuralgia and trigeminal neuralgia (Yuan et al., 2009, Zhang et al., 2011b, Chen et al., 2015, 
Xiao et al., 2010, Morra et al., 2016). BoNT/A isn’t the only serotype of BoNT to have potential in 
treatment of painful conditions, as the BoNT/B product Myobloc® is FDA approved for the 
treatment of pain arising from cervical dystonia (Chen, 2012, Solstice Neurosciences, 2009). 
Research on further uses of BoNT/B in chronic pain is lacking however (Pavone and Ueda, 2014). 
The long lasting anti-nociceptive effects of BoNT/A (ranging from 8 – 24 weeks) seem to be 
consistent in a number of different chronic pain conditions, including chronic refractory (treatment 
resistant) pain (Hu et al., 2013, Sandrini et al., 2017, Park and Park, 2017, Jabbari and Machado, 
2011). These results indicate that BOTOX® has potential as a treatment for multiple forms of chronic 
pain, even those resistant to modern treatments, and has a low risk of tolerance or addiction. From 
here on “BoNT/A” will refer to the pure 150 kDa neurotoxin, while reports on the anti-nociceptive 
effects of BoNT/A complexes will be referred to by the specific brand of BoNT/A complex. 
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Peripheral anti-nociceptive mechanisms of BoNT/A in rodent models of pain 
 
At first, the anti-nociceptive effects of BOTOX® were assumed to be the result of its effect on 
relaxing hyper-excitable skeletal muscle, but reports from patients with painful cervical dystonia 
showed reductions in pain scores after BOTOX® treatment without accompanying improvements 
in head posture (Tarsy and First, 1999). These findings implied that the neurotoxin could potentially 
act on nociceptors and not just at the neuromuscular junction. BoNT/A has been shown to gain 
access to these neurons in vitro and cleave SNAP-25 (Meng et al., 2007), indicating that BoNT/A 
could inhibit the release of pro-inflammatory neuropeptides from nociceptors at the site of 
injection, inhibiting neurogenic inflammation and peripheral sensitisation. BoNT/A and BOTOX® 
have been shown to inhibit the release of a number of different neurotransmitters in vitro, including 
CGRP, glutamate and substance P (Durham et al., 2004, McMahon et al., 1992, Welch et al., 2000). 
These three molecules are well known pain mediating neurotransmitters and neuropeptides, with 
their inhibition likely to play a role in the reduction of pain. Secondly, BoNT/A is reported to prevent 
induced upregulation of the receptor TRPV1 and TRPA1 to the plasmalemma in cultured sensory 
neurons (Meng et al., 2016). Both of these receptors are well characterised as nociceptive 
transducers (Julius, 2013) and are upregulated by TNFα and NGF in peripheral sensitisation (Ji et 
al., 2002, Meng et al., 2016) which is crucial in the development of chronic pain in inflammatory 
conditions such as rheumatoid arthritis. By potentially preventing the upregulation of these 
channels and inhibiting the release of pain mediators such as CGRP, it’s no surprise that BoNT/A 
and BOTOX® are effective in relieving hypersensitisation in a number of animal models (Pavone and 
Luvisetto, 2010).  
The first reports of BOTOX®-induced anti-nociceptive effects in a rodent pain model were reported 
by Cui et al. (2004) where they tested intra-plantar injections of the neurotoxin complex as a 
prophylactic intervention to reduce formalin-induced pain. Pre-injection of BOTOX® into the hind-
paws of rats inhibited formalin-induced inflammatory pain behaviour (hind-paw lifting and licking 
behaviour), within 5 hours before injection of formalin into the same hind-paw. BOTOX® was found 
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to still inhibit formalin pain even when injected 12 days before injection of formalin. Pre-injection 
of BOTOX® also inhibited formalin-induced hind-paw oedema and levels of glutamate found in the 
hind-paw extracellular fluid (Cui et al., 2004). These results supported the hypothesis that BoNT/A 
could inhibit peripheral release of mediators of neurogenic inflammation (shown by reduced hind-
paw swelling and inhibition of induced glutamate increases). The authors suggested that inhibition 
of peripheral sensitisation indirectly prevented mechanisms of central sensitisation, contributing to 
the decreases in formalin-induced pain behaviour. Importantly this study also showed that BOTOX® 
had no effect on baseline nocifensive thresholds and thus only affected pain induced by 
sensitisation. These results have been reproduced in rodent models of chronic inflammatory pain, 
particularly the Complete Freunds Adjuvant (CFA) model of knee and ankle pain. Intra-articular 
injections of Dysport® (BoNT/A complex - Ipsen Biopharm Ltd.) into inflamed knee joints was found 
to reduce CFA-induced swelling of the knee at one and two weeks post injection of toxin, and 
reduce CFA increased upregulation of IL-1β in the synovium of the articular cartilage (Yoo et al., 
2014). Intra-articular injections of BOTOX® into CFA inflamed ankle joints inhibited CFA-induced 
hyperalgesia between 5 – 14 days after injection of toxin; the circumference of CFA inflamed joints 
was reduced at 7- and 14-days post toxin intervention. CFA increased levels of TNFα and IL-1β in 
the articular synovium were also reduced by injections of BOTOX® at these same time points (Wang 
et al., 2017c). Interestingly, while the anti-nociceptive effects of BoNT/A injections were 
reproduced in other rodent models of inflammatory pain (capsaicin-induced acute pain and 
Carrageenan sub-acute inflammatory pain), the anti-inflammatory effects were not (Bach-Rojecky 
and Lackovic, 2005). Furthermore, while inhibition of formalin-induced inflammation had been 
present using higher doses of BOTOX® (7 U/Kg), it was not induced by injections of 3.5 U/Kg, yet 
this lower dose was able to inhibit formalin-induced pain. These results suggest a disconnect 
between the anti-inflammatory effects and anti-nociceptive effects of BoNT/A, and possibly that 
inhibition of neurogenic inflammation is not the main mechanism of BoNT/A-induced analgesia.  
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Central anti-nociceptive mechanisms of BoNT/A in rodent models of pain 
 
Substantial work has been performed exploring the effects of BoNT/A neurotoxin or complex 
interventions in other animal models of pain, to identify its anti-nociceptive potential and further 
explore the possible mechanisms of action. It has been suggested that the toxin/complex 
predominantly affects models of pain driven by mechanisms of central sensitisation (Matak and 
Lackovic, 2014), which is reflected in the number of chronic neuropathic pain models treatable by 
BoNT/A or BOTOX®. Intra-plantar injections of BoNT/A or BOTOX® have been found to relieve 
mechanical allodynia (measured by von Frey – refer to Methods, Behaviour assays of 
somatosensory function, von Frey test) in models of peripheral nerve injury, including the spinal 
nerve ligation model (Park et al., 2006), partial sciatic nerve transection (Bach-Rojecky et al., 2005) 
and the chronic constriction injury model (Luvisetto et al., 2007). In models of inflammatory pain 
BoNT/A complex had been injected into the site of inflammation and thus, could act to directly 
inhibit increased propagation of nocifensive signals to the dorsal horn, indirectly preventing central 
sensitisation. However, in rodent neuropathic pain models the toxin was injected distally to the site 
of neuro-inflammation. This means that BoNT/A is not at the origin sites of increased nocifensive 
signalling, which in neuropathic pain can be found at the injured nerve or the DRG, and so cannot 
inhibit the ectopic activity driving neuropathic pain leading to central sensitisation (Costigan et al., 
2009, Campbell and Meyer, 2006, Amir et al., 2005). Despite this limitation, mechanical allodynia 
in these models is still reduced by intra-plantar injections of BoNT/A, distal to sciatic nerve injury 
or DRGs.  Interestingly, following intra-plantar injections of BoNT/A in the CCI rodent model, 
immunohistochemical analysis revealed LC/A cleaved SNAP-25 (SNAP-25A) in the plantar skin from 
the ipsilateral hind-paw, the sciatic nerve, DRG and L4/L5 dorsal horns of the spinal cord, indicating 
potential retrograde transport of BoNT/A (Marinelli et al., 2012). If BoNT/A activity is in fact not 
restricted to the injection site, it may inhibit neuro-inflammation from the injured nerve itself, 
prevent ectopic activity originating at the DRG, or even result in the blockade of neurotransmitter 
release from the central nociceptive terminals. Studies using rodent models of “mirror pain” (pain 
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induced in both hind-paws by injections of acidic saline into gastrocnemius muscle of one hind-
limb) have reported the intriguing observation of a bilateral anti-nociceptive effect from a unilateral 
injection of BOTOX®. In the mirror pain model “ipsilateral” refers to the leg receiving injections of 
acidic saline which induce the model, resulting in hypersensitivity in both hind-paws (ipsilateral and 
contralateral). Injection of BOTOX® into the ipsilateral hind-paw of the mirror pain model reduced 
mechanical allodynia in both hind-paws, yet a contralateral injection of BOTOX® only relieved 
hypersensitivity in the contralateral hind-paw (Bach-Rojecky and Lackovic, 2009). The mechanisms 
of contralateral hypersensitivity are believed to mediated by central sensitisation, since this leg has 
not received injections of acidic saline (Da Silva et al., 2010, Sluka et al., 2001). Therefore, the effect 
of ipsilaterally injected BoNT/A on contralateral allodynia supports the hypothesis of a central 
action of BoNT/A. As contralateral injections of BoNT/A only relieved the contralateral 
hypersensitivity, this indicated the anti-nociceptive effects were not mediated by systemic spread 
of the toxin. The mechanisms in which BoNT/A can relieve symptoms of mirror pain are still unclear 
but the authors have suggested in follow up studies that it may be a result of transcytosis of the 
toxin from the nociceptor terminals in the ipsilateral dorsal horn to the central terminals of 
nociceptors in the contralateral dorsal horn (Bach-Rojecky et al., 2010).  
The hypothesis that the anti-nociceptive effect of BoNT/A is mediated by retrograde transport 
remains a controversial one. While retrograde transport of BoNT/A has been observed in the past 
(Black and Dolly, 1986), it was assumed that this may be a mechanism of toxin degradation, due to 
lack of evidence showing toxin activity in the CNS (Hagenah et al., 1977, Habermann, 1974). Work 
using compartmentalised rat neuron cultures has shown that while SNAP-25A can be detected in 
neuron cell bodies after application to neurites, indicating retrograde transport, this was only 
observed at exceptionally high doses (far greater than those used in animal or human studies). 
Furthermore, inhibition of evoked excitatory postsynaptic potentials was not inhibited by 
application of BoNT/A to the neurite compartment, unless exceeding doses 150,000-fold higher 
than those used in studies testing BoNT/A in rats (Lawrence et al., 2012). Experiments using a highly 
specific antibody for SNAP-25A has shown that BoNT/A activity is only detected in the spinal cord at 
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high doses, likely resulting from systemic spread (Cai et al., 2017). The authors have challenged the 
detection of SNAP-25A in sites distal to the injection site described above (Marinelli et al., 2012) on 
the basis that antibodies used may have lacked specificity. While the antinociceptive mechanisms 
of BoNT/A remained to be fully illuminated, the widespread anti-nociceptive effect across different 
animal and human models highlight its therapeutic importance. 
Limitations of BoNT/A for the treatment of chronic pain 
 
Although Botox has shown great promise in pain management, it is not free from side effects. These 
can include flu like symptoms, pain at the injection site and muscle weakness, but these occur 
infrequently and recover rapidly (Allergan, 2018). Despite the promising results in off label use of 
BOTOX®, most of these studies lack statistical power and the correct study design to satisfy FDA 
requirements (Pirazzini et al., 2017, Matak and Lackovic, 2014). Furthermore, not all patients 
suffering from chronic migraine respond to BOTOX® treatments and the reason for this is still 
unclear (Silberstein et al., 2015). Lastly, due to the extremely high potency of BoNT/A (lethal oral 
doses for humans can be as low as 30 ng) (Dhaked et al., 2010), the amount of BOTOX® that can be 
injected is very limited, reducing its potential as a treatment for chronic pain. Efforts are being made 
worldwide to improve this promising potential therapeutic by understanding its antinociceptive 
mechanism of action and how this can be altered to tailor BoNTs for better pain treatment. 
Developing an improved BoNT chimera for the relief of pain 
 
To overcome the limitations of BoNT/A for the treatment of chronic pain, efforts to improve the 
anti-nociceptive impact of SNAP-25 cleavage were explored. One constraint of LC/A cleavage of 
SNAP-25 is that it is unable to inhibit the release of CGRP from cultured TGNs induced by capsaicin 
stimulation, despite blocking CGRP release induced by bradykinin or K+ depolarisation (Meng et al., 
2007). The authors attributed this limitation to the known ability of increases in intracellular Ca2+ 
to reverse BoNT/A effects (Lundh et al., 1977). Considering the strong role increases in intra-cellular 
Ca2+ play in different pain states (Hagenacker et al., 2008, Latremoliere and Woolf, 2009), this could 
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mean that BoNT/A is unable to completely inhibit increased CGRP release in painful conditions. To 
overcome this, it was envisaged that BoNT/E, whose LC (LC/E) cleaves 26 terminal residues (cleaves 
at residues 180 – 181) from SNAP-25 compared to the 9 terminal residues cleaved by BoNT/A (LC/A 
cleaves at residues 197 - 198) (Chen and Barbieri, 2006), would induce a more stable blockade of 
CGRP release and provide greater antinociceptive benefits. However, BoNT/E lacks the long-lasting 
paralytic action of BoNT/A with patients recovering 4 weeks after injection (Eleopra et al., 1998); 
cultured sensory neurons were also found to be insensitive to BoNT/E (Meng et al., 2009). By 
developing an E/A chimera (BoNT/E di-chain with the /E HC replaced with the HC of BoNT/A) it was 
demonstrated that the LC/E could be redirected into BoNT/E insensitive sensory neurons via the HC 
of BoNT/A. Furthermore, the LC/E that was re-targeted in this fashion also cleaved SNAP-25 
(producing SNAP-25E) and resulted in a blockade of capsaicin-induced CGRP release, unlike LC/A 
(Meng et al., 2009). Despite this progress in successfully re-targeting the superior LC/E into sensory 
neurons and preventing capsaicin-induced CGRP release, the E/A chimera retained the transient 
action of BoNT/E and so was not a suitable improvement over BoNT/A for development as 
treatment for chronic pain. To further develop an E/A chimera for the relief of pain, a method of 
increasing the half-life of LC/E was required. Research by Foran et al. (2003) using cultured sensory 
neurons showed that after co-incubation with both BoNT/A and BoNT/E, SNAP-25E gradually 
diminished while levels of SNAP-25A remained intact, indicating the longer half-life of BoNT/A over 
BoNT/E is not affected by turnover of SNAP-25 (Foran et al., 2003). The longer half-life of BoNT/A 
was eventually found to be a property of the LC/A (Wang et al., 2011a); thus by fusing the LC/E to 
the entire BoNT/A di-chain the longevity of LC/A was expected to be retained while allowing the 
LC/E access into nociceptors for the treatment of chronic pain. To test this hypothesis the chimeric 
protein LC/E-BoTIM/A was designed and produced. This consisted of the LC/E gene tethered to a 
BoNT/A mutant (BoTIM/A- see Fig. 1.5 A), which had a mutation in the gene for LC/A that rendered 
the LC/A inactive (mutation at active site H227 to Y). LC/E-BoTIM/A was found to successfully enter 
sensory neurons in vitro, cleave SNAP-25 and produce SNAP-25E only and inhibit capsaicin-induced 
CGRP release. Unlike the E/A chimera, LC/E-BoTIM/A induced long-lasting paralysis in mice that 
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matched the half-life of BoNT/A yielding a potential therapeutic for chronic pain. LC/E-BoTIM/A 
could significantly reduce the symptoms of capsaicin-induced acute pain in rats, however while 
LC/E-BoTIM/A showed a trend towards further anti-nociceptive activity than BoNT/A, this did not 
reach statistical significance (Wang et al., 2011a). 
To further improve the BoNT chimera for the treatment of chronic pain, it was hypothesised that 
retaining a fully active LC/A instead of a proteolytically inactive mutant such as BoTIM/A would 
preserve more analgesic potential. Thus, LC/E-BoNT/A was designed and produced, which consisted 
of a fully active BoNT/A di-chain with the LC/E tethered to the protein (Fig. 1.5 B). LC/E-BoNT/A, 
like LC/E-BoTIM/A could enter cultured sensory neurons and produced SNAP-25E and inhibited the 
release of capsaicin-induced CGRP release, but also produced SNAP-25A since it’s LC/A retained 
proteolytic activity (Wang et al., 2017a). Next, LC/E-BoNT/A would need to be compared to LC/E-
BoTIM/A and BoNT/A to determine if a chimera retaining an active LC/E and LC/A was a superior 
therapeutic than proteins consisting of a single active LC/E or LC/A only. The rodent pain models 
used to screen the BoNT chimeras are described below. 
 
 
 
 
A B 
Fig. 1.5: Graphical depiction of BoNT chimeras, LC/E-BoNT/A and LC/E-BoTIM/A Schematics of (A) 
LC/E-BoTIM/A, (B) LC/E-BoNT/A structure. HN/A – translocation domain of BoNT/A. HC/A – binding 
domain of BoNT/A. BoTIM/A is a BoNT/A mutant with LC/A mutation at active site H227 to Y. 
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Selection of rodent pain models for testing of BoNT derived therapeutics 
Rodent model of peripheral nerve injury pain 
 
The spared nerve injury (SNI) model of neuropathic pain was first established in rats by Decosterd 
and Woolf (2000); it is induced by surgically revealing the point where the three terminal branches 
(sural, tibial and common peroneal nerves) of the sciatic nerve intersect, cutting and then ligating 
the tibial and peroneal nerves, “sparing” the sural nerve. This model was developed to investigate 
the roles that injured and nearby un-injured nerves play in the development of neuropathic pain 
(Decosterd and Woolf, 2000). Unlike models where all innervation of the hind-paw is axotomized 
(Wall et al., 1979), which are only reflective of conditions such as phantom-limb pain, the SNI model 
has the benefit of being a model of partial nerve injury, more reflective of clinical peripheral nerve 
injury cases. The SNI model has been found to be a more reproducible model of pain induced by 
peripheral nerve injury due to the relative ease of the surgery compared to other neuropathic pain 
models (Kumar et al., 2018). A rapid onset of prolonged mechanical and cold allodynia in the 
ipsilateral hind-paw regions innervated by the spared sural, and the saphenous nerves is another 
advantageous characteristic of the model. Based on the reliability of the model, the clinical 
relevance of it being a model of partial nerve injury and the long-lasting hypersensitivity induced, 
the SNI model was selected to test the therapeutic potential of BoNT derived therapeutics in 
neuropathic pain. 
Rat model of Varicella zoster virus-induced neuropathic pain 
 
As neuropathic pain can result from such a broad range of disease mechanisms such as infection, 
mechanical trauma, cancer, spinal cord injury etc. (Costigan et al., 2009), it was necessary to 
ascertain if BoNT chimeras proved effective in different neuropathic pain pathologies. Post-herpetic 
neuralgia (PHN) is a painful condition occurring after adult reactivation of the Varicella zoster virus 
(Vzv), which can develop into a chronic pain condition (Tontodonati et al., 2012).  Reports have 
shown that BOTOX® can reduce visual analogue scale pain scores (patients score pain on a scale of 
1-10), improve sleep quality and reduce opioid co-treatment in PHN patients, compared to patients 
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treated with lidocaine or saline (Xiao et al., 2010, Apalla et al., 2013). Therefore, it was decided to 
evaluate if BoNT variants could reduce the painful symptoms of the Vzv rat model of PHN. Injections 
of Vzv infected cells into the hind-paws of rats are reported to induce Vzv infection of the DRG 
(Sadzot-Delvaux et al., 1990) and results in mechanical and heat hypersensitivity, lasting in excess 
of 60 days (Dalziel et al., 2004, Jaggi et al., 2011); it is the only rodent model of PHN available. The 
symptoms of Vzv-induced mechanical hypersensitivity in rodents are relieved by several analgesics, 
including morphine, ibuprofen and the anti-convulsant gabapentin (a common treatment for 
neuropathic pain) (Hasnie et al., 2007). 
Complete Freunds Adjuvant (CFA)-induced rat model of chronic, inflammatory, joint pain 
 
It is hypothesised that the anti-nociceptive effect of BoNT/A could be mediated by its inhibition of 
the release of pro-algesic and pro-inflammatory mediators from peripheral nociceptors. This was 
first suggested by Cui et al. (2004) who demonstrated that intra-plantar pre-injection of BOTOX® 
could inhibit formalin-induced nocifensive behaviour and swelling. Interestingly, this anti-
inflammatory effect was only present at a dose of 7 U/Kg while anti-nociceptive effects were 
observed at doses as low as 3.5 U/Kg, indicating that a greater amount of BOTOX® is required to 
have an anti-inflammatory effect (Cui et al., 2004). Unexpectedly, this anti-inflammatory effect is 
not present in other models of inflammatory pain as intra-plantar injections of BOTOX® do not 
reduce carrageenan or capsaicin-induced inflammation (Bach-Rojecky and Lackovic, 2005). These 
reports indicate that BOTOX® may have a potential anti-inflammatory effect in specific 
inflammatory pain conditions, although the mechanisms behind a differential anti-inflammatory 
effect between models is unclear. Pain from rheumatoid arthritis has been successfully treated with 
injections of BOTOX® (Mahowald et al., 2006, Singh et al., 2009, Mahowald et al., 2009), and an 
anti-inflammatory effect of Dysport® BoNT/A complex had also been shown in the CFA model of 
chronic inflammatory pain (Yoo et al., 2014). Since LC/E-BoNT/A and LC/E-BoTIM/A can induce a 
more stable block of capsaicin-induced release of CGRP from sensory neurons in vitro (Wang et al., 
2011a, Wang et al., 2017a), it was hypothesised that these chimeras may show a more profound 
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anti-nociceptive and anti-inflammatory effect than BoNT/A in the CFA rat model. Intra-articular 
injections of CFA into the knee induce long-lasting inflammation, impaired weight-bearing ability of 
the injected joint (measured by the incapacitance test) (Wilson et al., 2006) and mechanical 
hyperalgesia measured by the pressure application method (PAM) (Barton et al., 2007). 
Importantly, treatment of the model with the NSAID rofexib can reduce CFA-induced hyper-
sensitivity and CGRP up-regulation in the DRG (Staton et al., 2007). If BoNT/A can inhibit the release 
of up-regulated CGRP from peripheral neurons to reduce CFA-induced inflammation, then LC/E-
BoNT/A should prove a more efficacious inhibitor of CFA-induced pain and inflammation. 
Formalin rat model of acute, inflammatory pain 
 
Injections of diluted formalin into the hind-paw of rodents induces a distinct bi-phasic behaviour 
profile. Phase 1 (0-5 min) is driven by direct activation of nociceptors by formalin, attributed to 
TRPA1 activation (Fischer et al., 2014, McNamara et al., 2007), which can be inhibited by centrally 
acting analgesics such as morphine or codeine (Hunskaar and Hole, 1987). Consistent with the 
inability of BoNT/A to block normal nociception, BoNT/A complex has no effect on phase 1 of the 
formalin test, unless injected centrally  (Lee et al., 2011b). Following phase 1 there is a brief (5-15 
min) phase of reduced nocifensive behaviour called the “interphase”, which is mechanistically still 
not understood (Fischer et al., 2014). Following the interphase is phase 2 of nocifensive behaviour, 
which is believed to be driven by increased peripheral nocifensive activity and central sensitisation 
(Fischer et al., 2014, Latremoliere and Woolf, 2009). The inflammatory reaction to formalin plays a 
role in driving peripheral sensitisation of neurons (Parada et al., 2001) and local application of 
lidocaine can inhibit both phase 1 and phase 2 nocifensive behaviours (Dallel et al., 1995), indicating 
that incoming peripheral activity is required to initiate and maintain both phase 1 and phase 2 
behaviour. The relentless incoming nocifensive signals from the formalin tissue injury leads to 
phosphorylation of dorsal horn NMDA receptors mediated by Src kinase; when Src was decoupled 
from NMDA receptors, phase 2 behaviours were reduced while normal nocifensive behaviours 
were retained (Liu et al., 2008). 
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Capsaicin rat model of acute inflammatory pain 
 
Intra-plantar injection of capsaicin induces short lasting nocifensive behaviour (most intense in first 
3 minutes after injection) with longer lasting hypersensitivity to heat (~ 45 min) and mechanical 
stimuli (~ 4 hours) (Gilchrist et al., 1996). The model is driven by binding of capsaicin to TRPV1, 
directly activating nociceptors to induce the sensation of burning pain and the peripheral release 
of CGRP from the nociceptors, resulting in capsaicin-induced flare. The heat hyperalgesia is 
mediated by peripheral sensitisation of TRPV1 while secondary mechanical hyperalgesia 
surrounding the injection site is believed to be mediated by activity dependent central sensitisation 
(O'Neill et al., 2012). Centrally released SP can bind to NK1 resulting in long-lasting membrane 
depolarisation, contributing to temporal summation and unblocking the Mg2+ block on NMDA 
receptors (Latremoliere and Woolf, 2009, Murase et al., 1986, Sivilotti et al., 1993). 
Project aims: 
 
The overall aim of this project was to investigate if BoNT therapeutics including LC/E could relieve 
the symptoms of acute or chronic pain in rats. The LC/E was expected to have a superior anti-
nociceptive effect over currently used BoNT/A, since LC/E can inhibit the release of CGRP from 
sensory neurons when stimulated with capsaicin. However, the half-life of LC/E was known to be 
far less than that of LC/A (Eleopra et al., 1998). To overcome this issue, the chimera LC/E-BoTIM/A 
was developed which tethered an active LC/E to a proteolytically inactive BoNT/A mutant, BoTIM/A. 
While this new toxin could inhibit the release of capsaicin-induced CGRP release from sensory 
neurons in vitro, and retained the longer activity of LC/A, it’s anti-nociceptive effect on capsaicin-
induced pain was not significantly greater than that of BoNT/A (Wang et al., 2011a). To further 
improve this chimera, the activity of LC/A was retained and the chimera LC/E-BoNT/A was 
produced. LC/E-BoNT/A also retained the longer paralytic action of BoNT/A while still inhibiting 
capsaicin-induced CGRP release in vitro (Wang et al., 2017a). This was to be compared to LC/E-
BoTIM/A in order to identify if the inclusion of two active LCs would increase anti-nociceptive 
potency. 
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To determine the most efficacious potential therapeutic for further screening in pain models, both 
LC/E-BoTIM/A and LC/E-BoNT/A were to be tested in a rodent chronic pain model. Since 
neuropathic pain represents patients more resistant to conventional analgesics (Dworkin et al., 
2007), the SNI model of chronic neuropathic pain was selected to identify the more promising 
therapeutic candidate between LC/E-BoTIM/A and LC/E-BoNT/A. As BOTOX® and 150-kDa BoNT/A 
had been shown to have well documented effects in rodent models of neuropathic pain (Luvisetto 
et al., 2007, Park et al., 2006), it was expected that both chimeras would have superior effects due 
to the active LC/E. Furthermore, a comparison of the two chimeras would discern if the addition of 
an active LC/A provided any benefits over LC/E-BoTIM/A.    
Once the top priority chimera between LC/E-BoNT/A or LC/E-BoTIM/A was selected for further 
testing, the second goal was to establish what effect the molecule would have in a virus-induced 
model chronic neuropathic pain, representing a different form of neuropathic pain. For this 
purpose, the Vzv model was to be tested to confirm its viability as a model of neuropathic pain and 
then used to screen the anti-nociceptive effects of LC/E-BoTIM/A or LC/E-BoNT/A. Following testing 
in the Vzv rat model, the candidate therapeutic was to be screened in the CFA model of chronic 
inflammatory pain. This was to compare the anti-nociceptive effects of the chimera in chronic 
neuropathic and inflammatory pain. Lastly, rat models of acute inflammatory pain (intra-plantar 
injections of formalin and capsaicin) would be used to investigate the prophylactic effects of the 
neurotoxin on acute pain induction and inflammation. Testing the chimera in all these different 
models would allow for a comprehensive investigation into the interventional and prophylactic 
effects on models of both neuropathic and inflammatory pain. 
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Chapter 2 - Materials & Methods  
Materials 
Buffers 
 
0.1 M Phosphate buffer:  
95 mL of 0.1 M NaH2PO4H2O mixed with 405 mL of 0.1 M Na2HPO42H2O, made up to 1 L 
with dH2O, pH 7.4 
Homogenisation buffer:  
50mM HEPES, 1mM EDTA, 150mM NaCl, 10% (v/v) glycerol, 1% (v/v) Igepal, 0.5% (w/v) 
sodium deoxycholate, pH to 7.5. Immediately before adding plantaris muscle to buffer, 
protease inhibitor cocktail (1:100), phosphatase inhibitor cocktail (1:100) and Benzonase® 
(endonuclease preparation 1:1000) were added to the buffer. 
MOPS running buffer: 
250 mM MOPS, 250 mM Tris, 5 mM EDTA,0.1% SDS, pH 7.0 
TBS:  
 10 mM Tris-HCl, 100 mM NaCl, pH 7.4 
TBS blocking/incubation buffer: 
 10mM Tris-HCL, 100 mM NaCl, 5% (w/v) BSA, pH 7.4 
In vitro potency assay buffer: 
 20 mM HEPES, 100 mM NaCl, 10 µM ZnCl2, 5 mM dithiothreitol, 10 µg/mL BSA, pH 7.4 
Immunohistochemistry blocking buffer: 
 PBS with 0.3% (v/v) Triton X-100 and 5% (v/v) goat serum 
Immunohistochemistry incubation buffer: 
 PBS with 0.1% (v/v) Triton X-100 and 1% (v/v) goat serum 
Formaldehyde fixative solution: 
 4% (w/v) paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 
Normal saline: 
 0.9% (w/v) NaCl in water, pH 7.4 
Heparinised saline: 
 5000 IU heparin in normal saline, pH 7.4 
Injection vehicle 1:  
 0.5% (w/v) BSA, normal saline 
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Injection vehicle 2: 
 0.05% (w/v) HSA, 10 µM ZnCl2, normal saline 
Capsaicin: 
0.1% (v/v) capsaicin, 5% (v/v) ethanol, 5% (v/v) Tween 80, normal saline 
Formalin: 
 5% (v/v) formalin, normal saline 
Equipment and chemicals 
 
EQUIPMENT SUPPLIER 
INCAPACITANCE TESTER Linton, UK 
TISSUE HOMOGENISER, IKA®-T10 IKA, Germany 
MICROSCOPE - OLYMPUS IX71  Olympus, Mason Technology Ltd. Ireland 
OLYMPUS TH4-200 HALOGEN LAMP POWER SUPPLY 
UNIT 
Olympus, Mason Technology Ltd. Ireland 
OLYMPUS U-RFL-T REFLECTED FLUORESCENCE 
SYSTEM 
Olympus, Mason Technology Ltd. Ireland 
G: BOX CHEMI-16 GEL DOCUMENTATION SYSTEM Syngene, Fisher-Scientific, Ireland 
PIERCE™ POWER BLOTTER Thermo-Fisher, Ireland 
HARGREAVES APPARATUS Ugo Basile, Italy 
HOT/COLD PLATE Ugo Basile, Italy 
PRESSURE APPLICATION MEASUREMENT (PAM) Ugo Basile, Italy 
RANDALL SELITTO Ugo Basile, Italy 
ROTAROD Ugo Basile, Italy 
VON FREY APPARATUS Ugo Basile, Italy 
DIGITAL CALLIPERS World Precision Instruments, UK  
 
COMPANY Country Web address 
SIGMA ALDRICH Ireland www.sigmaaldrich.com/ireland 
BIO-SCIENCES Ireland www.biosciences.ie 
BOC Ireland www.boconline.ie 
LENNOX Ireland www.lennox.ie 
THERMO-FISHER Ireland www.fishersci.ie 
VWR Ireland www.vwr.ie 
ALOMONE Israel www.alomone.com 
UGO BASILE Italy www.ugobasile.com 
ATCC UK www.lgc-standards-atcc.org 
ENVIGO UK www.Envigo.com 
JACKSON IMMUNORESEARCH UK www.jieurope.com 
MERCK MILLIPORE UK www.merckmillipore.com./ie 
OLYMPUS UK www.olympus.co.uk 
WPI UK www.wpi-europe.com/ 
 
 
Table 2.1 Equipment & suppliers 
Table 2.2 List of suppliers 
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REAGENTS/CHEMICALS COMPANY PRODUCT 
CODE 
CAPSAICIN Alomone, Israel  C-125 
MRC-5 CELLS ATCC, LGC, UK CCL-171 
VZV ELLEN STRAIN ATCC, LGC, UK VR-1367 
HOECHST 33342 Biosciences, Ireland H3570 
MEDICAL OXYGEN 99% BOC, Ireland 101-F 
IMMOBILON WESTERN CHEMILUMINESCENT 
HRP SUBSTRATE 
Fannin, Bio-Rad, UK WBKLS0500 
PRECISION PLUS PROTEIN™ ALL BLUE 
PRESTAINED PROTEIN STANDARDS 
Fannin, Bio-Rad, UK 1610373 
HUMAN SERUM ALBUMIN (HSA) Irvine Scientific, Ireland 9988 
ETHANOL Lennox, Ireland CC458600 
BENZONASE® Merck Millipore, Ireland 71205-3 
BOVINE SERUM ALBUMIN (BSA) Sigma Aldrich, Ireland B8655 
CFA Sigma Aldrich, Ireland   F5881 
DITHIOTHREITOL Sigma Aldrich, Ireland D0632 
EDTA Sigma Aldrich, Ireland EDS 
FLUOROMOUNT™  Sigma Aldrich, Ireland  F4680 
FORMALDEHYDE 37% (W/W) Sigma Aldrich, Ireland 252549 
GLYCEROL Sigma Aldrich, Ireland G5516 
GOAT SERUM Sigma Aldrich, Ireland  G9023 
HEPARIN Sigma Aldrich, Ireland  H3393 
HEPES Sigma Aldrich, Ireland H3375 
IGEPAL Sigma Aldrich, Ireland I3021 
MOPS Sigma Aldrich, Ireland M1254 
NACL Sigma Aldrich, Ireland  S3014 
PARAFORMALDEHYDE Sigma Aldrich, Ireland  P6148 
PBS Sigma Aldrich, Ireland  D8662 
PHOSPHATASE INHIBITOR COCKTAIL Sigma Aldrich, Ireland  P5726 
PROTEASE INHIBITOR COCKTAIL Sigma Aldrich, Ireland  P8340 
SDS Sigma Aldrich, Ireland L3771 
SODIUM DEOXYCHOLATE Sigma Aldrich, Ireland D6750 
SODIUM PHOSPHATE MONOBASIC DIHYDRATE Sigma Aldrich, Ireland 71500 
SODIUM PHOSPHATE MONOBASIC 
MONOHYDRATE 
Sigma Aldrich, Ireland 71507 
SUCROSE Sigma Aldrich, Ireland  S7903 
TRIS Sigma Aldrich, Ireland T6066 
TRIS-HCL Sigma Aldrich, Ireland T5941 
TRITON X Sigma Aldrich, Ireland  T8787 
TWEEN-80 Sigma Aldrich, Ireland  P1754 
ZNCL2 Sigma Aldrich, Ireland 208086 
4X LITHIUM DODECYL SULPHATE SAMPLE 
BUFFER (LDS) 
Thermo-Fisher, Ireland B0007 
TISSUE-TEK® OPTIMUM CUTTING TEMPERATURE 
COMPOUND (O.C.T) 
VWR, Ireland  25608-930 
BUPRENORPHINE Veterinary prescription   
EUTHATAL (SODIUM PENTOBARBITAL 200 
MG/ML) 
Veterinary prescription 
 
ISOFLURANE Veterinary prescription   
  Table 2.3 Chemicals, reagents and suppliers 
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Antibodies 
 
PRIMARY ANTIBODIES DILUTION SPECIES RAISED COMPANY PRODUCT CODE 
ANTI C-FOS 1:5000 Rabbit  Merck Millipore ABE457 
ANTI-VARICELLA -
ZOSTER VIRUS 
ANTIBODY, 
GLYCOPROTEIN I 
1:100 Mouse Merck Millipore MAB8612 
ANTI-SNAP 25 1:5000 Rabbit Sigma-Aldrich S9684 
ANTI Α-TUBULIN 1:5000 Mouse Sigma-Aldrich T5168 
 
 
SECONDARY 
ANTIBODIES 
DILUTION SPECIES 
RAISED IN 
COMPANY PRODUCT 
CODE 
CONJUGATE 
ANTI-RABBIT  1:500 Goat Thermo-
Fisher 
A-11008 Alexa Fluor 
488 
ANTI-MOUSE 1:1000 Goat Thermo-
Fisher 
 A2114 Alexa Fluor 
488 
ANTI-MOUSE 1:5000 Donkey Jackson 
Immunorese
arch Europe 
715035150 Horseradish 
peroxidase 
(HRP) 
ANTI-RABBIT 1:10000 Donkey Jackson 
Immunorese
arch Europe 
711035152 Horseradish 
peroxidase 
(HRP) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.4 Primary antibodies 
Table 2.5 Secondary antibodies 
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Methods 
In vivo study design 
Animals and study approval 
 
Male Sprague Dawley rats and female Hsd: OLA TO mice were purchased from Envigo, UK (formerly 
Harlan) or bred in the Dublin City University (DCU) Bio-Resource Unit. Rats and mice were housed 
in an approved Specific Pathogen Free Bio-Resource Unit at DCU. Animals were group-housed (no 
more than 5 per cage) in Techniplast, double-decker, seal safe +, individually ventilated cages, with 
food and water available ad libitum. Bedding and environmental enrichment were provided, using 
sizzle-pet nesting material and gold chip sawdust supplied by LBS Biotechnology (UK) Room 
temperature was maintained between 19 and 22 °C and relative humidity from 45 to 65%, with a 
12 h light/12 h dark schedule (lights on from 08:00–20:00) operated. All procedures were approved 
by the University Research Ethics Committee and authorised by the Health Products Regulatory 
Authority (HPRA), Ireland, thereby, fulfilling the requirements of Directive (2010)/63/EU and the 
National Statutory Instrument S.I. No 543 of 2012 (as amended by S.I. No. 434 of 2013 and S.I. No. 
174 of 2014) on the protection of animals used for scientific purposes. Housing and regulatory 
details were the same for the entire report and will not be repeated for each section. Animal 
weights are detailed in relevant figure legends. 
Randomisation and blinding 
 
Age/weight-matched animals were randomly assigned to treatment groups by the random 
permuted blocks method. Experimenters carrying out injections and/or behavioural assessments 
were blinded to the treatment of each animal by coding of syringes by an independent researcher. 
Each cage housed rats with randomised treatments. Treatment codes were available to the 
researcher at the end of the study. Animals were identified by tail markings, each with a unique 
number written on the tail in permanent marker. It was not possible to blind the researcher to 
which animals were in a sham or pain model, due to the distinctive phenotypes of the different 
models (joint swelling, paw curling etc.). Final sample sizes are detailed in the figure legends. 
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Expression and characterisation of BoNTs 
Production of BoNTs 
 
Experimentation on recombinantly expressed BoNTs has been approved by the Environmental 
Protection Agency of Ireland and performed under containment level 2, according to a detailed and 
strictly enforced safety protocol. All toxins were produced by Drs Om Prakash Edupuganti, Gary 
Lawrence and Seshu Kazar (DCU); full details of toxin construction, expression and purification can 
be found in the following publications (Wang et al., 2017a, Wang et al., 2011a, Dolly et al., 2011, 
Wang et al., 2008). Briefly, synthesised genes for single chain BoNT/A, LC/E-BoTIM/A (mutation at 
active site H227 to Y) or LC/E-BoNTA were cloned into a prokaryotic expression vector, expressed in 
E. coli BL21 (DE3) strain and purified by Immobilized Metal Affinity Chromatography. Nicking of the 
single chain to an active di-chain was accomplished by incubation in thrombin (1 U/mg of toxin); 
this was monitored by SDS-PAGE and followed by Coomassie protein staining and Western blotting 
using antibodies for BoNT/A and LC/E. Three different batches of LC/E-BoNT/A, one batch of LC/E-
BoTIM/A and BoNT/A were tested in the project. The three batches of LC/E-BoNT/A include an 
initial “lab sample” that was only used in Fig. 3.1. Consecutive experiments with LC/E-BoNT/A were 
performed with the refined “batch 1”, which had been tested and found to have identical anti-
nociceptive effects as the lab sample in the rat SNI model and an equivalent rat MaxTD dose (Wang 
et al., 2017a). Following observed decreases in toxin activity with batch 1, a further refined “batch 
2” of LC/E-BoNT/A was used. 
Potency testing of batch 2 of LC/E-BoNT/A 
 
Study management was conducted by Dr Tom Zurawski and Dr Gary Lawrence (DCU). Non-lethal 
end-points have been suggested as a refinement for the mouse LD50 in efforts to replace it for 
potency testing of BoNT/A (NIEHS, 2008), and were required by the HPRA to conduct potency 
testing of BoNTs. The humane endpoints used included “severe indrawn scaphoid abdomen with 
respiratory distress, or weight loss of 20% versus pre-study weight”, and were deemed suitable for 
research purposes to establish BoNT potency estimates. Intra-peritoneal injections of different 
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concentrations of batch #2 LC/E-BoNT/A, or vehicle (0.5% HSA, 0.9% NaCl), in a volume of 0.2 mL 
were administered to female Hsd: OLA TO mice. The mice were checked every 3 hours for signs of 
toxicity, then checked hourly after the first signs of distress (e.g. ocular/nasal discharge, rough coat, 
rapid breathing etc.) over four days. Animals were euthanised once they reached the endpoints 
listed above, or after four days. The number of mice reaching humane endpoints was used to 
calculate an estimated minimum lethal dose (LD50). 
Injections of BoNTs or buprenorphine 
Intra-plantar injections of BoNTs or vehicle 
 
Animals were briefly anaesthetised with 3% inhalable isoflurane in 99% medical oxygen at flow rate 
of 1 l/min (this anaesthesia protocol was used for all procedures requiring anaesthesia). Injections 
of 20 µl BoNTs or vehicle (0.5% BSA, normal saline or 0.05% HSA, 10µM ZnCl2, normal saline) were 
conducted four-five days before formalin injection (Cui et al., 2004), four days before capsaicin or 
seven days after SNI. Vehicle details are noted in figure legends if they included BSA or HSA. LC/E-
BoNT/A, LC/E-BoTIM/A, BoNT/A or vehicle were loaded into 0.3 mL disposable insulin syringes with 
a 29 G needle and injected intradermally into the plantar surface of the right hind paw. Animals 
were rehoused in their clean cages following injections and monitored daily for the first week after 
procedure and at least once a week after this. 
Intra-articular injections of BoNTs or vehicle 
 
Rats were briefly anaesthetised; the knee was flexed and the joint palpated until the patella tendon 
was felt to bend slightly under pressure. BoNTs/vehicle were administered using 0.3 mL syringes 
with a 29 G needle.  The needle was then inserted 2mm into this space until resistance was noted, 
and BoNTs (50 µl) or vehicle (0.5% BSA, 0.9% NaCl) were delivered into the articular space. If 
injections were performed on CFA inflamed knees, then the needle was inserted until the first sign 
of resistance was noted. Animals were rehoused in their clean cages following injections and 
monitored daily for the first week after procedure and at least once a week after this. 
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Sub-cutaneous (systemic) administration of buprenorphine 
 
Buprenorphine is an opioid modulator, which acts as an agonist for the µ-opioid receptor and an 
antagonist for the /κ-opioid receptors (Coe et al., 2019, Cox et al., 2015). It is an highly potent and 
consistent treatment for moderate to severe acute pain, such as immediate postoperative pain 
(Harcus et al., 1980) and sub-cutaneous injections of 0.1-0.5 mg/kg of Buprenorphine have 
successfully relieved capsaicin-induced pain in rats (Barrett et al., 2003).  Buprenorphine at doses 
of 0.1-0.2 mg/Kg in 200 µl normal saline was loaded into a 1 mL syringe with a 25 G needle and 
injected sub-cutaneously into the nape of the conscious, restrained rat, 30 minutes before intra-
plantar injection of capsaicin.  
Determination of maximum tolerated dose (MaxTD) of all batches of BoNT/A and LC/E-
BoNT/A 
Rats used for dosing studies were tested (using the assays described below) before intra-plantar or 
intra-articular injections of BoNTs to establish baseline behaviour, and then up to 7 days after 
injections of BoNTs to record onset of paralysis, and the animal’s recovery. MaxTD doses are 
required to identify the maximum amount of BoNTs that can be injected without inducing motor 
paralysis that would impair behavioural testing in models of pain, which rely on the rat’s ability to 
withdraw the treated hind-paw/limb. 
Rotarod test 
 
The rotarod is a test to assess locomotor impairment in animals. The test consists of placing animals 
on a suspended, motorised cone. Rats walk to attempt to stay on the device as it rotates; impaired 
motor function is reflected by a reduction in the time it takes to fall during a testing period of a 
fixed length. Rats were trained at a fixed speed of 15 rpm until they could successfully complete 
three sequential trials of 180 s. On testing days, rats were placed on a rotarod running at a fixed 
speed of 15 rpm and the latency to fall was recorded, 180 s was used as a cut off. Rats were given 
a break of at least 3 minutes per trial. Each rat underwent three trials per testing session, which 
were averaged to give the mean latency to fall in seconds.  
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Digit abduction score (DAS) 
 
 The DAS is a measure of hind-paw paralysis following intra-plantar or intra-articular injection of 
BoNTs. Rats were restrained as depicted in Fig. 2.1 A, then a drop was simulated by flipping the rat 
90 ° (head descending) to the final position in Fig. 2.1 B. This causes a digit abduction reflex as the 
rat prepares to land in response to the drop; muscle paralysis is quantified by the number of digits 
that can abduct. The DAS response was scored based on Fig. 2.1 C (Broide et al., 2013); for each 
digit that was unable to abduct after induction of the startle reflex, the DAS score increased. A score 
of 0 represented no paralysis while a value of 4 indicated maximum paralysis of the hind paw. Rats 
underwent three DAS trials with a break of 1 minute in between each trial and the responses were 
averaged to give a final score. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1 Rat DAS scoring method (A) Starting position of DAS test, (B) Simulated drop that causes 
digit abduction reflex. (C) Scoring system for paralysis of digit abduction, onset of digit paralysis 
varies depending of site of injection of BoNT/A complex, injection sites noted in each image as 
G = Gastrocnemius or TA = Tibialis anterior muscles (Broide et al., 2013). 
A B C 
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Kondziela inverted screen test 
 
 This test of grip strength is a laboratory standard for assessing fore-limb and hind-limb strength in 
rodents (Golli et al., 2016). Animals were placed on a wire screen mesh which was then rotated so 
the rat’s head descended last. Bedding was placed under the rat to prevent injury after falling. The 
latency to fall from the screen mesh was recorded in seconds and each rat received 3 trials, with a 
break of at least 3 minutes between each trial.   
Visual assessment score 
 
Inspection of animal health was performed based on published scoring criteria (Hendriksen et al., 
1999), to assess if the rats were suffering any adverse side effects from toxin injections. Briefly, 
animal monitoring sheets were used to record any potential adverse effects of procedures on 
animals and these were quantified as a health score using the scoring table below (Table 2.6). The 
scores were averaged to give an overall health score and plotted as a time course relative to toxin 
injection. 
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ANIMAL APPEARANCE NOTES SCORE 
 
Normal 0 
 
Rough coat 1 
 
Piloerection, ocular and/or nasal discharge 2 
 
Piloerection, hunched posture 3 
 
All of the above, orbital tightening. 4 
ANIMAL BEHAVIOUR NOTES SCORE 
 
Normal 0 
 
Lack of exploratory/inquisitive behaviour 1 
 
Isolated, reduced mobility but alert 2 
 
Restless or immobile, unresponsive. 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.6 Rat health score chart: Side effects induced by BoNTs were graded using a scoring 
system adapted from (Hendriksen et al., 1999). BoNT induced side effects are visible in the 
animal’s appearance and behaviour. These can include patches of rough/unkempt fur in rats 
which are indicative of a lack of grooming, piloerection (raised fur/“goosebumps”) over entire 
body indicative of stress, ocular and nasal discharge indicative of a lack of grooming, and an 
abnormal hunched posture which is a sign of discomfort and stress. Orbital tightening 
(narrowing of the eyes) is also indicative of discomfort in rats. Healthy rats typically 
demonstrate exploratory and inquisitive behaviour, reductions in this behaviour are signs of 
discomfort induced by BoNTs. Reductions in mobility and isolation from cage-mates indicate 
discomfort and potential weakness from injection of BoNTs. Restless behaviour (struggling 
during handling) is indicative of high stress while immobility and unresponsiveness would result 
from BoNT induced side effects. 
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Pain models 
Preparation and injection of viral inoculum 
 
The Ellen strain of Vzv (ATCC® VR-1367™) was selected to induce the model as it was the most 
readily available and major differences in inducing hypersensitivity when compared to the Dumas 
strain had not been reported (Hasnie et al., 2007). This standard laboratory strain was propagated 
on human primary embryonic lung fibroblast cells (MRC-5 cells, ATCC® CCL-171™) by Dr Tom 
Zurawski according to published methods (Hasnie et al., 2007). Briefly, MRC-5 cells were inoculated 
with Vzv and harvested once the cells displayed an 80% cytopathic effect (syncytial rounding and 
sloughing) after inspection by microscopy. The infected cells were scraped from the flasks and the 
cell suspension was centrifuged at 1000 X g for 5 mins at room temperature. The supernatant was 
discarded, and the pellet re-suspended in 4 °C sterile PBS to be used for injections. 
Animals were briefly anaesthetised and intra-dermally injected with 50 µl of PBS containing 1 × 104 
– 3.9 × 106 infected cells into the mid plantar area of the right hind paw. Sham animals received an 
injection of equal amounts of uninfected cells and all treated rats were returned to their housing 
cages after the procedure. Animals were monitored at least twice a week after injection of viral 
inoculum for any adverse health effects. 
Intra-articular injections of CFA 
 
Rats were briefly anaesthetised and CFA (Sigma Aldrich) was loaded into 1 mL syringes with 25 G 
needles. The right hind limb was shaved to reveal the skin of the right knee joint, the knee was 
flexed and the joint palpated until the patella tendon was felt to bend slightly under pressure. 
Before injection the knee was swabbed with a 70% isopropyl or ethanol alcohol wipe. The needle 
was then inserted 2mm into this space until resistance was noted, and 150 µl of CFA was slowly 
delivered into the joint cavity. BoNTs (50 µl) or vehicle (0.5% BSA, 0.9% NaCl) were administered 7 
days after injection of CFA. Animals were monitored daily for the first week after procedure and at 
least once a week after this. 
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Formalin testing 
 
 Nocifensive behaviour induced by formalin was recorded on a raised Perspex platform above a 
video camera, with rats placed in a box with blacked out walls and a clear lid for a dimly lit 
environment (light intensity within testing chamber recorded as 57 lx). One day prior to testing, 
rats were acclimatised to the chamber for 20 minutes. On the testing day rats were placed into the 
recording chambers for 5 minutes before injections. Formalin was prepared by diluting 100% 
formalin (equal to 37% formaldehyde) in normal saline (0.9% NaCl) to a final concentration of 5%. 
Diluted formalin (50 µl) was loaded into 0.5 mL disposable insulin syringes with 29 G needles, then 
an intra-plantar injection administered to the right hind paw of lightly restrained conscious rats. 
Nocifensive behaviour was recorded for 60 minutes after injections and videos of the behaviour 
were scored by a single blinded investigator. Nocifensive behaviour was taken as the time spent 
licking and lifting the paw along with the number of flinches. These were recorded in 5-minute time 
bins and plotted.  
Induction of capsaicin model 
 
 Nocifensive behaviour induced by capsaicin was recorded in the same chamber as the formalin 
test. Acclimatisation was conducted in the same fashion as the formalin test protocol. On the 
testing day, rats were placed into the recording chambers for 5 minutes before injections; 0.1% 
capsaicin was prepared in a vehicle consisting of 5% Tween-80, 5% ethanol and 0.9% NaCl and 20 
µl loaded into 0.3 mL disposable insulin syringes with 29 G needles, then injected in the same 
manner as the formalin injections. Paw lifting, licking and flinching behaviour were recorded for 10 
minutes after capsaicin injections, and videos of the behaviour were scored by a single blinded 
investigator. 
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Spared nerve injury model 
 
These surgeries were performed by either Drs Laura Casals, Tom Zurawski or Orla Moriarty (DCU). 
Rats were briefly anaesthetised with 3% isoflurane. The fur was shaved from the right thigh and 
exposed skin cleaned with gauze soaked in surgical soap. The anaesthetised animal was placed on 
a pre-heated platform. A skin incision in the lateral surface of the thigh was made to expose the 
muscles, using a sterile scalpel blade. The skin around the cut was separated from its underlying 
loose connective tissue to expose the muscle layers, using blunt dissection. At approximately mid-
thigh level, a portion of the sciatic nerve and its three terminal branches (the sural, common 
peroneal and tibial nerves) were exposed, using blunt dissection. Immediately distal to the 
trifurcation point, the common peroneal and tibial nerves were gently lifted using sterile forceps, 
tight-ligated and transected distal to the ligature. The wound was closed in layers, using sutures for 
the muscle; the overlaying skin was closed with wound clips/staples. Sham surgery was performed 
in the same manner, but the nerves were only exposed. Animals were monitored daily for the first 
week after procedure and at least once a week after this. Final sample sizes are described in figure 
legends. 
Behaviour assays of somatosensory function 
Hargreaves test 
 
The Hargreaves test was used to measure behavioural responses to heat stimuli and establish a 
nocifensive threshold. The device consists of isolated testing chambers on top of a glass floor which 
the rats can freely move within, and an infra-red generator underneath which can heat the floor 
below the rat hind-paw. Rats were acclimatised in the Hargreaves testing chambers for 20 minutes, 
one day before testing began. The Hargreaves heat source was calibrated to induce a baseline 
nocifensive response in ~ 12 seconds, with a cut-off of 20 s to avoid sensitisation of the paw. On 
the day of testing, the rats were placed in the Hargreaves testing chamber 20 minutes before the 
test began. The Hargreaves probe was placed below the plantar surface of the left hind-paw and 
the test was started. Sudden flinching, raising, shaking or licking behaviours were recorded as 
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nocifensive responses. The left hind-paw of each rat was tested, and the test was then repeated for 
the right hind-paw. Rats were then given a 5-minute break before the left hind-paw was tested 
again. A total of three trials were recorded for each hind-paw and the average response was plotted 
for each paw per time point. 
von Frey test 
 
The von Frey test allows for measurement of tactile sensitivity. Rats are tested within isolated 
chambers on an elevated mesh floor; this allows application of nylon filaments to the paws. Each 
filament will bend under a different force, allowing for quantification of mechanical thresholds. 
Rats were acclimatised as per the Hargreaves test. On the day of testing the rats were placed in the 
von Frey testing chamber 20 minutes before the test began. The 4 g filament was applied to the 
plantar surface of the left hind-paw until it began to bend slightly, this was held for three seconds. 
Sudden flinching, raising, shaking or licking behaviours were recorded as nocifensive responses. If 
the filament produced a response, the next lower force filament was selected. Conversely, if the 
filament failed to produce a response, the next higher weight filament was used. Increasing or 
decreasing filaments were used until a change was recorded (e.g. increasing filaments eventually 
elicit a response), then four further trials were recorded, and the test concluded. The raw von Frey 
data were analysed using the Dixon method (Dixon, 1980) to calculate the 50% paw withdrawal 
thresholds (PWT). 
Randall Selitto test  
 
This allows measurement of mechanical pressure thresholds, which are larger than those elicited 
with the von Frey test, indicating that different aspects of mechanical sensitivity are being tested 
(Drew et al., 2007). The device consists of an automated, weighted lever that applies pressure 
through a blunt tip to the rat’s paw. The test was terminated when the rats flinched, squeaked or 
attempted to escape restraint. A modified Randall Selitto device was used (Fig. 2.2) to allow for 
easier testing of the plantar surface of the hind-paw. This consisted of adhering a blunt soldering 
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iron tip to the device as depicted in Fig. 2.2. The rats were habituated to the device by daily handling 
and placing the paw into the testing position at the minimum setting, at four days before testing 
began. On the testing day rats were restrained and the hind-paw was placed in the test starting 
position. Only the ipsilateral hind-paw was tested due to the stressful nature of the test on the rats. 
The device was then activated so that a constant increase in mechanical pressure was applied to 
the rat hind-paw. Once the rat showed any one of the behaviours described above the test was 
terminated and the threshold recorded. A break of 5 minutes was provided to the animals between 
each test. Three trials were recorded per hind-paw, averaged, and converted to grams (using the 
formula supplied in the instruction manual). Baseline thresholds pre-Vzv injection were averaged 
and post-Vzv injection thresholds were converted into % changes from the average baseline. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2 Modified Randall Selitto test, a soldering iron tip was adhered to the white base (red 
arrow) for the plantar surface of the hind-paw to rest on. Pressure was applied to the dorsal 
side of the hind-paw from the flat surface above (green arrow). 
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Incapacitance test 
 
This measures the weight bearing ability of the hindlimb. Since this is compromised in models of 
joint inflammation, it is a useful tool to measure potential recovery of limb function following 
administration of BoNT. The test was also used to measure limb paralysis induced by injecting high 
doses of BoNT, as the induced paralysis compromised weight bearing ability. The rats were 
restrained in a chamber with each hind-paw placed on a scale, which records the force applied to 
each scale and, therefore, shows how much bodyweight is distributed per hind limb. Rats were 
placed in the incapacitance tester for 5 minutes each day, in the four days leading up to the first 
testing day, to acclimatise them to the device. During testing rats were placed in the incapacitance 
meter; once the rat was stationary with both hind paws on the scales while facing straight forward 
(Fig. 2.3), the test was started and values (in grams) recorded. The rat was then returned to the 
home cage and the next animal tested. Each rat received four trials which were averaged to get the 
mean weight bearing values. These were converted into a % of the total body weight distributed to 
the ipsilateral hind limb. 
 
 
 
 
 
 
 
 
Fig. 2.3 Rat testing position for the incapacitance test, image taken from (Svard, 2016) 
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Pressure application method (PAM) 
 
The PAM test is a measure of mechanical sensitivity, used specifically for joints. A pressure 
transducer is applied to the joint and force is gradually increased manually by the user until a 
nocifensive response is elicited (flinch, squeak, struggle behaviour etc.). Four days prior to testing, 
rats were restrained daily and held in a testing position for less than 1 minute, to acclimatise them 
to the testing position. On the test day, each rat was removed from the testing cage, restrained and 
the PAM sensor applied steadily to the knee joint, gradually increasing the pressure until a 
nocifensive response was noted. The peak force (measured in grams) was recorded from the PAM 
display. The animal was then returned to the cage. Rats received a 5-minute break in between trials 
and were tested three times per knee to get an average threshold. Both knees were tested, and the 
average values of each joint were plotted as a time-line. 
Knee diameter 
 
Rats were acclimatised to testing in the same manner as the PAM. Transverse knee diameters were 
measured using digital callipers and the rat returned to the home cage. Three measurements were 
taken per knee, averaged and plotted as a time-line; the animals were given a 5-minute break 
between each test. 
Hot-plate/Cold-plate test 
 
 The hotplate provides a means to measure thresholds to heat stimuli. The rat is placed in a sealed 
chamber on a pre-heated plate. The latency for the animal to show a nocifensive response (licking 
of the hind-paw) is recorded. Animals were acclimatised to the hot-plate/cold-plate device at room 
temperature for 5 minutes one day before testing. At 50 minutes post capsaicin injection, rats were 
placed on the hotplate pre-set to either 54.5 or 51 °C (specified in the figure legends). The cut-off 
set for the hot-plate was 20 - 40 s to prevent tissue damage (20 s cut-off used for 54.5 °C test, 40 s 
for 51 °C test). Each rat received a single trial and latency to lick the injected hind paw was plotted. 
For cold-plate testing, the device was set to 5 °C and rats were tested throughout the SNI studies. 
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Behaviour was recorded before SNI surgeries, after surgeries and after injections of BoNTs. Rats 
were placed on the cold plate and the number of hind-paw raises and licks were recorded within 
180 s.  
Tissue harvesting and immunohistochemistry 
Transcardial perfusion 
 
Rats were sacrificed by overdose of anaesthetic (sodium pentobarbital, 200 mg/kg), 90 minutes 
after capsaicin injection. After confirming a deep plane of anaesthesia (lack of response to toe and 
tail pinch), the skin and body wall below the diaphragm were lifted using a blunt end forceps and 
abdominal muscles cut through, with body cavity opened and extended laterally. An incision was 
made along the border of the diaphragm muscle to expose the heart, which was held gently with 
blunt forceps. A blunt needle was inserted no more than ¼ inch into the left ventricle. The right 
atrium was then cut with an iridectomy scissors. Heparinised saline (5000 IU heparin/0.9% NaCl, pH 
7.4) was perfused through the heart using 50 mL syringes attached to the needle inserted into the 
heart. This was done until the animal was completely exsanguinated. Between 200-500 mL 
(depending on the size of the rat) of 4% formaldehyde was perfused to fix the rat. 
Tissue harvesting 
 
Dissection to isolate tissue samples was performed on fixed or unfixed animals. To isolate plantaris 
muscles from unfixed animals, first the plantar skin was gently cut away using a scalpel blade to 
expose the plantaris muscle. This was raised using curved forceps and then excised from the hind-
paw using a spring-loaded surgical scissors. Plantaris muscle samples were then stored at -80 °C. To 
isolate the spinal cord from fixed animals, the spinal cord was exposed by laminectomy. A bone 
cutter was used to cut the sides of the spinal cord, allowing the dorsal half of the spinal column to 
be lifted away using a forceps, revealing the spinal column. The hip bones were used as anatomical 
landmarks to identify the L4-L5 DRGs. The dorsal roots of the spinal nerves were traced back from 
the L4-L5 DRG to identify the L4-L5 region of the spinal cord. This was excised using a scalpel and 
forceps, then stored in 4% formaldehyde overnight at 4 °C. 
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Cryosectioning 
 
The L4-L5 region of the spinal cord was stored in 30% sucrose solution (30% sucrose, 0.05%sodium 
azide, phosphate buffered saline - PBS) after an overnight fixation in 4% formaldehyde. After 24 
hours in 30% sucrose, the ipsilateral and contralateral sides of the spinal cord were separated using 
a scalpel and frozen in optimal cutting temperature compound (OCT). The spinal cord was cut into 
40 µm thick transverse sections using a cryostat (Leica – CM 3050S) and the L4-L5 regions stored in 
30% sucrose at 4 °C.  
Immunohistochemistry 
 
 Spinal cord sections were stained using a free-floating method, where they were washed 3 times 
with PBS and blocked in PBS with 0.3% Triton X-100 and 5% goat serum. The sections were then 
incubated over the weekend in an anti-c-fos primary antibody (rabbit polyclonal) at a 1:5000 
dilution in PBS with 0.1% Triton X-100 and 1% goat serum at 4 °C. Sections were washed with PBS 
three times and incubated in a secondary fluorophore conjugated antibody (goat anti-rabbit IgG, 
Alexa Fluor 488) for 2 hours at room temperature. Sections were then mounted on microscopic 
slides and cover-slipped using Fluoromount™ mounting medium. Magnified images were captured 
on an Olympus IX71 microscope, U-RFL-T reflected fluorescence system and TH4-200 lamp. C-fos 
positive cells in the ipsilateral and contralateral LI-LII regions of the L4-L5 dorsal horns were counted 
using a manual Image J cell counter plug in. Immunostaining of Vzv infected cells was performed by 
Dr Tom Zurawski. MRC-5 cells were co-stained with anti-Vzv Glycoprotein I primary antibody and 
Hoechst 33342, and an anti-mouse fluorescent secondary antibody. Bright-field and fluorescent 
images were captured on the microscope system described above. 
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Detection of cleaved SNAP-25 in vitro and ex vivo 
In vitro potency assay 
 
The in vitro potency of BoNT/A and LC/E-BoNT/A was assessed using an established in vitro SNAP-
25 cleavage assay (Wang et al., 2012). Toxins were diluted into the assay buffer and a C-terminus 
GFP-tagged, recombinant SNAP-25 fragment substrate (residues 134-206) was added to the diluted 
toxin, to a final concentration of 0.5 mg/mL. This was incubated at 37 °C for 30 min, then the 
reaction quenched by the addition of 4X LDS, to a final concentration of 1X LDS. To determine the 
% of intact SNAP-25, SNAP-25A and SNAP-25E, the samples were resolved on SDS-PAGE, Coomassie 
stained (see protein staining below), imaged and subjected to densitometric analysis using ImageJ 
software. 
Tissue homogenisation  
 
Frozen plantaris muscles were defrosted on ice and added to 200 µl of homogenisation buffer (see 
Materials). The tissue was cut in the buffer using spring-loaded surgical scissors, then blended using 
an electric tissue homogeniser (IKA® T-10) in short 3 second bursts, then homogenised by 3 second 
bursts with a battery powered mortar equipped with a polypropylene pestle. The homogenate was 
spun at 10,000 g for 15 minutes at 4 °C, the supernatant pipetted and then frozen at -20 °C. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)  
 
Protein samples were diluted in 4X LDS sample buffer (see materials) to a final concentration of 1X 
and heated at 95 °C for 10 minutes. The samples were loaded into pre-cast Bolt™ 12% Bis-Tris Plus 
Gels and run at 140 V at 4 °C, in MOPS running buffer (see Materials), until proteins were separated 
according to their molecular masses, indicated by pre-stained protein markers (10-250 kD, see 
materials). 
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Western-blotting 
 
Following SDS-PAGE, proteins were electrophoretically transferred to a PVDF membrane by semi-
dry transfer method, using a Pierce™ power blotter according to the prescribed protocol. Non-
specific binding to membranes was inhibited by immediate incubation in blocking buffer (TBS 
containing 5% BSA). The membrane was then incubated in an anti-SNAP-25 primary antibody 
diluted in the same buffer, gently rocking at 4 °C overnight. This was then washed 3 times by gentle 
rocking in TBS buffer for 10 minutes, followed by incubation with a secondary antibody conjugated 
to HRP (diluted in TBS with BSA) for 90 minutes at room temperature. After a final 3 washes in TBS, 
the membrane was treated with an ECL kit to release a chemiluminescent signal which was 
captured G: BOX Chemi-16 gel documentation system.  
Protein staining 
 
Following SDS-PAGE gels were stained using the Pierce™ power blotter, according to the pre-
programmed protein staining protocol. This allows for rapid Coomassie staining of the gel. 
Following staining, the gel was rinsed in deionized water and gently agitated at room temperature. 
Images of the gel were captured on the G: BOX Chemi-16 gel documentation system.   
Data analysis and statistical procedures 
 
All analysis was performed using GraphPad Prism 6 for Windows. Full details of statistical analyses 
are found in figure legends. Statistical analysis was not performed on dosing study assays used to 
determine the MaxTD, as the MaxTD is determined using cut-offs in these assays. In some cases, 
timelines were missing data-points (e.g. due to corruption of video recordings) which rendered 
them unsuitable for analysis by two-way ANOVA. These cases are noted in the relevant figure 
legends and the data also processed as the area under the curve for t-test or one-way ANOVA 
analysis. 
56 
 
Chapter 3 – Results  
Testing of BoNT derived therapeutics in rodent models of pain 
Neuropathic pain  
Selection of prime candidate BoNT chimeras for screening as potential chronic pain 
therapeutics 
 
As the overall aim of this project was assessment of novel therapeutics, the first goal was to select 
the most promising candidate for future investigation between LC/E-BoNT/A and LC/E-BoTIM/A. 
LC/E-BoTIM/A was shown to be effective on capsaicin-induced heat hypersensitivity in rats and 
showed a trend towards greater pain relief compared to BoNT/A (Wang et al., 2011a).  As 
mentioned in the introduction, LC/E-BoNT/A was expected to be a superior therapeutic compared 
to LC/E-BoTIM/A as it retained two active LCs, whose SNARE cleaving capabilities were expected to 
underpin the neurotoxin’s analgesic activity. In collaboration with Drs Laura Casals and Tom 
Zurawski, both novel molecules, and BoNT/A, were screened in the rat SNI model of neuropathic 
pain to compare the efficacy of these chimeras against BoNT/A and select the therapeutic candidate 
for further testing.  
LC/E-BoNT/A reduced SNI-induced mechanical allodynia to a greater extent than either LC/E-
BoTIM/A or BoNT/A 
 
As mentioned in the methods, the MaxTD is the maximum amount of toxin that can be injected 
without inducing paralysis of the hind-limb which would interfere with behaviour testing. The 
MaxTD for intra-plantar injections of BoNT/A and LC/E-BoNT/A in the rat had previously been 
identified at 15 and 75 U/Kg, respectively (Wang et al., 2017a), and these doses were tested in the 
SNI model. To provide a direct comparison with LC/E-BoNT/A, LC/E-BoTIM/A was also tested at 75 
U/Kg, thus, indicating the superior chimera for future therapeutic investigations. Rats underwent 
SNI surgeries and 7 days after surgery were given intra-plantar injections of either LC/E-BoNT/A, 
LC/E-BoTIM/A, BoNT/A or vehicle (0.5% BSA, 0.9% NaCl). Both LC/E-BoNT/A and LC/E-BoTIM/A 
were found to significantly reduce SNI-induced mechanical hypersensitivity, which was measured 
by the von Frey test as a quantification of tactile allodynia. Though BoNT/A showed a visible 
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increase in the mechanical thresholds, this did not reach statistical significance (Fig. 3.1 A-B). 
Furthermore, LC/E-BoNT/A proved to be significantly more effective than BoNT/A at relieving the 
induced mechanical allodynia on days 3-7 post injection (Fig. 3.1 A) and had a greater effect on 
tactile hypersensitivity overall, shown by the area under the curve (AUC) analysis (Fig. 3.1 B). LC/E-
BoNT/A also reduced mechanical hypersensitivity to greater extent than LC/E-BoTIM/A, but only at 
days 3 and 7 post injection (Fig. 3.1 A) and did not have a significant effect in relieving sensitisation 
overall (measured by AUC) than LC/E-BoTIM/A (Fig. 3.1 B). Notably, LC/E-BoNT/A relieved 
mechanical allodynia to the point that it was no longer significantly different compared to the sham 
surgery group on days 3 and 7 post injection, indicating a temporary full recovery in neuropathic 
mechanical allodynia. As LC/E-BoNT/A showed a significant advantage over LC/E-BoTIM/A in 
relieving mechanical hypersensitivity, this molecule was prioritised for testing in a range of pain 
models as a potential novel pain therapeutic. 
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Fig. 3.1 LC/E-BoNT/A alleviates mechanical hypersensitivity following SNI surgery more effectively than 
LC/E-BoTIM/A at equal doses, and to a greater extent than the MaxTD of BoNT/A (A) Time course of the 
relief of mechanical hyperalgesia (measured as paw withdrawal threshold - PWT) by BoNT variants relative 
to days after toxin injection (vertical dotted line). (B) AUC analysis of SNI groups from panel (A). Data 
represents means ± SEM; statistical analysis for (A) was performed using repeated measures two-way 
ANOVA and Bonferroni post hoc tests. As not all points aligned in the timeline, only data from days 3-10 
post injection were analysed. There was a significant main effect of group (F (3, 31) = 33.0, p<0.001). SNI was 
associated with a significant decrease in paw withdrawal threshold in vehicle-treated animals compared 
with sham controls and this effect was attenuated by LC/E-BoNT/A on days 3-10 post injection (*, p<0.05, 
***p<0.001 vs. SNI vehicle). The SNI-induced hypersensitivity was also attenuated by LC/E-BoTIM/A on 
days 3-10 post injection (*p<0.05). Withdrawal thresholds were significantly higher in the SNI + LC/E-
BoNT/A group than in the SNI + LC/E-BoTIM/A group on days 3 and 7 post injection (*p<0.05) and also the 
BoNT/A group (*, P<0.05, *** P<0.001). The time course data are summarised in a histogram of the AUC 
(B), where an increase in the AUC is indicative of reduced sensitivity. SNI groups only were analysed by 
one-way ANOVA followed by Bonferroni post hoc tests. LC/E-BoNT/A- and LC/E-BoTIM/A-treated SNI rats 
showed reduced sensitivity compared with their vehicle-treated counterparts. Data are presented as 
means ± SEM, sham group: n ≥ 6, SNI groups: n ≥ 8. (*p<0.05, **p<0.01, ***p<0.001, red symbols: SNI + 
LC/E-BoNT/A vs SNI + vehicle, blue symbols: SNI + LC/E-BoTIM/A vs SNI + vehicle, green symbols SNI + 
LC/E-BoNT/A vs SNI + BoNT/A, black symbols SNI + LC/E-BoTIM/A vs. SNI + LC/E-BoNT/A, ns: not significant 
vs. sham control. Rats weighing 200-250 g at time of SNI surgery were used. Dr Casals tested the LC/E-
BoNT/A, BoNT/A, saline and sham groups while John Nealon tested the LC/E-BoTIM/A group in the rat SNI 
model. Dr Tom Zurawski performed SNI surgeries. Injection vehicle consisted of 0.5% BSA and normal 
saline. 
B                                       von Frey A                                von Frey 
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Testing of Vzv model of neuropathic pain for screening of BoNT derived therapeutics 
  
The experiments presented below were to demonstrate that intra-plantar injection of Vzv-infected 
cells in rats would induce hypersensitivity to mechanical and heat stimuli as reported in the 
literature (Furlan et al., 2006, Hasnie et al., 2007). Consulting the literature indicated that injection 
of MRC-5 human diploid fibroblast cells infected with the Ellen Vzv strain would induce the model 
(Hasnie et al., 2007, Garry et al., 2005, Raftery et al., 2012). These reports showed that heat 
hypersensitivity was not consistent between research groups and so the Randall Selitto test for 
mechanical hyperalgesia was selected to test this model in place of the Hargreaves test of heat 
allodynia (refer to Methods, Behaviour assays of somatosensory function, Hargraves test/Randall 
Selitto test). First, confirmation of infection of MRC-5 cells with Vzv was demonstrated with 
immunohistochemical staining. Secondly, to identify an optimum number of virus infected MRC-5 
cells required to induce plantar hypersensitivity, different virus titres were administered by intra-
plantar injection into the right hind-paw of rats. 
MRC5 cells showed signs of infection post Vzv application, confirmed by positive antibody 
staining for Vzv glycoprotein I  
 
MRC5 cells cultured and infected with Vzv began to show signs of cell rounding from day one post 
inoculation as expected (Fig. 3.2 A) (Leske et al., 2012).  By day 2 ~70% of the cells displayed 
rounding of the cell body, with sloughing of cells indicated by gaps that were previously populated. 
By day 3 post Vzv, the cells were no longer suitable for injection into rats as they had exceeded 80% 
cytopathic effect. The standard protocols for inducing the Vzv model stipulate that cell cultures 
must not exceed an 80% cytopathic effect (Hasnie et al., 2007, Dalziel et al., 2004). To confirm 
presence of the virus, infected MRC5 cells were stained with antibodies against Vzv Glycoprotein I, 
a glycoprotein expressed in Vzv infected cells (Cohen and Nguyen, 1997) (Fig. 3.2 B, green). 
Individual cells were identified with the nuclei marker, Hoechst 33342 (Fig. 3.2 B, blue). These 
images confirmed Vzv infection at dilutions of the virus as low as 10-6, with higher concentrations 
of Vzv (10-1-10-2) proving toxic to the MRC-5 cells indicated by the sparse Hoechst staining. 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.2 Infection of MRC-5 cells confirmed by light microscopy and immunohistochemical 
staining (A) MRC-5 human lung fibroblast cells showed signs of Vzv infection (syncytial rounding 
and sloughing) at day 1 post infection. The cytopathic effect reaches ~ 80% by day 2 post 
inoculation and can be used for injections into animals. By day 3, the MRC-5 cells are no longer 
viable for inducing the model. (B) Presence of Vzv Glycoprotein I, 4 days after addition of serially 
diluted Vzv infected MRC-5 cells. Green fluorescent staining marks Vzv glycoprotein I present in 
cells, blue staining marks cell nuclei (Hoechst 33342).  Infection of MRC-5 cells, antibody staining 
and imaging performed by Dr Tom Zurawski.  Scale bar: 200 µm 
 
A
 
B 
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Vzv-induced mechanical and heat hypersensitivity was insufficient for investigating BoNT 
mediated anti-nociceptive effects 
 
To induce hypersensitivity in the hind-paw, rats received intra-plantar injections of 1 × 104, 2.8 × 
106 or 3.9 × 106 Vzv-infected MRC-5 cells. These doses were based on reports on this model (Garry 
et al., 2005, Dalziel et al., 2004). Sham groups received injections of sham-infected cells, equal in 
number to their corresponding infected group. As there were no behavioural differences between 
the two tested sham groups (1 × 104 or 2.8 × 106 sham infected cells), they were merged into a 
single group of 15 animals. Decreases in mechanical thresholds (measured by von Frey and Randall 
Selitto tests) post administration of Vzv-infected cells were found to be inconsistent and not dose-
dependent. The von Frey time course demonstrated that following Vzv injections all infected groups 
showed a trend towards decreased thresholds, but surprisingly, the greatest effect was induced by 
the lowest viral titre given (Fig. 3.3 A). This is also reflected in the Randall Selitto time course where 
only the 1 × 104 infected cells group showed obvious decreases in mechanical thresholds (Fig. 3.3 
B). As the behaviour testing days for von Frey and Randall Selitto tests didn’t fully synchronise, the 
time course data were not suitable for statistical analysis by repeated measures two-way ANOVA 
and is instead presented as AUC for analysis, as described in the figure legend (Fig. 3.4). One-way 
ANOVA of AUCs confirmed that only the lowest number of Vzv infected cells injected (1 × 104), 
induced significant mechanical allodynia as measured by the von Frey test, but not in the Randall 
Selitto test (Fig. 3.4 A-B). Since the Randall Selitto test showed no significant mechanical 
hyperalgesia, heat allodynia (measured by the Hargreaves test) was investigated in rats injected 
with 3.9 × 106 infected cells. These animals showed insignificant reductions in thresholds to heat 
stimuli (Fig. 3.3 C). The Hargreaves data were suitable for analysis by two-way repeated measures 
ANOVA as detailed in the figure legend and an AUC analysis was not necessary.  
Together, these results showed striking inconsistencies in the magnitude and duration of reported 
Vzv-induced hypersensitivity and failed to demonstrate the previously described dose response of 
Vzv intervention on mechanical sensitivity (Hasnie et al., 2007). Thus, a more in-depth review of the 
literature was conducted. A lengthy investigation uncovered a thesis indicating a lack of 
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reproducibility in the model that could not be resolved by the authors despite multiple attempts 
and protocol variations (Medhurst, 2011). Herein, while some effect was observed from the lowest 
dose of Vzv administered (1 × 104 infected cells), the mechanical allodynia was too transient to 
effectively screen LC/E-BoNT/A. It is plausible that rat strains used in this case (Sprague Dawley) 
was resistant to the Ellen Vzv strain that we propagated on MRC-5 cells specifically, this is further 
explored in the Discussion chapter. As the published dose response of this model could not be 
reproduced and the sensitisation experienced by the rats was too transient, it was deemed an 
unethical use of animals to pursue this model further due to the lack of a consistent response. 
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Fig. 3.3 Intra-plantar injections of Vzv infected MRC-5 cells induced transient tactile allodynia 
measured by von Frey peaking between 3-6 days after injection, minor reductions in Randall 
Selitto and Hargreaves test thresholds were observed (A) Von Frey and (B) Randall Selitto 
thresholds were recorded before and after Vzv injections (denoted by the dotted vertical lines). 
(C) Time course of heat thresholds in ipsilateral and contralateral hind-paws (measured by 
Hargreaves test) of 3.9 × 106 infected cells group. Data presented as means ± SEM; time course 
in (C) were analysed by repeated measures two-way ANOVA and Bonferroni post hoc tests. 
Sham group: n=15, Vzv (1 × 104): n=7, Vzv (2.8 × 106): n=7, Vzv (3.9 × 106): n=5. Rats weighed 
200-300 g at the time of Vzv injections. Cells injected in PBS vehicle. NRT = Nocifensive response 
threshold, PWL = Paw withdrawal latency. 
B                Randall Selitto C                 Hargreaves 
A                              von Frey 
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Fig. 3.4. Intra-plantar injections of Vzv infected MRC-5 cells induced transient tactile allodynia 
measured by von Frey with no dose response, insignificant reductions in Randall Selitto 
thresholds were observed (A) AUC summary of von Frey and (B) Randall Selitto time courses. 
Statistical analysis was conducted by one-way ANOVA followed by Bonferroni post hoc tests. 
Data presented as means ± SEM; **, P<0.01, 1 × 104 infected cells vs sham. Sham group: n=15, 
Vzv (1 × 104): n=7, Vzv (2.8 × 106): n=7, Vzv (3.9 × 106): n=5. Rats weighed 200-300 g at the time 
of Vzv injections. Cells injected in PBS vehicle. 
 
B 
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Chronic inflammatory pain 
Maximum intra-articular doses of BoNT injections into the rat knee were 1/3rd of the intra-
plantar MaxTD  
 
With the anti-nociceptive effects of LC/E-BoNT/A confirmed in the SNI model of neuropathic pain, 
the next step was to determine if its superior anti-nociceptive effect over BoNT/A would be 
reproduced in a rat model of chronic inflammatory joint pain. Dosing studies were first carried out 
to identify the  MaxTD of LC/E-BoNT/A and BoNT/A for rat knee joint injections. Once the MaxTD 
of each toxin was set, these doses were tested in the CFA model of chronic inflammatory pain, to 
identify BoNT mediated reductions in joint swelling, mechanical hypersensitivity and functional 
recovery. An initial dose of 70 U/Kg for intra-articular injections of BoNT/A and LC/E-BoNT/A into 
the knee was selected, based on the dose of Dysport® used by Yoo et al., which was shown to 
reduce swelling around the knee joint in the rat CFA model (Yoo et al., 2014). Yoo et al. injected 20 
U per rat, which was estimated to be 50 – 80 U/Kg based on the reported rat weights. To confirm 
paralysis from injection of BoNT/A or LC/E-BoNT/A into the knee (and therefore set an upper limit 
on what could be injected into the rat knee), 100 U/Kg of BoNT/A and 140 U/Kg of LC/E-BoNT/A 
were tested. A higher dose of LC/E-BoNT/A (140 U/Kg) was selected as it was shown to be better 
tolerated than BoNT/A when administered into the plantar skin of the hind-paw (Fig. 3.1) (Wang et 
al., 2017a).  
As expected, 100 U/Kg of BoNT/A impaired locomotor ability from day one post injection but so did 
the 70 U/Kg dose by day 2 post injection, as measured by latency to fall from the rotarod (Fig. 3.5 
A). LC/E-BoNT/A was observed to have less of an effect on motor function as only animals treated 
with 140 U/Kg showed a decrease in rotarod performance, while the LC/E-BoNT/A 70 U/Kg group 
were unaffected. Despite the lack of impact of 70 U/Kg of LC/E-BoNT/A on the rotarod, distinctive 
limping/dragging of the hind limb was noted in these animals, indicating that the rotarod test was 
not sensitive enough to detect hind limb paralysis following intra-articular injections in the knee 
joint. This limping behaviour was present in all groups in this study and so these doses were deemed 
unsuitable for analgesic assessment using the CFA model. While profound local paralysis associated 
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with all test groups in this study, the overall effects on animal welfare (measured by weight gain) 
were less severe. Fig. 3.5 B shows that all animals gained weight at an equal pace for 24 hours while 
rats injected with 100 U/Kg BoNT/A began to show impaired rotarod performance. No other 
treatment groups lost weight respective to the pre-injection values, although rats given 70 U/Kg of 
BoNT/A did show slowed weight gain 24 hours post toxin injection. Surprisingly, there were no 
obvious differences on animal weight gain between 70 U/Kg or 140 U/Kg of LC/E-BoNT/A. Since 140 
U/Kg of LC/E-BoNT/A had less effect on both rotarod performance and weight gain than 70 U/Kg of 
BoNT/A, it is likely that LC/E-BoNT/A is better tolerated than BoNT/A when injected into the knee 
joint.  
The doses of BoNT/A were decreased to 40 and 20 U/Kg while 60 and 40 U/Kg were selected for 
LC/E-BoNT/A. Increases in rat weight post toxin injection (Fig. 3.5 D) showed that 40 U/Kg of BoNT/A 
was the only dose which caused an obvious change in weight gain compared to the other test doses, 
further indicating that BoNT/A was less tolerable than LC/E-BoNT/A. Only the higher doses of each 
toxin reduced rotarod performance below the cut-off point of 80% of baseline fall latency (Fig. 3.5 
C), yet all four doses of the toxins produced limping behaviours in the rats. This reveals an 
inconsistency in the previous experiment where 70 U/Kg of LC/E-BoNT/A hadn’t caused a 
noticeable drop in rotarod performance in Fig. 3.5 A, yet a lower dose of 60 U/Kg had resulted in 
reduced fall latencies in Fig. 3.5 C, with both groups showing limping behaviour. This indicated that 
while limping was consistently induced by the intra-articular injections, this did not always result in 
reduced rotarod performance in the rats, most likely due to inter-animal variability resulting from 
the small sample sizes (n=2). To find a more sensitive method to quantify the motor effects of BoNTs 
following intra-articular injection, the incapacitance test was used to measure the % of the animal’s 
total bodyweight being placed on the ipsilateral hind limb. Healthy, untreated rats equally 
distributed their bodyweight on each hind limb, therefore a cut-off of 40% of total bodyweight 
being placed on the ipsilateral limb was used to indicate detectable motor deficiency. All doses 
(except 40 U/Kg of LC/E-BoNT/A) reduced the weight placed on the ipsilateral hind limb below 40% 
of the total body weight, indicating a reduction of hind limb function (Fig. 3.5 E). While this seemed 
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a more sensitive test than the rotarod, it still wasn’t acceptable as 40 U/Kg of LC/E-BoNT/A had 
induced limping behaviours. Since all doses induced noticeable limping of the ipsilateral hind limb 
they were deemed unsuitable to be tested for analgesic effects in the CFA model. As neither 
incapacitance nor rotarod testing could be used to quantify the paralytic effects of lower doses in 
the knee joint, a new assay was required. It was observed that the rats were unable to abduct the 
digits of the treated hind paws, possibly by spread of excess BoNT from the knee joint to nearby 
nerves innervating the extensor digitorum longus muscle responsible for digit abduction. Therefore, 
the rat digit abduction assay (Broide et al., 2013) was selected to identify the MaxTD in the final 
dosing study.  
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Fig. 3.5. Intra-articular injections of BoNT/A and LC/E-BoNT/A as low as 10 U/Kg and 30 
U/Kg, respectively, caused motor impairment as measured by assays of locomotor 
function and digit abduction Time courses of rotarod tests are depicted in (A) and (C) with 
the corresponding weight gain data presented in (B) and (D). Weight gain data are indicative 
of potential systemic toxicity from BoNT injections. Impaired weight bearing is presented in 
(E) and paralysis of the DAS reflex is presented in (F). Vertical, dotted lines indicate injection 
date and horizontal dotted lines show cut-offs set for the dose effects on rats. Sample sizes 
for all groups was n=2 and all data presented as means ± SEM. 22 of the 24 rats used 
weighed 170 – 220 g at the time of BoNT injections, the remaining 2 rats weighed 320-365 
g at the time of BoNT injections. This was due to a limited number of animals available at 
the time of this study. Vehicle: 0.5% BSA in normal saline. 
A   Rotarod B             Weight gain 
C  Rotarod D   Weight gain 
E          Incapacitance F   DAS 
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Four final doses were screened using the DAS (a measure of digit abduction paralysis) post injection, 
namely 15 and 30 U/Kg LC/E-BoNT/A, 5 and 10 U/Kg of BoNT/A. Of these four doses, only 10 U/Kg 
of BoNT/A and 30 U/Kg of LC/E-BoNT/A showed limping behaviour in the treated hind limb. 
Furthermore, both these groups gave a DAS score greater than one by day three post injection, 
reaching the cut-off point for the MaxTD (Fig. 3.5 F). Hence, both doses were deemed unsuitable 
for testing in knee pain models. The MaxTD of BoNT/A was set at 5 U/Kg, as it showed no paralytic 
effects in the DAS test, nor did it induce obvious limping post injection. Since the 30 U/Kg dose of 
LC/E-BoNT/A only induced a mild and transient paralytic effect as measured by the DAS (1 day), it 
was expected that a 50% decrease to 15 U/Kg would be too great and not reflective of a MaxTD. 
Hence, the MaxTD  of LC/E-BoNT/A was set at 25 U/Kg, a 16.67% decrease from 30 U/Kg. 
MaxTD of BoNT/A and LC/E-BoNT/A had no anti-nociceptive or anti-inflammatory effect on 
the rat CFA model of chronic inflammatory pain 
 
Baseline incapacitance performance and PAM thresholds were recorded two days before intra-
articular injection of CFA into the knee joint. Transverse knee diameter was measured on the day 
of injection while the animals were anaesthetised, prior to induction of the model. Within one day 
after CFA injection, functional performance of the ipsilateral limb deteriorated as measured by 
incapacitance testing (Fig. 3.6 A), thresholds to mechanical pressure on the ipsilateral knee joint 
decreased (Fig. 3.6 B) and considerable swelling around the ipsilateral joint developed (Fig. 3.6 C). 
Both weight bearing, and mechanical thresholds were shown to gradually improve right up to the 
last testing day (31 days post CFA). Transverse knee diameter on the other hand decreased from 
peak swelling for up to 8 days after induction of the model but remained stable for the rest of the 
study. Seven days after model induction, rats were injected with either vehicle, 5 U/Kg of BoNT/A 
or 25 U/Kg of LC/E-BoNT/A. Neither toxin improved functional weight bearing, mechanical 
thresholds or transverse knee diameter in comparison to vehicle injections. It is possible that the 
doses injected into the knee were too low to have a significant anti-nociceptive effect. This is 
reflected in Fig. 3.6 D, where both toxins only slow the growth curves of the rats slightly. Based on 
previous experience the MaxTD dose of BoNTs would be expected to have a greater effect on 
70 
 
slowing rat weight gain. Furthermore, these doses were far lower than the analgesic dose of LC/E-
BoNT/A (75 U/Kg) and the dose of BoNT/A that showed a statistically non-significant increase 
improvement in mechanical sensitivity in SNI model (15 U/Kg, refer to Fig. 3.1). Considering the 
persistent, painful inflammation of the knee joint (lasting 28+ days) the symptoms of this model 
were likely too severe to be effectively reduced by such low doses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6 Intra-articular injections of BoNTs MaxTD doses lacked an anti-nociceptive or anti-
inflammatory effect in the CFA model of knee pain and inflammation Time courses of (A) 
functional weight bearing, (B) mechanical thresholds, (C) transverse knee diameter, and (D) 
weight gain. All data presented as means ± SEM. Vertical dotted line shows day of CFA 
injection; solid vertical line indicates toxin injection day. Statistical analysis was conducted 
by repeated measures two-way ANOVA and Bonferroni post hoc tests. No statistical 
significance was found between any of the three treatment groups at any time points post 
BoNT injection. (B) ***, P<0.001, All ipsilateral knees vs. all contralateral knees, ** P<0.01, 
Vehicle ipsi vs vehicle contra, **BoNT/A ipsi vs BoNT/A contra. (C) ***, P<0.001, All 
ipsilateral knees vs. all contralateral knees. Saline: n=8, BoNT/A: n=7, LC/E-BoNT/A: n=8. 
Rats weighing 250 – 300 g at the time of CFA injections were used. Vehicle: 0.5% BSA and 
normal saline. 
B     PAM 
D       Knee diamaeter C             Weight gain 
A            Incapacitance 
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Acute inflammatory pain 
LC/E-BoNT/A reduces nocifensive behaviour in rats induced by intra-plantar injection of 
formalin 
 
To further investigate the anti-nociceptive potential of LC/E-BoNT/A in relieving inflammatory 
based pain, the chimera was tested against vehicle in the formalin model of acute inflammatory 
pain. This model was selected as BOTOX® has previously been shown to reduce formalin-induced 
lifting and licking behaviour in phase 2 of the model but not phase 1 (Cui et al., 2004). Rats were 
pre-treated with LC/E-BoNT/A or vehicle by intra-plantar injection five days before receiving 
injections of formalin to the same hind-paw. The formalin-induced behaviours assessed were hind-
paw flinching, lifting, licking and combined lifting/licking. After injection of formalin the 
characteristic bi-phasic response was observed; the animals initially spent up to 5 minutes 
displaying nocifensive behaviour (phase 1), followed by a longer period of nocifensive behaviour 
(phase 2) gradually decreasing over a total of 60 minutes after injection of formalin (Fig. 3.7 A-D). 
As some time-points in Fig. 3.7 were missing due to corrupted recordings of animal behaviour, the 
time-courses were not suitable for statistical analysis, and so this was performed by area under the 
curve analysis instead (Fig. 3.8). Animals pre-treated with LC/E-BoNT/A did not show a clear 
difference in flinching behaviour between 5 and 10 minutes after formalin (Fig. 3.7 A) which was 
likely due to an anti-nociceptive effect of LC/E-BoNT/A on flinching behaviour in phase 1 (Fig. 3.8 
A); this was not observed in the other phase 1 behavioural parameters. Animals pre-treated with 
LC/E-BoNT/A showed reduced flinching behaviour in phase 2 (15-60 min) (Fig. 3.8 E) and reductions 
in lifting behaviour in phase 2 when compared to vehicle (Fig. 3.7 B, 3.8 F). Unexpectedly, rats 
treated with LC/E-BoNT/A showed some increase in phase 2 licking behaviour compared to those 
treated with vehicle, although this was not found to be statistically significant (Fig. 3.7 D, 3.8 H). 
When lifting and licking behaviour were combined, pre-treatment with LC/E-BoNT/A was found to 
reduce overall phase 2 nocifensive behaviour, but this did not achieve statistical significance (Fig. 
3.7 C, 3.8 G). Although BOTOX has previously been demonstrated to cause a dose-dependent 
reduction in phase 2 lifting/licking scores, it has never been shown to affect phase 1 formalin-
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induced flinching behaviour. Here, LC/E-BoNT/A was found to decrease phase 1+2 flinching and on 
phase 2 lifting, but not on phase 2 licking or combined lifting/licking behaviour. Together, these 
results indicate that pre-injection of LC/E-BoNT/A provides a moderate antinociceptive effect in the 
formalin model of acute inflammatory pain.   
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
C D 
Fig. 3.7 Time courses show antinociceptive effects of LC/E-BoNT/A in the rat formalin model 
on phase 1 hind-paw flinching, phase 2 hind-paw flinching and lifting, but no effect on hind-
paw licking Hind-paw flinching (A), lifting time (B), combined lifting and licking time (C) and 
licking time (D) were plotted as time courses relative to formalin injection. Time points 
represent total behaviour within a 5-minute block. Data plotted as means ± SEM. Rats weighing 
between 190 – 250 g at the time of BoNT/vehicle injections were used. LC/E-BoNT/A n=4-5, 
vehicle n=5. Vehicle: 0.5% BSA and normal saline. 
A B 
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Fig. 3.8 AUC analysis of antinociceptive effects of LC/E-BoNT/A in the rat formalin model show 
significant effects on phase 1 hind-paw flinching, phase 2 hind-paw flinching and lifting Total 
hind-paw flinching (A), lifting time (B), combined lifting and licking time (C) and licking time (D) 
up to 5 minutes after formalin injection were plotted (phase 1). Total hind-paw flinching (E), 
lifting time (F), combined lifting and licking time (G) and licking time (H) from 15-60 minutes 
after formalin injection were plotted (phase 2). Data plotted as means ± SEM and analysed by 
unpaired t-tests. *, P<0.05, LC/E-BoNT/A vs. vehicle, ns, no significant difference LC/E-BoNT/A 
vs vehicle. Vehicle n=5, LC/E-BoNT/A n=4-5. Rats weighing between 190 – 250 g at the time of 
BoNT/vehicle injections were used. Vehicle:  0.5% BSA and normal saline.  
D 
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LC/E-BoNT/A demonstrates further anti-nociceptive effects than BoNT/A on capsaicin-
induced lifting and licking behaviours 
 
As LC/E-BoTIM/A and BoNT/A have both been shown to reduce capsaicin-induced nocifensive 
behaviours and heat hyperalgesia (Wang et al., 2011a), the capsaicin model was selected to further 
explore the anti-nociceptive effects of LC/E-BoNT/A in acute, inflammatory pain. Buprenorphine, a 
μ‐opioid receptor agonist as well as a κ‐opioid receptor antagonist, has been shown to have an 
analgesic effect in the capsaicin rat model, thus it was used as the positive control (Kress, 2009, 
Barrett et al., 2003). LC/E-BoNT/A, BoNT/A and buprenorphine were all tested in the capsaicin 
model. Following completion of the behavioural analysis, spinal cords were dissected from 
euthanised rats and processed for immunostaining. Specifically, sections were analysed for c-fos 
expression, with c-fos upregulation being a common marker of pain signal induction to the dorsal 
horn (Hunt et al., 1987). Thus, it was tested if behavioural antinociceptive effects would correlate 
with a reduction in c-fos upregulation. 
Four days before capsaicin injections, rats received intra-plantar injections of either 75 U/Kg of 
LC/E-BoNT/A, 15 U/Kg of BoNT/A or vehicle. On the testing day, animals then received injections of 
capsaicin into the same hind-paw. The rats assigned to the positive control group, were given a sub-
cutaneous injection of 0.2 mg/kg of buprenorphine diluted in normal saline (Abbott and Bonder, 
1997) 30 minutes before capsaicin injections. Following injections of capsaicin, nocifensive 
behaviour and hypersensitivity to noxious heat was observed at levels consistent with the literature 
(Wang et al., 2011a). Sub-cutaneous buprenorphine significantly reduced all nocifensive behaviours 
induced by capsaicin, as well as inhibiting heat hyperalgesia compared to rats pre-treated with 
vehicle four days before capsaicin injection (Fig. 3.9 A-D). Buprenorphine also significantly inhibited 
capsaicin-induced increased c-fos expression in the ipsilateral dorsal horn in comparison to vehicle, 
to the point where there was no significant increase in ipsilateral c-fos expression compared to 
contralateral dorsal horns (Fig. 3.10 D-E).  
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LC/E-BoNT/A injections 4 days prior to capsaicin significantly reduced the combined lifting + licking 
behaviour and lifting time in comparison to vehicle (Fig. 3.9 A-B) but had no effect on licking 
behaviour or latency to respond on the hotplate (Fig. 3.9 C-D). LC/E-BoNT/A did not significantly 
improve the affected parameters compared to BoNT/A pre-treatment, however BoNT/A was shown 
to only be effective on lifting behaviour and not significantly reduce lifting + licking time (Fig. 3.9 A-
B). Unlike buprenorphine treated animals, capsaicin-induced ipsilateral c-fos counts for LC/E-
BoNT/A or BoNT/A treated animals were not significantly different from vehicle treated rats (Fig. 
3.10 E). Thus, although both BoNTs showed moderate antinociceptive behavioural effects, these 
were not correlated with a reduction in capsaicin-induced c-fos upregulation (Fig. 3.10 E). 
While there were detectable anti-nocifensive effects of both toxins in the capsaicin model, those 
induced by BoNT/A were noticeably diminished in comparison with a previous study using BoNT/A 
produced by this lab, in the capsaicin pain model (Wang et al., 2011a). Furthermore, animals 
injected with 15 U/Kg of BoNT/A gained weight at the same rate as rats injected with vehicle, while 
animals injected with 75 U/Kg of LC/E-BoNT/A exhibited a slower growth curve (Fig. 3.9 E). This may 
indicate a drop in BoNT/A activity, explaining the reduced anti-nociceptive effect.   
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Fig. 3.9 LC/E-BoNT/A and BoNT/A reduce capsaicin evoked nocifensive pain behaviours but 
not on heat hyperalgesia overall in rats Total hind-paw lifting + licking time (A), lifting time (B), 
licking time (C) and heat thresholds on a hot plate set to 54.5 °C (±0.5 °C) (D) were plotted. 
Histograms represent total behaviour up to 10 minutes after capsaicin injection. Data plotted as 
means ± SEM and was analysed by one way ANOVA by group with a significant effect detected 
in licking (F (3, 23) = 12.86, p<0.001), lifting (F (3, 23) = 15.24, p<0.001), licking (F (3, 23) = 10.13, 
p<0.001) and hot plate (F (3, 23) = 23.74, p<0.001). Bonferroni post hoc tests: *, P<0.05, vs vehicle, 
**,  P<0.01, vs vehicle, ***, P<0.001, vs vehicle, **, P<0.01, ***, P<0.001 vs. BoNT/A, *, P<0.05, 
vs LC/E-BoNT/A, ***, P<0.001, vs. LC/E-BoNT/A. Vehicle n=6, LC/E-BoNT/A (75 U/Kg) n= 7, 
BoNT/A (15 U/Kg) n=7, buprenorphine (0.2 mg/Kg) n=4. Rats weighed between 186 – 270 g at 
the time of capsaicin injections. Behaviour tests performed in collaboration with Dr Orla 
Moriarty. Vehicle: 0.5% BSA and normal saline. 
D           Hot-plate 
E          Weight gain 
B              Lifting time A Lifting and licking time 
C           Licking time 
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A             Ipsilateral Contralateral B    Ipsilateral     Contralateral 
C D 
Fig. 3.10 Buprenorphine reduced capsaicin-induced c-fos expression in the L4-L5 dorsal horn 
of the spinal cord unlike LC/E-BoNT/A or BoNT/A, representative images and histograms (A) 
Vehicle, (B) LC/E-BoNT/A (75 U/Kg), (C) BoNT/A (15 U/Kg) pre-treatment (4 days before 
capsaicin) and (D) buprenorphine (0.2 mg/Kg) pre-treatment (30 minutes before capsaicin). 
Ipsilateral dorsal horns depicted on the left, contralateral on the right. (E) Data were analysed 
by a two-way ANOVA with side (ipsi vs. contra) and group as factors. There were significant main 
effects of both side (F (1, 28) = 49.67, p<0.001) and group (F (3, 28) = 18.4, p<0.001). Bonferroni post 
hoc tests showed that the number of c-fos positive cells increased in the superficial lumbar 
dorsal horn on the side ipsilateral to intra-plantar capsaicin injection compared with the 
contralateral side. Black symbols ipsi vs. respective contra; green symbols vs. vehicle; blue 
symbols vs BoNT/A; red symbols vs. LC/E-BoNT/A. Data are presented as means ± SEM, n=3-5. 
Each n number is an average of counts from a minimum of 4 sections/rat from L4-5 of the spinal 
cord. Rats used weighed 186 – 270 g at the time of capsaicin injections. Vehicle: 0.5% BSA and 
normal saline. Scale bar: 200 µm 
E 
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Inconsistencies in effect of LC/E-BoNT/A and BoNT/A in rodent pain 
models and testing of a fresh batch of LC/E-BoNT/A 
Observations of decreased LC/E-BoNT/A activity  
Re-testing of LC/E-BoNT/A manifested a reduced anti-nociceptive profile in the rat formalin 
model, while BoNT/A pre-injection showed no anti-nociceptive effect 
 
To reproduce the anti-nociceptive effect of LC/E-BoNT/A in the formalin model (Fig. 3.8) and 
determine its effectiveness vs BoNT/A, both toxins were tested using the formalin model, along 
with a vehicle control. Four days prior to formalin testing animals were pre-treated with either 75 
U/Kg of LC/E-BoNT/A, 15 U/Kg of BoNT/A or vehicle (Fig. 3.11-3.12). Unexpectedly, the analgesic 
effect of LC/E-BoNT/A on formalin-induced behaviours was not reproduced in this study. Pre-
injection of LC/E-BoNT/A did not reduce phase 2 hind-paw lifting behaviours, as shown in the pilot 
study (Fig. 3.11 B vs. Fig. 3.8 F). Curiously, LC/E-BoNT/A was shown to significantly reduce licking 
behaviour at 15 minutes after injection of formalin (Fig. 3.11 A), which was not observed in the 
initial pilot study (Fig. 3.8 C); LC/E-BoNT/A also seemed to show a trend in reducing hind-paw licking 
behaviours over the entire time-course. Examining the AUC of formalin-induced licking behaviours 
highlights that the overall anti-nociceptive effect of LC/E-BoNT/A on hind-paw licking was 
significantly greater than the vehicle pre-injection (Fig. 3.12 A). Pre-treatment of BoNT/A, however, 
showed no significant effect in reducing any of the formalin-induced nocifensive behaviours 
compared to vehicle injection (Fig. 3.11 A-C. 3.12 A-C). This result differs from previous reports by 
Cui et al., 2004, where BOTOX® pre-treatment reduced formalin-induced nocifensive behaviours in 
rats, and by Luvisetto et al., 2006, where isolated 150 kDa BoNT/A reduced formalin-induced licking 
behaviours in mice. Both BoNTs had a minor inhibitory effect on weight gain at 4 days post toxin 
(Fig. 3.11 D), less than the normal effect on rat growth curves expected of these toxin doses based 
on previous experience (see effect of LC/E-BoNT/A in Fig. 3.9 E). This lack of an obvious effect on 
weight gain and the inconsistent anti-nociceptive effect in the formalin model indicated that there 
may have been a potency decrease in both toxins since their last use. 
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C                      Lifting and licking time 
Fig. 3.11 Time-course shows anti-nociceptive effect of LC/E-BoNT/A on formalin-induced 
licking behaviours but not lifting, no effect of BoNT/A observed in rat formalin model Hind-
paw licking time (A), lifting time (B), combined lifting and licking time (C) relative to formalin 
injection, and rat weight gain (D) relative to toxin injection were plotted. Data plotted as means 
± SEM and was analysed by repeated measures two-way ANOVA with time and experimental 
group as factors. For all licking and lifting + licking there was a significant main effect of time 
(F (11, 242) = 29.3, p < 0.001; F (11, 264) = 22.3, p < 0.001) but not in lifting. No significant effect of 
group was detected in any parameters. Bonferroni post hoc tests showed a significant effect of 
LC/E-BoNT/A on licking time at 15 minutes post formalin, **, P<0.01, LC/E-BoNT/A vs. vehicle. 
BoNT/A n=9, LC/E-BoNT/A n= 8, Vehicle n=8. Rats weighing between 190 – 250 g at the time of 
BoNT/vehicle injections were used. Behaviour tests performed in collaboration with Dr Orla 
Moriarty. Vehicle: 0.5% BSA and normal saline. 
D                      Weight gain 
A                           Licking time B                                Lifting time 
Saline BoNT/A, 15 U/Kg
BoNT/A, 15 U/Kg
LC/E-BoNT/A, 75 U/KgVehicle 
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LC/E-BoNT/A and BoNT/A retained activity in vitro and was of acceptable purity, LC/E-BoNT/A 
showed reduced activity compared to results when initially produced 
 
To determine whether long term storage at -20 °C affected the biological activity of LC/E-BoNT/A 
and BoNT/A, in vitro potency and purity tests were conducted. Both toxins were assessed using an 
established in vitro substrate cleavage assay (Wang et al., 2012) and sample purity and integrity 
was investigated by SDS-PAGE and protein staining. Fig. 3.13 B shows that aliquots of both toxins 
retained proteolytic activity, albeit diminished from when first produced (discussed in chapter 4). 
In Fig. 3.13 A it can be seen that under non-reducing conditions some of the LC/E-BoNT/A lacked 
C 
Fig. 3.12 AUC analysis confirms significant effect of LC/E-BoNT/A on overall formalin-induced 
licking behaviour Total hind-paw licking (A), lifting time (B), and combined lifting and licking 
time (C). Histograms represent total behaviour (60 min) after formalin injection. Data plotted 
as means ± SEM and was analysed by one-way ANOVA by group with a significant effect 
detected in licking (F (2, 24) = 3.91, p<0.05). Bonferroni post hoc tests showed a significant effect 
of LC/E-BoNT/A vs vehicle, *, P<0.05. Vehicle n=8, LC/E-BoNT/A (75 U/Kg) n= 8, BoNT/A (15 
U/Kg) n=9. Rats weighing between 190 – 250 g at the time of BoNT/vehicle injections were used. 
Behaviour tests performed in collaboration with Dr Orla Moriarty. Vehicle: 0.5% BSA and normal 
saline. 
B A 
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intact di-sulphide bonds, as shown by the presence of a faint band at the same size marker as the 
DTT reduced sample. This was unlikely to affect the analgesic ability of LC/E-BoNT/A as most of the 
non-reduced sample retained the di-sulphide bonds, while BoNT/A non-reduced sample contained 
only toxin with intact di-sulphide bonds. Estimated EC50 of the two neurotoxins (Fig. 3.13 C) showed 
that their LCs had similar levels of activity.  
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Fig. 3.13 LC/E-BoNT/A and BoNT/A samples retain integrity and proteolytic activity in 
vitro (A) Separation of the LC and HC are observed in the presence of DTT, which reduces 
the di-sulphide bond connecting the LC to the HC. A single, dense band can be seen in the 
lane with LC/E-BoNT/A + DTT, as the molecular mass of two LCs is equal to that of the HC 
(100 kDa) (B) Both LC/E-BoNT/A and BoNT/A cleaved recombinant SNAP-25 substrate at 
concentrations as low as 0.1 nM. (C) Estimated EC50 values were calculated from the 
cleavage assay for both toxins. A-B: Samples resolved by SDS-PAGE and Coomassie stained. 
Representative results: n=1. 
B 
C 
Protein stained Protein stained 
A 
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MaxTD of LC/E-BoNT/A was found to have increased by 47%, indicating reduced activity 
 
Following the results of the in vitro activity and purity tests for LC/E-BoNT/A and BoNT/A, a dose 
range study was conducted to confirm if the intra-plantar MaxTD of LC/E-BoNT/A had deviated 
since first being set at 75 U/Kg. Efforts were focused on LC/E-BoNT/A and not BoNT/A, to limit use 
of animals for these experiments. A broad range of LC/E-BoNT/A doses were injected into rats to 
find the upper limit where the toxin would induce locomotor dysfunction (rotarod test), muscle 
weakening (Kondziela grip test) and adversely affect animal health (weight gain). A “paralysis cut 
off” of 144 s (80% of baseline trial length of 180 s on rotarod) and 70% of pre-injection grip test 
performance was used to identify paralytic doses. A 3.5% decrease in weight from pre-treatment 
values was used as a cut-off for toxin doses considered to be unsuitable for screening in animal 
models. Intra-plantar injections of LC/E-BoNT/A showed a dose-response relationship in the effects 
on animal weight changes (Fig. 3.14 A). Based on weight loss combined with visual assessment of 
rat health (criteria in methods) (Fig. 3.14 D), 225-300 U/Kg were deemed unsuitable for further 
study. Both 225 and 300 U/Kg greatly impaired rotarod performance (Fig. 3.14 B) from day 1 post 
injection which began to recover at day 5 post injection. Both doses decreased grip strength (Fig. 
3.14 C) to below the cut-off within two days after injection. Surprisingly, the rat treated with 125 
U/Kg showed a greater decrease in grip strength performance than 175-225 U/Kg. This is likely due 
to the low sample sizes used per dose in this experiment and the variability between animals (n=1). 
Importantly, 75 U/Kg was shown to be almost indistinguishable from vehicle in its effects on weight 
gain, visual assessment and rotarod, but did have a minor effect on grip strength. Furthermore, 
there were no differences between 75-175 U/Kg on rotarod performance, and 125-175 U/Kg had 
no deleterious effects on animal weight gain.  
Based on the initial dose range study, 90-150 U/Kg was selected to identify the new MaxTD for intra-
plantar injections of LC/E-BoNT/A. The MaxTD was selected based on weight gain only since the 
visual assessment score, rotarod and grip test were not sensitive enough to consistently detect 
effects of the toxins at doses below 225 U/Kg, based on Fig. 3.14 B-C. Unexpectedly, 110-150 U/Kg 
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all induced weight loss in rats after injection (Fig. 3.14 E), contrary to the previous results which 
showed no weight loss until the dose exceeded 225 U/Kg (Fig. 3.14  A). This may be because the 
rats used in this dose experiment were older and less resilient to BoNT side-effects than those used 
in the previous study (190-230 g vs 275-350 g). To summarise the figure, 150 U/Kg caused a long-
lasting decrease in body weight, reaching the cut-off at day 3 post toxin and therefore was 
unsuitable for further investigations. There were no major differences between 90-100 U/Kg and 
as neither dose induced greater than a 1% decrease in weight, these doses were too low to be the 
MaxTD . Slightly more weight loss was noted in rats treated with 110 U/Kg than those injected with 
130 U/Kg, with both demonstrating similar patterns of weight change indicating that the doses had 
an approximately equal impact on animal health. The MaxTD was set at 110 U/Kg to ensure animals 
would not show severe adverse health effects, when the sample size was expanded for the pain 
studies. Together, these results show that ~47% more LC/E-BoNT/A could be injected than 
previously used by Wang et al., 2017a and in reported experiments until this point. This suggests 
that the observed inconsistency in anti-nociceptive effect between the formalin model experiments 
(Fig. 3.7-3.8 vs 3.11) and between the capsaicin experiment (Fig. 3.9) vs Wang et al. 2011a, may be 
due to decreases in potency of LC/E-BoNT/A during storage. 
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Fig. 3.14 MaxTD for intra-plantar injections of LCE/-BoNT/A was increased compared to first 
MaxTD of 75 U/Kg Time courses of % weight change (A), locomotor ability (B), hind limb 
strength (C) and overall animal health (D) relative to toxin injection (vertical dotted lines) 
presented. n=1 for all treatment groups. Horizontal lines in (B) and (C) indicate 80% 
performance cut off for rotarod (based on a 180 s trial cut-off) or 70% performance cut-off for 
grip strength based on average grip test performance before injection. Horizontal line in (D) 
indicates cut-off score for animal distress caused by toxin injections. (E) Time course of % weight 
change from pre-treatment weight. Data plotted as means ± SEM. The maximum tolerated dose 
selected for screening in the capsaicin model was based on 3.5% weight loss cut off (horizontal 
black line), indicating the maximum amount of weight loss that can be induced by LC/E-BoNT/A 
without impairing behaviour for pain studies. Horizontal dotted line at 0% (pre-injection 
bodyweight). Rats weighing 190 – 230 g at the time of BoNT injections were used in panels A-D, 
rats weighing 275 – 350 g at the time of toxin injection were used in (E). Vehicle: 0.5% BSA and 
normal saline. 
B A 
D C 
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110 U/Kg LC/E-BoNT/A did not reproduce the antinociceptive effect of 75 U/Kg LC/E-BoNT/A 
in the capsaicin rat model of acute inflammatory pain 
 
Vehicle and 110 U/Kg of LC/E-BoNT/A were injected into the hind-paw four days before intra-
plantar injection of capsaicin in the ipsilateral paw. Increasing the dose of LC/E-BoNT/A from 75 
U/Kg to 110 U/Kg caused a mild inhibitory effect of LC/E-BoNT/A on the rat growth curve, indicating 
toxin activity (Fig. 3.15 F). Despite this no significant effect on capsaicin-induced nocifensive 
behaviour (hind-paw flinching, lifting or licking) or heat hyperalgesia (hot-plate test) was observed 
(Fig. 3.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Fig. 3.15 Pre-treatment with 110 U/Kg LC/E-BoNT/A had no effect on all capsaicin-induced 
nocifensive behaviours in rats Total hind-paw flinches (A), lifting time (B), lifting + licking time 
(C) licking time (D) and heat thresholds (E) on a hot plate set to 51 °C (±0.5 °C) were plotted. 
Histograms represent total behaviour up to 10 minutes after capsaicin injection. Data plotted 
as means ± SEM and was analysed by unpaired t-tests. No significant differences between LC/E-
BoNT/A or vehicle pre-treatment four days before capsaicin injection. n=10 for both groups. 
Rats weighing 186 – 270 g at the time of capsaicin injections were used. Vehicle: 0.5% BSA and 
normal saline. Behaviour tests performed in collaboration with Dr Orla Moriarty. 
C D 
F E 
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Establishing potency and MaxTD of a second lot of LC/E-BoNT/A 
 
Since the anti-nociceptive effect of LC/E-BoNT/A was now absent at higher doses in the capsaicin 
model of pain, a new batch of LC/E-BoNT/A (batch 2) was produced and tested to reproduce the 
results from the capsaicin and SNI models of pain. Batch 2 was injected in a new vehicle consisting 
of 0.05% HSA, 10 µM ZnCl2 and 0.9% NaCl, the percentage of HSA in the vehicle being based on 
injections of BoNT/A complex in patients (Wohlfarth et al., 1997). Since BoNTs contain zinc 
dependent proteases, zinc was added to the vehicle to ensure activity of the LC/E-BoNT/A was 
retained after injection into the rat.  These pain behaviour studies were performed in collaboration 
with Dr Orla Moriarty. 
Potency of batch 2 LC/E-BoNT/A determined by refined mouse LD50 which was equal to 
potency of previous batch of LC/E-BoNT/A 
 
Potency of batch 2 of LC/E-BoNT/A was tested in a refined version of the mouse LD50 assay. Mice 
received intra-peritoneal injections of LC/E-BoNT/A diluted in normal saline with 0.05% HSA and 10 
µM ZnCl2. Once they reached a pre-determined humane endpoint (severe indrawn scaphoid 
abdomen with respiratory distress & pupillary dilation or weight loss of 20% from pre-injection 
weight), the mice were euthanized. This is a refinement to the typical BoNT/A LD50 assay so it does 
not rely on death as an endpoint (NIEHS, 2008), that was a requirement by the HPRA to gain 
approval for these animal studies. The final minimum lethal dose (LD50) value was estimated at 6 × 
107 U/mg (1 LD50 unit = 16.6 pg), based on the % of mice euthanised from each dose of LC/E-BoNT/A 
(Fig. 3.16 A). These values matched the potency of batch 1 LC/E-BoNT/A when it was first produced. 
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MaxTD of batch 2 LC/E-BoNT/A was set at 120 U/Kg; SNAP-25 cleavage was detected in 
ipsilateral plantaris muscles at doses of 75 U/Kg and signs of systemic spread of LC/E-BoNT/A 
found at doses of 150 U/Kg 
 
Injections of 150 – 300 U/Kg of batch 2 of LC/E-BoNT/A into the hind-paw of rats caused profound 
motor paralysis as shown by the rotarod test and weight loss that was unacceptable for further 
animal testing (Fig. 3.16 B-C). Doses between 75-125 U/Kg caused some impairment of rotarod 
performance, but it was unclear if this was due to motor impairment or inconsistent behaviour in 
rats, based on visual assessment of rotarod performance. While injections of 125 U/Kg did not result 
in any more motor impairment than 75-100 U/Kg, it did induce some mild weight loss along with 
toxicity symptoms such as nasal/ocular discharge. While none of the individual symptoms 
warranted reducing the MaxTD from 125 U/Kg, the cumulative stress of all the symptoms was at 
the threshold of what could be considered a MaxTD. Based on this, it was decided to reduce the 
MaxTD to 120 U/Kg to reduce toxicity symptoms.   
To confirm proteolytic activity of LC/E-BoNT/A at the site of delivery, animals that had been injected 
with 75 or 150 U/Kg of LC/E-BoNT/A, or vehicle, were euthanised after the dosing study behavioural 
tests. The plantaris muscle from the ipsilateral and contralateral paws was dissected and 
homogenised, these samples were used for Western blotting and subsequent staining with an anti-
SNAP-25 antibody, which detected intact SNAP-25, SNAP-25A and SNAP-25E. This would allow for 
detection of SNAP-25 cleavage post toxin injection in the hind-paw to correlate with effects on 
behaviour post injection. Lysate from a neuroblastoma cell line (SiMa cells) that had been 
intoxicated with 5 nM of LC/E-BoNT/A was used as a positive control, while naive SiMa cell lysate 
was used as a negative control. Ipsilateral and contralateral plantaris muscles from LC/E-BoNT/A 
injected animals were tested, along with an ipsilateral plantaris muscle sample from a vehicle 
injected animal. SNAP-25A and SNAP-25E were present in the LC/E-BoNT/A treated SiMa cell lysate 
and were absent in the un-treated SiMa cell lysate. LC/E and LC/A cleaved products were detected 
in both ipsilateral and contralateral paws of rats injected with 150 U/Kg indicating spread of the 
toxin to the contralateral limb, while at 75 U/Kg SNAP-25E and SNAP-25A were only present in the 
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ipsilateral paw (Fig. 3.16 D). These results coincided with the paralytic effects of 150 U/Kg on the 
rotarod and adverse effects on weight gain (Fig. 3.16 B-C), indicating greater systemic toxicity at 
higher doses. 
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Treatment pg/mL Mice reaching humane endpoint (%) 
LC/E-BoNT/A 500 100 
LC/E-BoNT/A 166.7 100 
LC/E-BoNT/A 100 100 
LC/E-BoNT/A 71.4 25 
Vehicle NA 0 
F -  75 U/Kg E - 100 U/Kg
A -  300 U/Kg
B -  200 U/Kg
C - 150 U/Kg B - 200 U/Kg
D  - 125 U/KgVehicle 
D 
Fig. 3.16 MaxTD of batch 2 LC/E-BoNT/A was set at 120 U/Kg, proteolytic activity was 
confirmed in the plantaris muscles of rat hind-paws (A) Potency testing of LC/E-BoNT/A listing 
% of mice dying per dose of LC/E-BoNT/A, n=4 mice per dose. Time courses of rat locomotor 
ability (B) and % weight change (C) relative to toxin injection presented. n=2 rats for all 
treatment groups, data represents means ± SEM. Horizontal dotted line in (C) indicates weight 
loss relative to pre-treatment weight. (D) SNAP-25 cleavage confirmed by Western blotting of 
homogenised plantaris muscles harvested from culled, toxin treated rats. 45 µl of each plantaris 
sample was loaded with protein concentrations normalised to intact SNAP-25 content, and 5 µl 
of SiMa cell lysate (treated or untreated) was loaded. Mice weighing 20-22 g and rats weighing 
252 – 367 g at the time of BoNT injection were used. Dr Tom Zurawski acted as lead researcher 
for potency testing of batch 2. Vehicle: 0.05% HSA, 10 µM ZnCl2, normal saline. 
B 
A 
C 
90 
 
Testing of batch 2 LC/E-BoNT/A in SNI and capsaicin rat pain models 
 
After establishing the MaxTD of batch #2 LC/E-BoNT/A, two studies were designed in parallel to 
explore the anti-nociceptive effects of this fresh lot of toxin. As SNAP-25 cleavage was detectable 
in the plantaris of rats injected with 75 U/Kg of batch 2 (Fig. 3.16 D), and there was a mild effect on 
weight gain (Fig. 3.16 B), it was decided to test if batch 2 could reduce SNI-induced hypersensitivity 
at a sub- MaxTD dose (75 U/Kg). Since batch 1 has shown efficacy in the SNI model in ranges of 35 
– 75 U/Kg (Wang et al., 2017a), it was expected that this dose response would be reproduced with 
batch 2. Meanwhile, to confirm that the inconsistent anti-nociceptive effects of batch 1 in the 
capsaicin and formalin models of pain were due to a loss of activity, the MaxTD (120 U/Kg) of batch 
2 was tested in the capsaicin model of acute pain, against vehicle and 0.1 mg/kg buprenorphine as 
a positive control. The dose of buprenorphine was reduced to 0.1 mg/kg from 0.2 mg/kg, which 
was used in Fig. 3.9, as the higher dose induced mild sedation. These studies were performed in 
collaboration with Dr Orla Moriarty.  
75 U/Kg of batch 2 LC/E-BoNT/A mildly inhibited SNI-induced cold hypersensitivity but had no 
effect on mechanical hypersensitivity 
 
As before, rats underwent either sham or SNI surgeries and received intra-plantar injections of 
either LC/E-BoNT/A or vehicle. No effect of LCE/-BoNT/A was found on mechanical hypersensitivity 
induced by the SNI model (Fig. 3.17 A). LC/E-BoNT/A demonstrated an anti-nociceptive effect on 
cold hyperalgesia compared to vehicle on day 14 post surgery (Fig. 3.17 B). Interestingly, sham LC/E-
BoNT/A treated rats showed increases in cold stimuli responses, with sham LC/E-BoNT/A exhibiting 
significantly more nocifensive behaviour than sham vehicle at day 10 post surgery. However, toxin 
treated animals showed marked weight loss (Fig. 3.17 C), which had not been observed in the 
previous dosing study (Fig. 3.16 C). It is unclear why this unexpected weight loss occurred although 
it may be due to variability between animals; therefore, larger sample sizes for dosing studies would 
be needed to address this.  
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Fig. 3.17 Intra-plantar injection of LC/E-BoNT/A inhibits SNI-induced cold hypersensitivity but 
not mechanical hypersensitivity Time courses of mechanical (A) and cold (B) hyperalgesia were 
plotted, including pre-SNI baselines, post-surgery baselines and post injection of LC/E-BoNT/A 
or vehicle (vertical dotted line). Data represents means ± SEM, statistical analysis was performed 
using repeated measures two-way ANOVA and Bonferroni post hoc tests. For both von Frey and 
cold plate tests there were significant effects of time (P<0.0001, F(6, 162) = 27.23, F(8, 216) = 5.215) 
and of group (P<0.0001, F(3, 162) = 41.12, F(3, 216) = 11.63). After induction of the spared nerve injury 
model, significant mechanical hypersensitivity (A) developed between the sham groups and the 
SNI groups (#, p<0.05, ##, P<0.005, ###, P<0.001, Sham LC/E-BoNT/A vs SNI LC/E-BoNT/A), (*, 
P<0.05, ***, P<0.001, Sham vehicle vs SNI vehicle). No significant differences were detected 
between any groups before surgery, between the two sham groups after surgery, or between 
the two SNI groups after toxin injections. (B) 75 U/Kg of batch 2 LC/E-BoNT/A mildly inhibited 
progression of SNI-induced cold hyperalgesia but also caused contralateral increases in cold 
hypersensitivity. (+++, P<0.001, LC/E-BoNT/A SNI vs vehicle SNI) (*, P<0.05, LC/E-BoNT/A sham 
vs SNI sham) (***, P<0.001, SNI vehicle vs SNI sham) (##, P<0.01, Sham LC/E-BoNT/A vs SNI LC/E-
BoNT/A). Rats weighing between 230-280 g at the time of SNI surgery were used. n=8 for all 
groups. Vehicle: 0.05% HSA, 10 µM, ZnCl2, normal saline. Surgeries and behaviour tests 
performed in collaboration with Dr Orla Moriarty. 
C 
A B 
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120 U/Kg of batch 2 LC/E-BoNT/A inhibited capsaicin-induced nocifensive behaviours and heat 
hypersensitivity 
 
Rats received intra-plantar injections of 120 U/Kg LC/E-BoNT/A four days before induction of the 
capsaicin pain model. Following intra-plantar injection of capsaicin, nocifensive like behaviour was 
recorded for 10 minutes. Hargreaves testing was performed at 30 minutes post capsaicin injection 
and hot plate testing was performed at 50 minutes post capsaicin injection. As shown in the SNI 
study that ran in parallel to this, the animals injected with 120 U/Kg of batch 2 LC/E-BoNT/A showed 
distinct weight loss (Fig. 3.18 F), indicative of systemic toxicity. Despite this, LC/E-BoNT/A 
significantly reduced capsaicin-induced hind-paw lifting behaviour (Fig. 3.18 B), combined lifting 
and licking behaviour (Fig. 3.18 A) and response to heat stimuli on the hot plate test (Fig. 3.18 D), 
compared to vehicle. LC/E-BoNT/A also showed no significant difference to buprenorphine in 
relieving these parameters, indicating a comparable effect to buprenorphine. However, LC/E-
BoNT/A showed no effect on hind-paw licking while buprenorphine was significantly more effective 
than both LC/E-BoNT/A and vehicle on reducing licking behaviour (Fig. 3.18 C). Lastly, capsaicin 
injection in the vehicle treated group was shown to significantly reduce ipsilateral heat thresholds 
(measured by Hargreaves test) compared to the contralateral thresholds, indicative of heat 
hypersensitivity. Interestingly, there was no significant difference between ipsilateral and 
contralateral thresholds in the LC/E-BoNT/A group, indicating LC/E-BoNT/A inhibited the 
development of capsaicin-induced heat hyper-sensitivity as measured by the Hargreaves test. 
Buprenorphine significantly increased both ipsilateral and contralateral thresholds to heat stimuli 
as expected (Gades et al., 2000), and these thresholds were significantly higher than the LC/E-
BoNT/A and vehicle group contralateral thresholds (Fig. 3.18 E).  
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Fig. 3.18 MaxTD of batch 2 LC/E-BoNT/A relieved all capsaicin evoked nocifensive behaviours 
excluding hind-paw licking in rats Total hind-paw lifting + licking time (A), lifting time (B), licking 
time (C), heat thresholds on a hot plate set to 51 °C (±0.5 °C) (D) and heat thresholds according 
to Hargreaves test (E) were plotted. Histograms A-C represent total behaviour up to 10 minutes 
after capsaicin injection. Histogram (D) displays data at 50 min post capsaicin and (E) shows data 
at 30 min post capsaicin. Data plotted as means ± SEM and were analysed by one way ANOVA 
by group with a significant effect detected in lifting + licking (F (3, 23) = 12.86, p<0.001), lifting (F 
(3, 23) = 15.24, p<0.001), licking (F (3, 23) = 10.13, p<0.001), hot plate (F (3, 23) = 23.74, p<0.001) and 
Hargreaves (F(5, 35) = 22.5, P<0.05). Bonferroni post hoc tests (A-D): *, P<0.05, **, P<0.01, ***, 
P<0.001, vs vehicle, **, P<0.01, vs. LC/E-BoNT/A. (E): ***, P<0.001, vs vehicle ipsi, ***, P<0.001, 
vs LC/E-BoNT/A ipsi, ##, P<0.01, vs vehicle contra, ++, P<0.01, vs vehicle contra, ++, P<0.01, vs 
LC/E-BoNT/A contra. Rats weighing 186 – 270 g at the time of capsaicin injections were used. 
Vehicle n=6, LC/E-BoNT/A (120 U/Kg) n= 6, buprenorphine (0.1 mg/Kg) n=6.  Vehicle: 0.05% HSA, 
10 µM, ZnCl2, normal saline. Behaviour tests performed in collaboration with Dr Orla Moriarty. 
94 
 
Summary of effects of BoNT/A and BoNT chimeras in rat models of pain  
 
To summarise the differences of batches 1 and 2 of LC/E-BoNT/A in the different rat pain models, 
the results of the different toxins (BoNT/A, LC/E-BoTIM/A, LC/E-BoNT/A) have been collated into 
table 3.1. Batch 1 of LC/E-BoNT/A had the highest anti-nociceptive effect overall while batch 2 LC/E-
BoNT/A showed a reduced anti-nociceptive effect in comparison. BoNT/A demonstrated mild or no 
anti-nociceptive effects overall while LC/E-BoTIM/A demonstrated a moderate effect in the SNI 
model, the only model it was tested in this project, and a moderate effect in the capsaicin model of 
pain (Wang et al., 2011a). 
 
 
 
 
 
 
 
  LC/E-BONT/A: BATCH 1 LC/E-BONT/A: BATCH 2 LC/E-BOTIM/A BONT/A  
SNI     
CFA X NA NA X  
FORMALIN ,  NA NA X  
CAPSAICIN X,      
VZV NA NA NA NA  
Table 3.1 Results of screening different BoNTs in rat models of inflammatory and 
neuropathic pain Effects of different toxins in different pain models summarised using a scale 
of no anti-nociceptive effect to maximum anti-nociceptive effect. Results of different 
experiments using the same toxin in the same model are separated by a comma.   - Mild 
anti-nociceptive effect,  - moderate antinociceptive effect,  - maximum nociceptive 
effect, X – no anti-nociceptive effect, NA – Not tested in model. Testing of LC/E-BoTIM/A in 
capsaicin model was reported in Wang et al., 2011a. 
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Chapter 4 - Discussion 
 
The Vzv rat model of post-herpetic neuralgia was found to not induce consistent 
hypersensitivity and thus was unsuitable for testing LC/E-BoNT/A 
 
During attempts to establish the rat Vzv model, unexpected complications arose in the inability to 
reproduce consistent hyper-sensitivity. While mechanical allodynia could be induced, this only 
occurred in the lowest cell titre administered and no dose response was observed as reported by 
(Hasnie et al., 2007, Garry et al., 2005). The model was also short lived (recovering in less than two 
weeks) which made it unsuitable for testing of BoNTs and conflicted with other reports (Medhurst 
et al., 2008, Fleetwood-Walker et al., 1999). Returning to the literature to identify a reason behind 
the lack of reproducibility in the Vzv model, a PhD thesis describing similar issues was found 
(Medhurst, 2011). The author was also unable to establish the Vzv model and tried several 
experiments to discern any possible reason as to why, even going so far as to combine a Vzv 
injection with an intra-plantar capsaicin injection, to see if a secondary insult would uncover latent 
Vzv-induced allodynia. This proved negative and the authors confirmed that Vzv infection of the 
DRG was also not feasible with intra-plantar injections of Vzv infected cells, contradicting the 
original publications reporting this (Sadzot-Delvaux et al., 1990). Taking this comprehensive 
investigation into account, along with the fact that different groups publishing on this model each 
demonstrate different phenotypes, with Fleetwood-Walker et al. (1999) reporting heat allodynia 
that was not reproduced by Hasnie et al. (2007), investigations into the Vzv model were stopped. If 
this model was to be further explored, comparisons between the different Vzv model protocols in 
the literature would possibly be necessary. Four different Vzv strains (Dumas, Ellen, pOka, KMcC) 
have been propagated using four different cell types (MeWo, ARPE-15, MRC-5, CV-1) and 
administered to three different rat strains (Sprague Dawley, Wistar, Random-hooded) (Hasnie et 
al., 2007, Guedon et al., 2015, Medhurst et al., 2008, Fleetwood-Walker et al., 1999, Zhang et al., 
2011a, Garry et al., 2005, Guedon et al., 2014). Considering the wide variety in protocols and the 
different presentations of the models seen in this work, by Medhurst (2011) and other published 
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reports (Fleetwood-Walker et al., 1999, Hasnie et al., 2007), it’s probable that the issues lie in the 
lack of standardised protocols for this model. The specific combination of rat, viral strain and cell 
type used in this work have all individually been used in successfully induced Vzv models in the 
literature, but the specific combination of these three has not been published on yet. Considering 
that different strains of rats (and even the same strain from different suppliers) can show 
significantly different pain behaviours within the same pain model or after treatment with the same 
analgesic (Benoliel et al., 2002, Kristensen et al., 2017, Banik et al., 2002), it is possible that the 
Sprauge Dawley rats used in this project were not as sensitive to symptoms of PHN induced by the 
Ellen strain of Vzv when administered via MRC-5 cells.  
Batch 1 LC/E-BoNT/A exhibited a promising anti-nociceptive effect in capsaicin and 
formalin rat models of pain, but did not show an effect on capsaicin-induced c-fos 
expression in the L4-L5 dorsal horn 
 
This project was the first to investigate the effects of LC/E-BoNT/A in the formalin model of acute 
pain, the first rodent pre-clinical model used to test the analgesic efficacy of BOTOX® (Cui et al., 
2004). Interestingly, a significant effect on phase I flinching behaviour in the LC/E-BoNT/A treated 
group was observed, although this was not seen in any other phase 1 behavioural parameters. As 
intra-plantar injections of BoNT/A or BOTOX® have previously been reported to have no effect on 
phase I formalin behaviour (Pavone and Luvisetto, 2010, Cui et al., 2004), it can be speculated that 
this analgesic effect of LC/E-BoNT/A is a result of the LC/E tethered to BoNT/A. Cleavage of SNAP-
25 by LC/A or LC/E produces truncated SNAP-25A or SNAP-25E, respectively, impairing correct 
SNARE complex formation, which prevents vesicular fusion to the plasma membrane, thus, 
inhibiting the release of neurotransmitters. BoNT/A inhibition of exocytosis has been reported to 
be reversed by increasing synaptic concentrations of Ca2+. Mice suffering from botulism recover 
after treatment with 4-aminopyradine (4-AP), a compound that increases free calcium inside nerve 
terminals (Lundh et al., 1977). Interestingly, SNAP-25A has been shown to retain the ability to form 
SDS-resistant SNARE complexes, while SNAP-25E cleavage products cannot; this discrepancy is likely 
due to the differences in cleavage length and suggests that LC/E-mediated cleavage may result in 
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more effective inhibition (Hayashi et al., 1994). This has been demonstrated in reports that BoNT/A 
inhibition of Ca2+ evoked norepinephrine release in vitro can be overridden by increasing Ca2+ 
concentrations in cell incubation media. Increasing the Ca2+ concentration did not undo BoNT/E-
induced blockades of NE release, demonstrating the Ca2+ resistant blockade of exocytosis resulting 
from SNAP-25E (Gerona et al., 2000, Banerjee et al., 1996). BoNT/A blockade of CGRP release was 
found to be reversed by capsaicin evoked increases in intracellular Ca2+ in vitro, and like the Ca2+ 
evoked release of NE, was also prevented by LC/E. Despite this, inhibition of CGRP release from 
either the peripheral (in the hind-paw) or central terminals (in the spinal cord) of nociceptors is 
unlikely to explain the LC/E-BoNT/A mediated reduction in phase 1 formalin flinching. This is 
because while phase 1 formalin pain is believed to be driven by activation of peripheral nociceptors 
by the initial injury (Cui et al., 2004), CGRP plays a facilitatory role in developing sensitisation e.g. 
via vasodilation at the injury site or by acting synergistically with substance P to drive wind-up in 
the spine (Latremoliere and Woolf, 2009, Oku et al., 1987, Le Greves et al., 1985). This is further 
supported by the evidence that CGRP KO mice show no change in phase 1 formalin behaviour 
compared to WT mice (Shinohara et al., 2017). Unfortunately, due to variations in the anti-
nociceptive effect of LC/E-BoNT/A between different experiments in this work it was not possible 
to obtain samples to investigate CGRP release in the LC/E-BoNT/A vs. vehicle treated rats in the 
capsaicin or formalin model experiments. Phase 1 of the formalin model is believed to be a 
behavioural response to fast depolarisation of nociceptors by a noxious stimuli (milliseconds) 
(McNamara et al., 2007), not from the prolonged effects of CGRP release (Oku et al., 1987). 
Inhibition of glutamate release at the central terminal of the nociceptor, which mediates the rapid 
transmission of a nocifensive signal at the dorsal horn (Millan, 1999), could explain this reduction 
in phase 1 nocifensive behaviours. Retrograde transport of LC/E-BoNT/A to the central nociceptor 
terminals in the dorsal horn could mediate this, where the production of SNAP-25E could 
hypothetically provide a more stable blockade of glutamate release, resistant to the sustained 
excitatory signals coming from the formalin injury. Interestingly, direct injection of BoNT/A into the 
spinal cord, at a dose 40-times lower than the normal intra-plantar dose can also inhibit phase 1 
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behaviours (Lee et al., 2011b, Matak et al., 2017). This would indicate that the amount of active 
LC/A transported to the central nociceptive terminals from an intra-plantar injection is insufficient 
to block glutamate release in response to formalin. Furthermore, it took 10 days for intrathecal 
injections of BoNT/A to inhibit phase 1 formalin behaviours, while only 1 day for an anti-nociceptive 
effect to be observed in phase 2. This could mean that it requires 10 days for sufficient SNAP-25A 
to accumulate, so the increase in intracellular Ca2+ from sustained nocifensive signalling doesn’t 
reverse the blockade of glutamate. Considering that a larger amount of LC/E-BoNT/A can be 
injected into the hind-paw compared to BoNT/A (75 vs 15 U/Kg), this could mean that a greater 
amount of active protein is successfully transported to the central terminal of the nociceptor to 
cleave SNAP-25. Secondly, as LC/E-BoNT/A contains the LC/E, this would induce a Ca2+ resistant 
blockade of glutamate release, despite sustained activity from formalin activation of nociceptors. 
Unfortunately, due to the lack of reproducibility of the anti-nociceptive effects of LC/E-BoNT/A, 
further studies into the mechanism behind these observations were not possible. 
Reports have provided strong evidence for retrograde transport of BoNT/A (Antonucci et al., 2008) 
and some researchers believe that this may be linked to its antinociceptive effect (Bach-Rojecky 
and Lackovic, 2009, Antonucci et al., 2008, Matak and Lackovic, 2014). However, the hypothesis 
that active BoNT/A can undergo retrograde transport and transcytosis to the CNS is still a point of 
contention in the literature with a comprehensive critique of this hypothesis provided by (Aoki and 
Francis, 2011), and experiments by (Cai et al., 2017) having shown that distal effects of BoNT/A may 
be due to systemic spread of high doses of neurotoxin and not necessarily retrograde transport. 
However, it is unclear how LC/E-BoNT/A could induce an effect on phase 1 formalin behaviour if its 
mechanism of action was solely limited to the hind-paw. LC/E-BoNT/A is not the only BoNT to have 
demonstrated an anti-nociceptive effect on phase 1 formalin behaviour. Intra-plantar 
administration of BoNT/B has been shown to reduce phase I formalin behaviours in mice (Luvisetto 
et al., 2006), although this has not been reproduced by other groups (Marino et al., 2014). BoNT/B 
cleaves different SNAREs (VAMP 1 and 2) to BoNT/A and BoNT/E, but its inhibition of 
neurotransmitter release has been shown to be resistant to Ca2+ triggers, like BoNT/E (Banerjee et 
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al., 1996, Gerona et al., 2000). This could mean that BoNT/B inhibition of phase 1 formalin 
behaviours is similar to the proposed mechanism for LC/E-BoNT/A, and that intra-plantar injection 
of BoNT/B is transported to the central terminal of nociceptors resulting in a blockade of glutamate 
release resistant to increased intracellular Ca2+ from incoming action potentials induced by 
formalin. 
As expected, LC/E-BoNT/A treated rats showed significant reductions in phase 2 lifting and flinching 
responses compared to the vehicle group; however, there was no effect on paw licking behaviour 
or combined lifting/licking behaviours, in contrast to previous findings with BOTOX® (Cui et al., 
2004). Considering previous reports that BoNT/A complex effectively relieved formalin phase 2 
behaviours (Cui et al., 2004), it is unexpected that the LC/E-BoNT/A analgesia is present in only two 
of the four behaviour paradigms in phase 2. Further investigations, administering intrathecal 
injections of LC/E-BoNT/A to rats before intra-plantar injection of formalin could provide more 
clarity on this anomaly, as intrathecal injections of BoNT/A have shown superior efficacy over intra-
plantar injections (Bach-Rojecky et al., 2010, Luvisetto et al., 2006, Lee et al., 2011b). If intrathecal 
injections of LC/E-BoNT/A were to provide superior pain relief on all four of the behaviours present 
in phase 1 and 2, it would indicate a limitation of the analgesia that can be induced by peripheral 
injections of LC/E-BoNT/A over central injections. To investigate whether the effects of LC/E-
BoNT/A on phase 1 are a result of cleavage of SNAP-25 in the hind-paw or retrograde transport of 
the toxin to the dorsal horn, a timeline of different intra-plantar injections of LC/E-BoNT/A could 
be compared to identify how long after treatment is required for an effect on phase 1 to occur. If it 
takes longer for analgesia to be induced on phase 1 than phase 2, this could indicate the phase 1 
analgesia is dependent on the length of time for a required amount of the toxin to be transported 
to central terminals in the dorsal horn to block release of glutamate from the central nociceptive 
terminals. If the onset of phase 1 analgesia were to correlate with detection of SNAP-25E in dorsal 
horn samples from treated animals, this would provide important data on the mechanism of phase 
1 pain relief by LC/E-BoNT/A. 
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To delve deeper into the differences between LC/E-BoNT/A and BoNT/A, a direct comparison was 
designed using the capsaicin model of pain. This model was selected as capsaicin induces the 
release of CGRP from nociceptors in vitro (Sauer et al., 1999) and induces hyperalgesia in vivo 
(Massaad et al., 2004), most likely through neurogenic inflammation of the hind-paw. As capsaicin-
induced CGRP release is blocked by cleavage of SNAP-25 by LC/E but not LC/A in vitro (Meng et al., 
2009), it was expected that LC/E-BoNT/A would outperform BoNT/A in pain relief of the capsaicin 
model. Both BoNT/A and LC/E-BoNT/A reduced hind-paw lifting behaviour compared to vehicle but 
neither toxin reduced paw licking or heat hyperalgesia against this control. Furthermore, LC/E-
BoNT/A significantly reduced overall lifting/licking behaviour, in contrast to BoNT/A which did not. 
While LC/E-BoNT/A outperformed BoNT/A on acute pain behaviours (compared to vehicle) as 
expected, it did not affect hypersensitivity to heat or acute paw licking. This was surprising, as LC/E-
BoTIM/A (which has one less active protease than LC/E-BoNT/A) reduced capsaicin-induced heat 
hyperalgesia and hind-paw licking (Wang et al., 2011a). Furthermore, buprenorphine-induced 
(analgesic positive control) pain relief correlated with a significant reduction in c-fos 
immunohistochemical staining in the superficial dorsal horn (L4-L5 region); neither LC/E-BoNT/A 
nor BoNT/A reduced c-fos staining despite showing significant anti-nociceptive effects. However, 
this result is not unique to neurotoxins tested within this project. While BOTOX®-induced analgesia 
has been shown to reduce c-fos expression in the formalin model (Matak et al., 2017), Bitox (a non-
paralytic variant of BoNT/A) was shown to have no effect on formalin or capsaicin-induced c-fos 
staining, and yet reduced capsaicin-induced mechanical hyperalgesia. Also, like the mixed anti-
nociceptive effects of BoNTs in this project, Bitox showed efficacy on only certain pain measures 
(capsaicin-induced mechanical hyperalgesia) but no effect on formalin-induced flinching or 
capsaicin-induced heat hyperalgesia (Mangione et al., 2016). The fact that two modified 
preparations of BoNT/A (LC/E-BoNT/A and Bitox) have shown unexpected differences in anti-
nociceptive effect compared to work published on BOTOX®, highlights the lack of understanding of 
the full mechanism of BoNT/A-mediated analgesia.  
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One possible explanation for the variations between the capsaicin experiment and those conducted 
by Wang et al., 2011 is that the batches of BoNT/A and LC/E-BoNT/A used in this study had a later 
time of onset than previous aliquots of BoNT/A and LC/E-BoTIM/A used by Wang et al. (2011a). In 
this experiment, both neurotoxins were injected four days before capsaicin, to replicate the 
experimental conditions by Wang et al. However, the samples of LC/E-BoNT/A and BoNT/A used in 
Fig. 3.9-3.10 may require more time to cleave sufficient amounts of SNAP-25 to have a similar anti-
nociceptive effect as those reported in Wang et al. Future experiments to identify the optimum 
time to inject LC/E-BoNT/A or LC/E-BoTIM/A before injection of capsaicin would help identify if 
these differences were a result of sample variation between studies. 
Potency changes of LC/E-BoNT/A batch 1 suggest that long-term storage affects toxin 
activity  
 
After the pilot study testing batch 1 LC/E-BoNT/A vs. vehicle in the rat formalin model (Fig. 3.7-3.8), 
the experiment was repeated  to reproduce the anti-nociceptive effect of batch 1 LC/E-BoNT/A and 
compare this with the anti-nociceptive effect of BoNT/A (Fig. 3.11-3.12). Surprisingly, re-testing the 
same batch of LC/E-BoNT/A only showed an effect in reducing phase 2 hind-paw licking behaviours 
and not on phase 2 paw lifting or on phase 1 flinching behaviours, as were previously observed. 
Furthermore, BoNT/A had no significant effect on acute pain behaviours. This unexpected result 
raised the question as to why BoNT/A showed no effect on the formalin model, when BOTOX® was 
reported to reduce formalin-induced pain (Cui et al., 2004). Since the tested batches of BoNT/A and 
LC/E-BoNT/A (batch 1) were produced in 2013-2014 it was deemed prudent to determine if there 
had been any loss of activity due to long term storage at -20 °C. Reports on the effect of long term 
freezing on BOTOX® potency are contradictory. FDA product labelling recommends that BOTOX® 
be disposed of 4 hours after reconstitution (Allergan, 2002), while one group have shown that 
freezing of reconstituted BOTOX® for up to 180 days has no effect on BOTOX® treatment 
satisfaction in humans (Parsa et al., 2007). These effects were not noted in a mouse LD50 however, 
where freezer storage at -70 °C for two weeks of reconstituted BOTOX® resulted in a 69.8% 
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decrease in bioactivity (231% increase in LD50 value) and a 43.9% potency decrease (78.4% LD50 
increase) as soon as 12 hours after freezing (Gartlan and Hoffman, 1993). 
To investigate the potential activity loss, both samples of LC/E-BoNT/A and BoNT/A were checked 
for purity and integrity by protein staining and activity of their proteases tested using the in vitro 
cleavage assay (Wang et al., 2008). When originally produced in 2014 BoNT/A was shown to 
produce SNAP-25 cleavage at a concentration of 0.39 nM, and re-testing of these samples showed 
detectable cleavage as low as 0.5 nM, therefore not indicating an obvious change in LC activity in 
vitro. However, the in vitro cleavage assay only tests the activity of the LC in the presence of a 
recombinantly expressed SNAP-25 fragment, not the ability of the neurotoxin to bind and enter 
neurons and translocate its LC into the cytosol, which could alter the potency of BoNT/A, if 
compromised. Testing of batch 1 LC/E-BoNT/A showed faintly detectable cleavage at a 
concentration of 0.01 nM and obvious cleavage at 0.1 nM when tested in 2013, yet retesting 
showed slight SNAP-25 cleavage only as low as 0.5 nM, indicating a noticeable shift in potency of 
the LCs in vitro. Thus, further investigations on potential effects of long-term storage at -20 °C of 
the neurotoxins used in this project are needed. As LC/E-BoNT/A was the only toxin to show a 
noticeable loss of potency in vitro, and the main objective of this project was testing of this toxin, 
efforts to confirm the inconsistent anti-nociceptive effect of LC/E-BoNT/A over BoNT/A were 
prioritised. 
While the BoNT/A sample showed no signs of precipitation or degradation, with the di-sulphide 
bonds remaining intact, the unreduced samples of LC/E-BoNT/A showed faint bands in line with the 
size of the reduced toxin, indicating that di-sulphide bridge of a small fraction of the neurotoxin 
was not correctly formed. However, these bands were also present when batch 1 LC/E-BoNT/A was 
initially produced and were therefore unlikely to cause the reduction in anti-nociceptive effect. The 
reduced potency in vitro of batch 1 LC/E-BoNT/A was mirrored in vivo by the increased MaxTD of 
110 U/Kg, 47% more than the original 75 U/Kg dose used for the pain studies until this point. 
Considering such a large increase in the MaxTD it was expected that this dose was now too low to 
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have an anti-nociceptive effect since BOTOX® has a very narrow margin between a therapeutically 
effective and ineffective dose. While BOTOX® has been shown to demonstrate a dose response in 
anti-nociceptive effect between 3.5 – 30 U/Kg (Cui et al., 2004), a decrease as low as 0.5 U/Kg was 
shown to be the difference between a therapeutically effective (3.5 U/Kg) and ineffective dose (3 
U/Kg) in rat models of carrageenan-induced inflammatory pain (Bach-Rojecky and Lackovic, 2005). 
After identifying such a large increase in the MaxTD of batch 1 LC/E-BoNT/A, it was anticipated that 
testing of 110 U/Kg of LC/E-BoNT/A in the capsaicin model of pain would demonstrate a clear anti-
nociceptive effect on all behavioural paradigms. However, 110 U/Kg of batch 1 of LC/E-BoNT/A had 
no effect on reducing capsaicin-induced pain-like behaviours. This was surprising as expected 
effects of 110 U/Kg on slowing weight gain were observed in the rats used in the capsaicin 
experiment, which indicated that batch 1 LC/E-BoNT/A was active in vivo. Furthermore, higher 
doses of batch 1 used in the study which identified 110 U/Kg as the new MaxTD, had induced 
paralysis indicating toxin activity. Based on the gradual loss of anti-nociceptive activity along with 
the increase in doses required to induce paralysis or weight loss in rats, it seemed LC/E-BoNT/A 
activity had diminished overtime, and the anti-nociceptive potency degraded more rapidly than the 
paralytic effects of the toxin. Since increasing the total amount of batch 1 LC/E-BoNT/A protein did 
not recover the analgesic effects, this implied that the analgesic potency of the entire sample was 
impaired.  As the anti-nociceptive effect was absent while paralytic symptoms were still observed, 
the two mechanisms may be independent of each other, with the analgesic effect dependent on 
successful entry into nociceptors, while paralysis is dependent on entry into motor neurons. 
Therefore, the putative binding and entry of batch 1 LC/E-BoNT/A into nociceptors may have been 
impaired during long term storage, while binding to motor neurons was retained. As successful 
binding of BoNT/A to neurons is dependent on the presence of SV2, with SV2C being the most 
sensitive to BoNT/A (Dong et al., 2006), it may be that hind-paw motor neurons express higher 
levels of SV2, or of SV2C specifically, than the nociceptors in the hind-paw. If the efficacy of batch 
1 LC/E-BoNT/A’s binding domain were reduced, then it may be more likely to enter motor neurons 
than nociceptors.  To investigate this, total protein levels of SV2 and its different isoforms in 
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cultured motor neurons and sensory neurons could be compared by Western blotting.  By also 
intoxicating motor neuron and sensory neuron cultures with batch 1 of LC/E-BoNT/A and measuring 
the amount of SNAP-25 cleavage at different time-points, any potential differences in the toxin’s 
ability to bind, enter and cleave SNAP-25 in each type of neuron culture can be identified. These 
experiments could shed light on this speculative hypothesis. 
Batches 1 and 2 of LC/E-BoNT/A demonstrate different anti-nociceptive and toxicity 
profiles in rat models of SNI and capsaicin-induced pain  
 
As batch 1 of LC/E-BoNT/A was no longer viable for testing, a fresh batch of LC/E-BoNT/A (batch 2) 
was produced and fully characterised to be used in animal studies. Based on behavioural tests the 
MaxTD of batch 2 was found to be 120 U/Kg, which was tested in the capsaicin model of pain against 
vehicle and buprenorphine. Since batch 1 had previously shown no effect on the hot-plate test (a 
measure of heat hyperalgesia) after injection capsaicin, the Hargreaves test was selected to 
measure heat allodynia in this experiment using batch 2. As the Hargreaves test measures response 
time to a gradually increasing temperature, a decrease in response time indicates a reduced heat 
threshold which is indicative of heat allodynia (Deuis and Vetter, 2016). The hot-plate measures 
latency to respond to an already noxious stimulus and so reductions in response time are taken as 
a hyperalgesic response (Richardson et al., 1997).  Using both tests would investigate if LC/E-
BoNT/A showed anti-nociceptive effects on only certain types of heat hypersensitisation, i.e. could 
LC/E-BoNT/A recover a decreased noxious heat threshold on the Hargreaves (allodynia), but not 
improve latency to respond to a constant noxious heat stimulus on the hotplate (hyperalgesia).  
Interestingly, batch 2 LC/E-BoNT/A was shown to have a significant effect on heat hyperalgesia 
compared to vehicle, as measured by the hotplate test, unlike batch 1. Furthermore, batch 2 
inhibited capsaicin-induced heat allodynia measured by the Hargreaves test. Capsaicin significantly 
reduced paw withdrawal latencies in the ipsilateral vs. contralateral hind-paws in the vehicle 
treated group, which is typical of the model (Gilchrist et al., 1996). While there was no significant 
difference on heat allodynia between the vehicle treated group and LC/E-BoNT/A treated group, 
there was also no significant difference between the contralateral and ipsilateral paw thresholds 
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for the LC/E-BoNT/A group after capsaicin injection. This indicated that pre-treatment of batch 2 
LC/E-BoNT/A prevented capsaicin-induced heat allodynia in comparison to contralateral hind-paw 
thresholds (unlike vehicle pre-treatment). This did not provide enough pain relief to be significantly 
improved over vehicle pre-treatment however. Interestingly, there was no significant difference 
between batch 2 LC/E-BoNT/A and buprenorphine-induced analgesia on the hot plate test, but 
there was a significant difference between the two groups on the Hargreaves test. Buprenorphine 
is known to increase thresholds to noxious heat (Abram et al., 1997), while BoNT/A is not (Cui et 
al., 2004). Despite this, batch 2 LC/E-BoNT/A increased the heat thresholds to a similar level as 
buprenorphine on the hot-plate test, but not on the Hargreaves test. This could be indicative of a 
greater effect of LC/E on heat hyperalgesia compared to the LC/A, likely via inhibition of peripheral 
CGRP release reducing neurogenic inflammation associated with capsaicin injections (O'Neill et al., 
2012, Wang et al., 2011a). To further investigate this a fresh batch of BoNT/A would need to be 
produced for a direct comparison with LC/E-BoNT/A in the capsaicin model. Overall, batch 2 of LC/E-
BoNT/A had an improved effect on heat hyperalgesia compared to the previous experiment with 
batch 1, and inhibited capsaicin-induced heat allodynia. 
The anti-nociceptive effect of batch 1 on capsaicin-induced hind-paw lifting and combined 
lifting/licking behaviour was reproduced with batch 2. Unlike batch 1, lifting and licking behaviour 
in batch 2 treated rats was not significantly different to buprenorphine treated rats, though this is 
likely due to the lower dose of buprenorphine used in this study, rather than a superior effect of 
batch 2 over batch 1. Like batch 1, there was no significant effect of batch 2 on reducing hind-paw 
licking behaviour, while this was inhibited by buprenorphine. As LC/E-BoTIM/A had been previously 
reported to reduce capsaicin-induced paw licking (Wang et al., 2011a), it was unexpected that this 
fresh batch of LC/E-BoNT/A would not have an effect on paw licking behaviour, despite reducing 
the other forms of pain measured. Furthermore, all rats treated with batch 2 LC/E-BoNT/A in this 
experiment showed greater weight loss than was expected from the dosing studies. As a result, it 
is possible that the changes in nocifensive behaviour in response to capsaicin were influenced by 
an adverse reaction to LC/E-BoNT/A and are not purely analgesia-induced. This indicates that future 
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experiments to calculate the MaxTD will need larger sample sizes (n ≥ 4) to improve accuracy and 
ensure rat behavioural responses are not altered by adverse reactions to neurotoxin injections in 
pain studies. The possibility of variation being derived from differences in the lead-researchers in 
charge of behaviour experiments and the facilities where tests were undertaken also remains. The 
experiments presented in Wang et al., 2011a were performed in the pain research animal facility in 
National University of Ireland Galway, while experiments described in this thesis were performed 
in DCU primarily by John Nealon, but some studies were also performed in collaboration with other 
researchers including Drs Orla Moriarty and Laura Casals. While all measures to reduce inter-
researcher variability were implemented where possible, due to the nature of behavioural testing 
in animals some differences in animal handling or testing could have been unaccounted for. 
In parallel to the experiments with batch #2 in the capsaicin model, a lower dose of batch #2 LC/E-
BoNT/A (75 U/Kg) was tested in the SNI model, to see if sub-MaxTD doses of batch #2 would also 
relieve SNI-induced pain, like the reports using batch 1 (Wang et al., 2017a). Interestingly, batch 2 
LC/E-BoNT/A had no effect on mechanical hypersensitivity but did prevent cold hyperalgesia 
increasing on day 7 after injection. Curiously, sham operated animals that received injections of 
LC/E-BoNT/A showed an increase in contralateral cold hyperalgesia, reaching significance on day 3 
post injection compared to the vehicle treated sham group. Furthermore, both sham and SNI 
groups that were treated with 75 U/Kg of batch 2 LC/E-BoNT/A showed significant weight loss. 
Therefore, it is likely this increase in cold allodynia was a symptom of the adverse reaction of the 
rats to batch 2 LC/E-BoNT/A. Batch 2 of LC/E-BoNT/A caused signs of toxicity at both 120 U/Kg and 
75 U/Kg, which were not observed in the dosing studies. As both the sham and SNI groups showed 
the same decrease in weight from 75 U/Kg of batch 2, the weight loss was not propagated by the 
severity of the SNI model. Not only did these injections of batch 2 show more adverse reactions in 
the animals than in the dosing study, but the dose response in weight loss observed in the dosing 
study was absent, as the 75 U/Kg dose had the same effect as 120 U/Kg. As the animals used for 
these different injections were all within the same weight range, this indicates differences between 
the aliquots of batch 2 that were defrosted for the dosing and pain experiments. Out of the two 
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behaviour studies conducted with batch 2 of LC/E-BoNT/A, 120 U/Kg significantly reduced 
capsaicin-induced pain and 75 U/Kg had a token effect on SNI-induced cold hyperalgesia, but both 
doses induced weight loss in rats. Since weight loss was consistent in both studies this could be 
interpreted that the anti-nociceptive effects were not a symptom of the toxicity, and more 
analgesia was induced with the higher dose of LC/E-BoNT/A. However, this highlights a difference 
between batch 1 and batch 2 of LC/E-BoNT/A. While batch 1 of LC/E-BoNT/A showed an analgesic 
effect with mild effects on animal weight, batch 2 induced more severe symptoms of weight loss, 
and required higher doses to induce an antinociceptive effect. Therefore, batch 2 of LC/E-BoNT/A 
may be entering motor neurons but less successfully binding to nociceptors until administered at a 
higher dose (120 U/Kg). After testing two different batches of LC/E-BoNT/A, with several different 
doses, in a number of different pain models, it is clear that further investigations into the batch 
differences need to be undertaken to understand the variation that is occurring in these studies, 
which will require careful comparison of the production of the different batches of LC/E-BoNT/A. 
Rat hind-limbs proved highly susceptible to paralysis after intra-articular injections of 
BoNTs, limiting the amount of toxin that could be administered 
 
Before induction of the model, appropriate doses of batch 1 LC/E-BoNT/A and BoNT/A for injection 
into the knee had to be determined. These results indicated that the knee joint was far more 
susceptible to paralytic effects than the paw, with final doses of each only at 1/3 of what could be 
injected into the paw (LC/E-BoNT/A - 25 vs. 75 U/Kg, BoNT/A - 5 vs. 15 U/Kg). However, these dose 
limitations for the knee joint are not reported or discussed in the literature. Reports from the clinic 
indicate that intra-articular injections of BOTOX® of 100 - 200 U produce no paralytic effects (Boon 
et al., 2010), which are in range with doses used for dermal injections in neuropathic pain conditions 
(typically between 50-200 U); however, dermal injections vary based on condition and are typically 
across multiple injection sites (Oh and Chung, 2015). Due to use of multiple intra-dermal injections 
for BOTOX® treatment of neuropathic pain across a broad range of injection sites, it is difficult to 
discern if the observed dose limitations in the rat knee vs. the rat hind-paw correlate with practises 
in the clinic.  
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Published data on BOTOX® injections in the rat knee are also limited. Only Yoo et al. (2014) have 
reported intra-articular injections of BOTOX® (20 U per rat, estimated at 50 – 80 U/Kg based on 
reported rat weights) into the rat knee joint but included no behaviour data or discussion of adverse 
paralytic effects. The closest comparison that can be made within the literature to susceptibility of 
the rat knee joint to BoNT-induced paralysis, are the injections of BOTOX® into the knee joint of 
mice (0.3-0.5 U) by Mahowald et al. (2009), which were similar to that of the intra-plantar doses 
used for mice by other labs (0.2-0.4 U) (Matak et al., 2017). Mahowald et al. commented in the 
discussion of the knee joint experiments that “the high doses of botulinum toxin used in the early 
studies were associated with temporary limb weakness, but not with systemic weakness or other 
observed toxicity”. This observation is very similar to the results in Fig. 3.5, where obvious limping 
of the injected hind-limb was noted while weight gain (indicative of systemic toxicity) wasn’t greatly 
affected, except by higher doses of BoNT/A (70 – 100 U/Kg). It is not clear if the high dose (causing 
limb weakness) they are referring to is 0.3 - 0.5 U or a higher dose not stated in the paper; therefore, 
the doses used in their experiments testing for therapeutic relief in their arthritic model may have 
had some motor effect.  
To identify any reported differences in intra-articular injections of BoNT/A the literature review also 
extended to published reports on injections of BOTOX® into the rat ankle joint. This was to 
investigate if the anatomical structure of a joint capsule played a role in the dose limitations 
observed, and if this was consistent with other joints. Two papers on injections of BOTOX® into the 
rat CFA inflamed ankle were found (Fan et al., 2017, Wang et al., 2017c); both studies tested 
injections of 10 U of BOTOX® into the rat ankle (estimated to be 25 U/Kg based on the reported rat 
weights), while Fan et al. also tested injections of 1 U and 3 U (~ 2.5 U/Kg and 7.5 U/Kg). These 
lower doses are in range of intra-plantar doses of BOTOX® used in rats in other pain models (Park 
et al., 2006, Cui et al., 2004); unfortunately Fan et al. only tested for adverse effects from the toxin 
injections by measures such as weight loss, hunched behaviour, and loss of appetite, without 
assessing limb weakness. From the reported dosing study for the knee MaxTD, it was found that 
weight loss did not always correlate with obvious limb dragging behaviours and used other 
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measures such as DAS and weight bearing to assess paralysis. Wang et al. (2017c) stated that no 
weakness was observed in the animals but did not explain how this was tested, however the 
authors acknowledged that side effects of the BOTOX® injections had not been fully evaluated and 
digital gait analysis would need to be used to identify an accurate dose to test in further studies. 
Based on the lack of appropriate evaluation of limb weakness it is not possible to confirm that the 
doses used did not induce paralysis and if there are similar dose limitations of the ankle joint as 
with the knee joint. 
Testing of LC/E-BoNT/A and BoNT/A in the CFA knee inflammation model showed no effects of 
either toxin on functional limb recovery, joint sensitivity or swelling. Considering the knee doses 
(LC/E-BoNT/A - 25 U/Kg, BoNT/A – 5 U/Kg) were much lower than the intra-plantar doses (LC/E-
BoNT/A - 75 U/Kg, BoNT/A – 15 U/Kg) that showed analgesic effects in the SNI and capsaicin models, 
it is likely that the doses administered were simply too low to have an anti-nociceptive or anti-
inflammatory effect on the model. Interestingly, injections of 2.5 U/Kg of BOTOX® (a lower dose 
than those used by Cui et al. 2004 and Bach-Rojecky and Lackovic et al., 2005) into the rat ankle 
have been shown to have a partial analgesic effect on reduced hind-paw thresholds in a model of 
CFA injection into the ankle (Fan et al., 2017). This may be due to the smaller amount of CFA injected 
into the ankle compared to the knee (50 µl vs. 150 µl), and so there is potentially less inflammation 
and pain to reduce in this model which could be accomplished with a lower dose of neurotoxin. 
One method to overcome the dose limitation of the knee would be to administer intra-plantar 
injections of the neurotoxins to rats that have received CFA injections to the ankle. This would take 
advantage of the higher dose limit of the rat hind-paw. Secondary hyperalgesia is induced in the 
hind-paw by injections of CFA into the ankle and would likely be reduced as shown by (Mangione 
et al., 2016) who tested intra-plantar injections of Bitox in this model. The group showed a 
reduction in hind-paw hypersensitivity induced by the CFA injection into the ankle after an injection 
of Bitox into the sensitised hind-paw. Furthermore, intra-plantar injection of the LC/E-BoNT/A or 
BoNT/A could also reduce primary hyperalgesia and swelling at the CFA injected joint in this model. 
Reports have shown that Dysport® can reduce hyperalgesia in both rat hind-paws (bilateral anti-
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nociceptive effect) in streptozotocin-induced diabetic polyneuropathy after an injection into only 
one hind-paw (unilateral injection) (Favre-Guilmard et al., 2017). Unilateral injection of Dysport® 
was also shown to have bilateral anti-nociceptive effects on rats injected in both hind-paws with 
Carrageenan (Favre-Guilmard et al., 2017). Considering these interesting analgesic effects are distal 
from the injection site, it is possible that an intra-plantar injection of LC/E-BoNT/A and BoNT/A 
could relieve hyperalgesia at the CFA inflamed ankle. 
LC/E-BoNT/A completely reversed SNI sensitivity at select time points, and attenuated 
mechanical hypersensitivity to a greater extent than BoNT/A or LC/E-BoTIM/A 
 
Injection of batch 1 LC/E-BoNT/A injection following SNI surgery was found to significantly improve 
mechanical pain withdrawal thresholds compared to LC/E-BoTIM/A, at days 3 and 7 post injection, 
and was significantly more efficacious than BoNT/A during days 3-10 post injection. It was also 
found to completely recover SNI-induced mechanical allodynia at days 3 and 7 post injection. There 
was no significant difference between LC/E-BoTIM/A and BoNT/A in relieving mechanical allodynia, 
however LC/E-BoTIM/A did improve von Frey thresholds compared to vehicle, while BoNT/A 
showed a non-significant increase in thresholds. This indicates that LC/E-BoTIM/A is a more viable 
therapeutic for the relief of neuropathic pain than BoNT/A, and LC/E-BoNT/A is the best of all three 
toxins tested. Since both LC/E-BoNT/A and LC/E-BoTIM/A contain an active LC/E, the greater 
number of amino acids cleaved from SNAP-25 by these molecules is assumed to underlie their 
greater efficacy in relieving mechanical allodynia. However, it is unclear as to what specific 
mechanism LC/E cleavage can act through to reduce SNI-induced pain at the hind-paw injection 
site. LC/E-BoNT/A and LC/E-BoTIM/A were expected to have a superior effect on pain relief to 
BoNT/A, based on their ability to block capsaicin-induced CGRP release in vitro (Wang et al., 2017a, 
Wang et al., 2011a). However, the SNI model shows decreased innervation of CGRP expressing 
neurons in the sensitised lateral side of the hind-paw (where the neurotoxins were injected) after 
injury (Duraku et al., 2012), indicating that inhibition of peripheral CGRP release by LC/E cleaved 
SNAP-25 is not the mechanism of analgesia for the chimeric neurotoxins in the SNI model. BoNT/A 
inhibits the fusion of TRPV1 and TRPA1 to the plasmalemma in vitro which can prevent upregulation 
111 
 
of these receptors in response to inflammatory mediators in painful conditions (Meng et al., 2016). 
LC/E-BoNT/A also inhibits the fusion of these channels (Nugent et al., 2018) and this was proposed 
to play another role in the anti-nociceptive mechanism of the toxin;  however, neither of these 
receptors play obvious roles in mechanical allodynia induced by the SNI model. Deletion of TRPV1 
expressing neurons by injections of resiniferatoxin (a TRPV1 agonist) showed no effect on von Frey 
thresholds while reducing pin prick hyperalgesia, indicating TRPV1 does not mediate static tactile 
allodynia in the SNI model (Yamamoto et al., 2013). TRPA1 knockdown mice have also shown 
mechanical hypersensitivity as measured by the von Frey test demonstrating that TRPA1 also does 
not mediate tactile allodynia in the SNI model (Eid et al., 2008).  Furthermore, mRNA expression of 
both TRPV1 and TRPA1 is reduced in the DRG after SNI and does not return to normal until 3 months 
after injury (Staaf et al., 2009). Therefore, peripheral activity of these molecules in the hind-paw is 
unlikely to play a role in BoNT mediated recovery of von Frey thresholds in the SNI model. Since the 
superior effects of SNAP-25E over SNAP-25A on CGRP release are mediated by intracellular 
Ca2+(Meng et al., 2009, Meng et al., 2007), there may be other pain inducing neurotransmitters and 
peptides whose Ca2+ dependent release is blocked by LC/E-BoNT/A and LC/E-BoTIM/A, which could 
underlie their effectiveness in in the SNI model. One can hypothesise that these two chimeras also 
prevent fusion of pain-inducing receptors other than TRPV1 and TRPA1, that BoNT/A may be unable 
to block due to sustained calcium uptake in peripheral or central sensitisation. P2X3 and P2X2/3 
receptors are of particular interest as P2X receptor antagonists have been shown to reduce SNI-
induced mechanical allodynia measured by von Frey tests (Chen et al., 2005). Exploring the effects 
of SNAP-25E on the docking of these receptors in vitro by immunohistochemical staining of P2X 
receptor docking pre and post intoxication with LC/E-BoNT/A could provide more information on 
the mechanisms of action behind these toxins’ analgesic effect in the SNI model. 
As neuropathic pain models are driven strongly by ectopic activity from the site of nerve injury and 
the DRG, these serve to initiate and maintain mechanisms of central sensitisation (Costigan et al., 
2009, Amir et al., 2005). If LC/E-BoNT/A is transported to either the DRG or central terminals in the 
dorsal horn via the spared sural nerve, then it could act as a potent inhibitor of the ectopic impulse 
112 
 
generation driving neuropathic pain. This spontaneous firing is expected to be driven by NaV 
channels (Wang et al., 2011b), and NaV 1.3 specifically is known to be upregulated in the DRG of SNI 
rats (Berta et al., 2008). Inhibition of NaV 1.3 upregulation in the DRG could be a target for LC/E-
BoNT/A mediated relief of SNI pain; however, blocking NaV 1.3 activity is not effective at relieving 
symptoms of SNI-induced neuropathic pain, and so the exact role the Nav channels play in 
generating spontaneous impulses in neuropathic pain is unclear (Lindia et al., 2005). While LC/E-
BoNT/A inhibition of CGRP release in the hind-paw is not likely to have an effect in inhibiting the 
development of SNI-induced pain, preventing CGRP release at the central terminals would aid in 
reducing the effects of SP release at the dorsal horn (Oku et al., 1987) and inhibiting action potential 
wind-up driven by these two neuropeptides(De Felipe et al., 1998). As increases of intracellular Ca2+ 
are characteristic of central sensitisation in the dorsal horn (Latremoliere and Woolf, 2009), LC/E-
BoNT/A inhibition of the release of CGRP would be resistant to Ca2+ concentrations, unlike BoNT/A, 
and explain its more effective relief of SNI mechanical allodynia.   
Lastly, it is also possible that the different doses of toxins injected could underlie the differences in 
anti-nociceptive effect. Since both LC/E-BoNT/A and LC/E-BoTIM/A were administered at higher 
doses than BoNT/A (75 vs 15 U/Kg), more total protein was being delivered to the hind-paw to 
cleave SNAP-25 and thus reduce SNI-induced pain. Converting the doses into raw values shows that 
approximately 38 pg of BoNT/A was injected per rat, compared to 320 pg of LC/E-BoNT/A and 938 
pg of LC/E-BoTIM/A. This highlights that ~10 times more LC/E-BoNT/A than BoNT/A could be 
injected into the hind-paw without inducing paralysis, and ~25 times more LC/E-BoTIM/A than 
BoNT/A could be injected. This is surprising as LD50 values for these toxins indicated that LC/E-
BoNT/A was only half as potent than BoNT/A, while LC/E-BoTIM/A was 5 times less potent than 
BoNT/A. These results show that it is possible that the paralytic potency of the toxin does not 
directly correlate with the anti-nociceptive mechanisms of BoNTs. Also, if the amount of SNARE 
cleaving protein being delivered was the main factor behind the analgesic mechanisms, it would be 
expected that LC/E-BoTIM/A would have had a greater effect in the SNI model than LC/E-BoNT/A, 
as 3 times more LC/E-BoTIM/A than LC/E-BoNT/A could be injected. Another question is why the 
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doses in LD50 units of each toxin varied at the plantar injection site? If LD50 units normalise the toxin 
concentrations based on activity, all toxins should have had the same MaxTD when injected into 
the hind-paw. The variation in MaxTD doses between the three toxins seems to indicate that the 
neurotoxins have different potencies in the hind-paw, which was not captured in the LD50 as this 
assay relied on intra-peritoneal injections, which is a very different environment for toxin uptake 
than the hind-paw. Further studies investigating the potency differences of these toxins and how 
this may contribute to their anti-nociceptive and paralytic effects are required. 
Another question that arises from the results of the SNI study is why does LC/E-BoNT/A provide 
superior analgesia to LC/E-BoTIM/A in neuropathic pain. LC/E-BoNT/A retains an active LC/A while 
LC/E-BoTIM/A has an inactive LC/A mutant. Since LC/E and LC/A both target SNAP-25 and both 
neurotoxins produce SNAP-25E, what additional benefit does LC/A provide to LC/E-BoNT/A over 
LC/E-BoTIM/A? As shown by the Western blots of plantaris muscle from LC/E-BoNT/A injected rats 
used in the dosing studies (Fig. 3.16 D), SNAP-25A and SNAP-25 E were present in vivo at 8-9 days 
post injection of toxin, while LC/E-BoTIM/A only produces SNAP-25E in vivo (Wang et al., 2011a). 
One possibility is that the presence of two different cleaved SNAP-25 products may have a 
synergistic effect on analgesia in the SNI model. While cleavage of SNAP-25 by LC/E induces a robust 
blockade of vesicular fusion, cleavage of SNAP-25 by BoNT/A results in production of SDS-resistant 
complexes, whose inhibition of vesicular fusion can be reversed by sustained increases in 
intracellular Ca2+ unlike LC/E (Hayashi et al., 1994, Meng et al., 2009, Lu, 2015). Sustained increases 
of intracellular Ca2+ is characteristic of both peripheral and central sensitisation (Hagenacker et al., 
2008, Latremoliere and Woolf, 2009). It is tempting to postulate that LC/E cleaved SNAP-25 may 
inhibit the docking of peripheral or central (if BoNTs undergo retrograde transport) opioid 
receptors, while LC/A inhibition of vesicular fusion will be reversed by increased intracellular Ca2+ 
and allow for fusion of opioid receptors to the plasma membrane. Evidence suggests that delta 
opioid receptors (DORs) in the rat DRG and dorsal horn are associated with LDCVs containing 
neuropeptides such as CGRP (Bao et al., 2003, Zhang et al., 1998), highlighting a SNARE mediated 
pathway of membrane fusion for DORs. Upregulation of μ-opioid receptors (MORs) have been 
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found in the DRG, dorsal horn and paw skin and upregulation of DORs have been found in DRGs 
and sciatic nerves in a number of nerve injury models (Stein et al., 2009, Bushlin et al., 2010) 
indicating that nerve injury may induce mechanisms to improve sensitivity to endogenous opioids, 
in order to inhibit pain. Hypothetically, a therapeutic that solely produces SNAP-25E will inhibit 
release of pain inducing neurotransmitters and neuropeptides more effectively than BoNT/A, but 
also potentially prevent opioid receptor docking, an endogenous mechanism of pain inhibition. As 
LC/E-BoNT/A produces a mixed population of SNAP-25E and SNAP-25A at the presynaptic terminal, 
there could be a population of partially functional SNARE complexes present to allow docking of 
opioid receptors for endogenous pain inhibition, while the LC/E prevents formation of enough of 
these complexes to reduce release of pain inducing neurotransmitters. Experiments designed to 
investigate the ability of BoNT/A and LC/E-BoNT/A to inhibit MOR or DOR fusion to the plasma 
membrane would shed light on the potential of this tentative hypothesis. 
Conclusions: 
 
While the analgesic effect of LC/E-BoNT/A varied between different batches and potentially lost 
potency over long term storage, promising results in both acute inflammatory and chronic 
neuropathic pain models indicate its value as an improvement over BoNT/A for pain relief. Future 
experiments to evaluate this novel chimera will rely on identifying the role the LC/A plays in the 
superior anti-nociceptive effect of LC/E-BoNT/A over LC/E-BoTIM/A. Further work into the role that 
the dose differences between LC/E-BoNT/A, LC/E-BoTIM/A and BoNT/A play in their analgesic 
mechanisms would also be of value, and if alternative injection routes would prove suitable to 
utilise LC/E-BoNT/A in relieving models of chronic joint inflammatory pain. This will allow for a 
greater understanding of not only the anti-nociceptive mechanisms of these neurotoxins, but of 
the mechanisms behind different pre-clinical pain models.  
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 BONT/A LC/E-BOTIM/A LAB SAMPLE LC/E-
BONT/A 
BATCH 1 LC/E-BONT/A BATCH 2 LC/E-BONT/A 
(TP.001) 
EXPRESSION Shaker culture, auto-
induction 
Shaker culture, auto-
induction 
Shaker culture, auto-
induction 
Bioreactor, auto-
induction 
Bioreactor, IPTG 
induction 
HARVESTING CELLS 
FROM CULTURE 
Centrifugation of E. coli 
expressing BoNT 
Centrifugation of E. coli 
expressing BoNT 
Centrifugation of E. coli 
expressing BoNT 
Tangential flow filtration 
of E. coli expressing 
BoNT 
Tangential flow filtration 
of E. coli expressing 
BoNT 
CELL LYSIS AND 
HARVESTING OF BONTS 
Cell pellet from culture 
incubated in lysozyme, 
protease inhibitor 
cocktail and benzonase 1 
Cell pellet from culture 
incubated in lysozyme, 
protease inhibitor 
cocktail and benzonase 1 
Cell pellet from culture 
incubated in lysozyme, 
protease inhibitor 
cocktail and benzonase 1 
Cell lysis by high 
pressure 
homogenisation 
Cell lysis by high 
pressure 
homogenisation 
 Centrifugation to 
remove insoluble 
particles 
Centrifugation to 
remove insoluble 
particles 
Centrifugation to 
remove insoluble 
particles 
Tangential flow filtration 
to remove insoluble 
particles 
Centrifugation to 
remove insoluble 
particles 
    Filtering to reduce host 
cells 
Filtering to reduce host 
cells 
TOXIN PURIFICATION IMAC purification IMAC purification IMAC purification IMAC purification IMAC purification 
 Gel filtration Gel filtration Gel filtration Gel filtration Gel filtration 
 Anion-exchange 
chromatography 
Cation-exchange 
chromatography 
Cation-exchange 
chromatography 
Cation-exchange 
chromatography 
Cation-exchange 
chromatography 
 Gel filtration Gel filtration Gel filtration Gel filtration  
 Thrombin incubation 2 Thrombin incubation 3 Thrombin incubation 3 Thrombin incubation 3 Thrombin incubation 4 
 Halt reaction with 1 mM 
final concentration of 
PMSF 
Halt reaction with 1 mM 
final concentration of 
PMSF 
Halt reaction with 1 mM 
final concentration of 
PMSF 
Freeze bulk purified 
toxin at -80 °C 
2nd Cation-exchange 
chromatography 
 Freeze bulk purified 
toxin -80 °C 
Freeze bulk purified 
toxin -80 °C 
Freeze bulk purified 
toxin at -80 °C 
End Freeze bulk purified 
toxin at -80 °C 
 End End End  Thaw, dilute sample and 
add excipients (HSA) 
     Freeze bulk 
concentrated lot -80 °C 
     End 
Table 4.1 - BoNT production batch differences: 1 - Lysozyme (2 mg/ml), protease inhibitor cocktail (1:200 v/v) and benzonase (1500 units), 2 - Thrombin 
1U/mg toxin at 22 °C for 1 hours, 3 - Thrombin 1U/mg toxin at 22 °C for 3 hours, 4 – Thrombin 4U/mg toxin at 22 °C for 4 hours, then at 8 °C for 20 hours, pH 6. 
Appendix 
